var title_f32_11_32944="Betaxolol: Drug information";
var content_f32_11_32944=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Betaxolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/53/4950?source=see_link\">",
"       Betaxolol (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/24/37255?source=see_link\">",
"       Betaxolol (systemic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9145 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32944=[""].join("\n");
var outline_f32_11_32944=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/53/4950?source=related_link\">",
"      Betaxolol (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/24/37255?source=related_link\">",
"      Betaxolol (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_11_32945="Sacroiliitis grade 4 example 1";
var content_f32_11_32945=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sacroiliitis grade 4 example 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral grade 4 sacroiliitis with complete fusion of sacroiliac joints.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet, Herne, Germany.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32945=[""].join("\n");
var outline_f32_11_32945=null;
var title_f32_11_32946="Warfarin-induced skin necrosis on extremity";
var content_f32_11_32946=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Warfarin-induced skin necrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A retiform purpuric lesion with bullae and skin necrosis is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32946=[""].join("\n");
var outline_f32_11_32946=null;
var title_f32_11_32947="Mobilization of left colon - Medial approach";
var content_f32_11_32947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Mobilization of left colon - Medial approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 556px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts mobilization of the left colon beginning the approach medially. The peritoneum is scored and the inferior mesenteric vessles are identified and ligated prior to mobilizing the colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32947=[""].join("\n");
var outline_f32_11_32947=null;
var title_f32_11_32948="Motor nerve conduction study";
var content_f32_11_32948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Motor nerve conduction study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 542px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stimulation at different proximal sites along the ulnar nerve while recording from the abductor digiti minimi muscle allows the conduction velocity (CV) of the motor neurons to be calculated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahram Khoshbin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32948=[""].join("\n");
var outline_f32_11_32948=null;
var title_f32_11_32949="Abdominal aortic aneurysm repair";
var content_f32_11_32949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Abdominal aortic aneurysm repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 705px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Top) For open surgical repair of abdominal aortic aneurysm, the aorta is clamped and the aneurysm sac opened. A graft is sutured into the aorta proximally and distally. A tube graft (illustrated) or a bifurcated graft is used depending upon the extent of iliac artery disease (aneurysm or stenosis). Once the graft is in place, the aneurysm sac and retroperitoneum are closed over the graft.",
"    <br>",
"     (Bottom) For endovascular repair, the folded endograft is introduced through the femoral (or iliac) artery and, once it is properly posititioned, the self-expanding endograft is deployed. Iliac artery extensions are positioned and deployed to complete the repair.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32949=[""].join("\n");
var outline_f32_11_32949=null;
var title_f32_11_32950="Pyomyositis";
var content_f32_11_32950=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pyomyositis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32950/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32950/contributors\">",
"     Larry M Baddour, MD, FIDSA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32950/contributors\">",
"     Anuwat Keerasuntornpong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32950/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32950/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32950/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32950/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/11/32950/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyomyositis is a purulent infection of skeletal muscle that arises from hematogenous spread, usually with abscess formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinical approach to pyomyositis will be reviewed here. Other soft tissue infections such as clostridial myonecrosis and necrotizing fasciitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12264?source=see_link\">",
"     \"Clostridial myonecrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyomyositis is classically an infection of the tropics, although it has been recognized in temperate climates with increasing frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. Tropical pyomyositis primarily occurs in two age groups: children (ages 2 to 5) and adults (ages 20 to 45), while the majority of temperate pyomyositis cases occurs in adults. Males appear to be more commonly affected than females. Most patients with tropical pyomyositis are otherwise healthy without underlying comorbidities, while most patients in temperate regions are immunocompromised or have other serious underlying conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Predisposing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predisposing factors for pyomyositis include immunodeficiency, trauma, injection drug use, concurrent infection, and malnutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2,8-12\">",
"     2,8-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunodeficiency has been implicated in the development of pyomyositis in both temperate and tropical climates. Forms of immunodeficiency associated with pyomyositis include HIV infection, diabetes mellitus, malignancy, cirrhosis, renal insufficiency, organ transplantation, and administration of immunosuppressive agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2,13\">",
"     2,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV is a particularly important risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2,4,7,11,14-18\">",
"     2,4,7,11,14-18",
"    </a>",
"    ]. A case-control series in Uganda demonstrated a significant association between pyomyositis and HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/7\">",
"     7",
"    </a>",
"    ]. In a review of 98 cases in North America, about half of pyomyositis patients with underlying medical conditions were seropositive for HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/4\">",
"     4",
"    </a>",
"    ]. The mechanism of HIV infection in the predisposition to pyomyositis is unclear; factors may include immune compromise, primary HIV myopathy, antiretroviral therapy, and increased rates of staphylococcal carriage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2,7,17,18\">",
"     2,7,17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma has been postulated as a predisposing factor for pyomyositis; about 25 to 50 percent of patients with pyomyositis report a history of trauma. In addition, pyomyositis has been described in temperate regions among athletes performing vigorous exercise, suggesting the potential role of minor muscle damage in the pathogenesis of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/19-25\">",
"     19-25",
"    </a>",
"    ]. Development of infection may be related to hematoma formation or increased muscle perfusion due to trauma, providing additional iron to the muscle bed for favorable bacterial growth conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/3,6\">",
"     3,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Injection drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection drug use has been associated with pyomyositis-induced bacteremia. Local injection site infection and abscess extension into muscle tissue should not be confused with true pyomyositis caused by hematogenous seeding of muscle groups distant from injection sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Concurrent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxocariasis has been associated with the subsequent development of pyomyositis, perhaps because of predisposing muscle damage and impaired local immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/30\">",
"     30",
"    </a>",
"    ]. Underlying skin conditions predisposing to secondary bacteremia, such as varicella infection, have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2,31\">",
"     2,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staphylococcus aureus is the most common cause of pyomyositis; it causes up to 90 percent of tropical cases and up to 75 percent of temperate cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2,4,6,8-10,12,32\">",
"     2,4,6,8-10,12,32",
"    </a>",
"    ]. Methicillin-resistant S. aureus (MRSA), including community-acquired strains, is also an increasingly important pathogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. In a retrospective review of 29 adults with pyomyositis, MRSA comprised 25 percent of cases due to S. aureus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Group A streptococci is the second most common pathogen. Less common causes include non-group A streptococci, pneumococci and gram-negative enteric bacilli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2,5,9,12,26,37-39\">",
"     2,5,9,12,26,37-39",
"    </a>",
"    ]. E. coli pyomyositis is an emerging infection among patients with hematologic malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/40\">",
"     40",
"    </a>",
"    ]. It is usually caused by members of E. coli ST131, a cause of fluoroquinolone-resistant, ESBL-positive E. coli infection worldwide.",
"   </p>",
"   <p>",
"    Mycobacterial pyomyositis has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/39,41-45\">",
"     39,41-45",
"    </a>",
"    ]. Pyomyositis can also be polymicrobial, particularly in diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyomyositis presents with fever and pain with cramping localized to a single muscle group. The disease occurs most often in the lower extremity (sites include the thigh, calf and gluteal muscles), but any muscle group can be involved, including the iliopsoas, pelvic, trunk, paraspinal and upper extremity muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2,46\">",
"     2,46",
"    </a>",
"    ]. Multifocal infection with involvement of more than one muscle group may be observed in up to 20 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2,47\">",
"     2,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pyomyositis can be divided into three clinical stages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 1 is characterized by crampy local muscle pain, swelling, and low-grade fever. Mild leukocytosis and induration of the affected muscle may be present. A deep abscess may not be discretely palpable, but the muscle may have a \"woody\" texture on palpation. Fluctuation is not present, and aspiration of the muscle will not yield purulent material. Only 2 percent of patients present at this stage.",
"     </li>",
"     <li>",
"      Stage 2 occurs 10 to 21 days after the initial onset of symptoms and is characterized by fever, exquisite muscle tenderness, and edema. A frank abscess may be clinically apparent, and aspiration of the affected muscle typically yields pus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/48\">",
"       48",
"      </a>",
"      ]. Marked leukocytosis is usually present. More than 90 percent of the patients present at this suppurative stage.",
"     </li>",
"     <li>",
"      Stage 3 is characterized by systemic toxicity. The affected muscle is fluctuant. Complications of S. aureus bacteremia such as septic shock, endocarditis, septic emboli, pneumonia, pericarditis, septic arthritis, brain abscess, and acute renal failure can occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. Rhabdomyolysis has also been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/38\">",
"       38",
"      </a>",
"      ]. Because pyomyositis occurs as a result of bacteremia, all patients (regardless of presenting stage) should be evaluated for presence of additional sequelae of bacteremia, including endocarditis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26649?source=see_link\">",
"       \"Complications of Staphylococcus aureus bacteremia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The course of pyomyositis is variable; although most patients present with stage 2 or 3 disease, some experience a more indolent course; a delay in diagnosis in such cases may result in involvement of multiple muscle groups, requiring prolonged therapy. Recurrent infection is rare but has been described in immunocompromised individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2\">",
"     2",
"    </a>",
"    ]. Mortality due to pyomyositis was reported to be as high as 10 percent in one retrospective cohort study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyomyositis may be confused with muscle strain, contusion, hematoma, cellulitis, deep vein thrombosis, osteomyelitis, septic arthritis, or neoplasm. It must also be distinguished from clostridial myonecrosis, necrotizing fasciitis, spontaneous gangrenous myositis, diabetic muscle infarction, septic arthritis, and other forms of myositis (",
"    <a class=\"graphic graphic_table graphicRef68260 \" href=\"mobipreview.htm?30/53/31580\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12264?source=see_link\">",
"     \"Clostridial myonecrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1526?source=see_link\">",
"     \"Diabetic muscle infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tools for diagnosis of pyomyositis include radiography, cultures, and laboratory data. Because pyomyositis occurs as a result of bacteremia, all patients (regardless of presenting stage) should be evaluated for presence of additional sequelae of bacteremia, including endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26649?source=see_link\">",
"     \"Complications of Staphylococcus aureus bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic imaging is the most useful tool for diagnosing pyomyositis, defining the site(s) of infection and for ruling out other entities. Computed tomography (CT) is helpful for detecting muscle swelling and well-delineated areas of fluid attenuation that display rim enhancement with contrast, as well as for radiographic-guided drainage of purulent material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/52\">",
"     52",
"    </a>",
"    ]. Although CT is preferable if available, ultrasonography is also a potentially useful diagnostic and therapeutic tool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/53\">",
"     53",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) can be helpful for identification of the extent of infection with greater subtlety than other modalities, if needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/5,8,54\">",
"     5,8,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteriologic diagnosis can be made by cultures of drainage specimens. Diagnostic drainage prior to antibiotic therapy is helpful for obtaining optimal microbiologic data and susceptibility testing to direct specific therapy. Blood cultures are positive in up to 10 percent of tropical cases and 35 percent of temperate cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/1,2,6\">",
"     1,2,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laboratory data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific laboratory findings include leukocytosis with left shift, and elevated inflammatory markers (erythrocyte sedimentation rate and C-reactive protein). Eosinophilia should raise suspicion for a concomitant parasitic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/55\">",
"     55",
"    </a>",
"    ]. Counterintuitively, creatine kinase levels are often normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although stage 1 pyomyositis can be treated with antibiotics alone, most patients present with stage 2 or 3 disease and therefore require both antibiotics and drainage for definitive management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT-guided percutaneous drainage is the modality of choice when feasible. In the setting of deep infection or extensive muscle involvement with significant necrosis, surgical intervention may be required. Diagnostic drainage prior to antibiotic therapy is helpful for obtaining optimal microbiologic data and susceptibility testing to direct specific therapy. In the setting of acute presentation with systemic toxicity, however, antibiotic therapy should be initiated without delay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;For immunocompetent individuals, initial empiric parenteral antibiotic therapy should be directed against staphylococci and streptococci. Empiric therapy for MRSA should be initiated for patients with a previous episode of proven MRSA infection, patients with risk factors for MRSA, and patients with systemic toxicity (",
"    <a class=\"graphic graphic_table graphicRef53504 \" href=\"mobipreview.htm?5/9/5275\">",
"     table 2",
"    </a>",
"    ). In addition, it should be considered in communities where the prevalence of MRSA is greater than 30 percent. Parenteral agents for treatment are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef77419 \" href=\"mobipreview.htm?40/55/41851\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For immunocompromised individuals, broad antibiotic coverage for gram-positive, gram-negative and anaerobic organisms should be administered. In such circumstances,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    may be combined with a broad spectrum regimen that has activity against gram-negatives and anaerobes (",
"    <a class=\"graphic graphic_table graphicRef64708 \" href=\"mobipreview.htm?34/61/35803\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The duration of antimicrobial therapy should be tailored to clinical and radiographic improvement. Three to four weeks of parenteral therapy is usually sufficient, although patients with extensive, multifocal or poorly drained infection may warrant longer courses of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. The course of therapy for patients with other sequelae of bacteremia (such as endocarditis or osteomyelitis) should be adjusted based on the nature of infection at these other sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/6\">",
"     6",
"    </a>",
"    ]. In rare cases of infections caused by mycobacteria, the nature and duration of treatment should be tailored to the microbiologic isolate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pyomyositis is a purulent infection of skeletal muscle that arises from hematogenous spread, usually with abscess formation. It is classically an infection of the tropics, although it has been recognized in temperate climates with increasing frequency. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for pyomyositis include immunodeficiency (particularly HIV infection), trauma, injection drug use, concurrent infection, and malnutrition. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Predisposing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Staphylococcus aureus is the most common cause of pyomyositis; it causes up to 90 percent of tropical cases and up to 75 percent of temperate cases. Methicillin-resistant S. aureus, including community-acquired strains, is also an increasingly important pathogen. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pyomyositis presents with fever and pain with cramping localized to a single muscle group. It develops most often in the lower extremity (sites include the thigh, calf, and gluteal muscles), but any muscle group can be involved, including the iliopsoas, pelvic, trunk, paraspinal, and upper extremity muscles. The clinical stages of pyomyositis are outlined above. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic imaging with computed tomography is the most useful tool for diagnosing pyomyositis, defining the site(s) of infection and for ruling out other entities. Bacteriologic diagnosis can be made by cultures of drainage specimens",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      blood. Nonspecific laboratory findings include leukocytosis and elevated inflammatory markers; creatine kinase levels are often normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2,5\">",
"       2,5",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although stage 1 pyomyositis can be treated with antibiotics alone, most patients present with stage 2 or 3 disease and therefore require both antibiotics and drainage for definitive management. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For immunocompetent individuals, initial empiric parenteral antibiotic therapy should be directed against staphylococci and streptococci. For immunocompromised individuals, broad antibiotic coverage for gram-positive, gram-negative, and anaerobic organisms should be considered. Reasonable antibiotic regimens are outlined in the tables (",
"      <a class=\"graphic graphic_table graphicRef77419 \" href=\"mobipreview.htm?40/55/41851\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef64708 \" href=\"mobipreview.htm?34/61/35803\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/1\">",
"      Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/2\">",
"      Crum NF. Bacterial pyomyositis in the United States. Am J Med 2004; 117:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/3\">",
"      Gibson RK, Rosenthal SJ, Lukert BP. Pyomyositis. Increasing recognition in temperate climates. Am J Med 1984; 77:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/4\">",
"      Christin L, Sarosi GA. Pyomyositis in North America: case reports and review. Clin Infect Dis 1992; 15:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/5\">",
"      Bickels J, Ben-Sira L, Kessler A, Wientroub S. Primary pyomyositis. J Bone Joint Surg Am 2002; 84-A:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/6\">",
"      Chauhan S, Jain S, Varma S, Chauhan SS. Tropical pyomyositis (myositis tropicans): current perspective. Postgrad Med J 2004; 80:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/7\">",
"      Horn CV, Master S. Pyomyositis tropicans in Uganda. East Afr Med J 1968; 45:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/8\">",
"      Small LN, Ross JJ. Tropical and temperate pyomyositis. Infect Dis Clin North Am 2005; 19:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/9\">",
"      Widrow CA, Kellie SM, Saltzman BR, Mathur-Wagh U. Pyomyositis in patients with the human immunodeficiency virus: an unusual form of disseminated bacterial infection. Am J Med 1991; 91:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/10\">",
"      Schwartzman WA, Lambertus MW, Kennedy CA, Goetz MB. Staphylococcal pyomyositis in patients infected by the human immunodeficiency virus. Am J Med 1991; 90:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/11\">",
"      Rodgers WB, Yodlowski ML, Mintzer CM. Pyomyositis in patients who have the human immunodeficiency virus. Case report and review of the literature. J Bone Joint Surg Am 1993; 75:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/12\">",
"      Gomez-Reino JJ, Aznar JJ, Pablos JL, et al. Nontropical pyomyositis in adults. Semin Arthritis Rheum 1994; 23:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/13\">",
"      Belsky DS, Teates CD, Hartman ML. Case report: diabetes mellitus as a predisposing factor in the development of pyomyositis. Am J Med Sci 1994; 308:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/14\">",
"      Ansalonl L, Acaye GL, Re MC. High HIV seroprevalence among patients with pyomyositis in northern Uganda. Trop Med Int Health 1996; 1:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/15\">",
"      Blumberg HM, Stephens DS. Pyomyositis and human immunodeficiency virus infection. South Med J 1990; 83:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/16\">",
"      Jellis JE. Viral infections: musculoskeletal infection in the human immunodeficiency virus (HIV) infected patient. Baillieres Clin Rheumatol 1995; 9:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/17\">",
"      Holbrook KA, Klein RS, Hartel D, et al. Staphylococcus aureus nasal colonization in HIV-seropositive and HIV-seronegative drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/18\">",
"      Miller M, Cespedes C, Vavagiakis P, et al. Staphylococcus aureus colonization in a community sample of HIV-infected and HIV-uninfected drug users. Eur J Clin Microbiol Infect Dis 2003; 22:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/19\">",
"      Burkhart BG, Hamson KR. Pyomyositis in a 69-year-old tennis player. Am J Orthop (Belle Mead NJ) 2003; 32:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/20\">",
"      Chusid MJ, Hill WC, Bevan JA, Sty JR. Proteus pyomyositis of the piriformis muscle in a swimmer. Clin Infect Dis 1998; 26:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/21\">",
"      Jayoussi R, Bialik V, Eyal A, et al. Pyomyositis caused by vigorous exercise in a boy. Acta Paediatr 1995; 84:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/22\">",
"      King RJ, Laugharne D, Kerslake RW, Holdsworth BJ. Primary obturator pyomyositis: a diagnostic challenge. J Bone Joint Surg Br 2003; 85:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/23\">",
"      Koutures CG, Savoia M, Pedowitz RA. Staphylococcus aureus thigh pyomyositis in a collegiate swimmer. Clin J Sport Med 2000; 10:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/24\">",
"      Meehan J, Grose C, Soper RT, Kimura K. Pyomyositis in an adolescent female athlete. J Pediatr Surg 1995; 30:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/25\">",
"      Viani RM, Bromberg K, Bradley JS. Obturator internus muscle abscess in children: report of seven cases and review. Clin Infect Dis 1999; 28:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/26\">",
"      Hsueh PR, Hsiue TR, Hsieh WC. Pyomyositis in intravenous drug abusers: report of a unique case and review of the literature. Clin Infect Dis 1996; 22:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/27\">",
"      Ebright JR, Pieper B. Skin and soft tissue infections in injection drug users. Infect Dis Clin North Am 2002; 16:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/28\">",
"      Lo TS, Mooers MG, Wright LJ. Pyomyositis complicating acute bacterial endocarditis in an intravenous drug user. N Engl J Med 2000; 342:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/29\">",
"      Crossley M. Temperate pyomyositis in an injecting drug misuser. A difficult diagnosis in a difficult patient. Emerg Med J 2003; 20:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/30\">",
"      Rayes AA, Nobre V, Teixeira DM, et al. Tropical pyomyositis and human toxocariasis: a clinical and experimental study. Am J Med 2000; 109:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/31\">",
"      Gubbay AJ, Isaacs D. Pyomyositis in children. Pediatr Infect Dis J 2000; 19:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/32\">",
"      Chiedozi LC. Pyomyositis. Review of 205 cases in 112 patients. Am J Surg 1979; 137:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/33\">",
"      Mart&iacute;nez-Aguilar G, Avalos-Mishaan A, Hulten K, et al. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004; 23:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/34\">",
"      Ruiz ME, Yohannes S, Wladyka CG. Pyomyositis caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2005; 352:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/35\">",
"      Zalavras CG, Rigopoulos N, Poultsides L, Patzakis MJ. Increased oxacillin resistance in thigh pyomyositis in diabetic patients. Clin Orthop Relat Res 2008; 466:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/36\">",
"      Fowler A, Mackay A. Community-acquired methicillin-resistant Staphylococcus aureus pyomyositis in an intravenous drug user. J Med Microbiol 2006; 55:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/37\">",
"      Wang TK, Wong SS, Woo PC. Two cases of pyomyositis caused by Klebsiella pneumoniae and review of the literature. Eur J Clin Microbiol Infect Dis 2001; 20:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/38\">",
"      Falasca GF, Reginato AJ. The spectrum of myositis and rhabdomyolysis associated with bacterial infection. J Rheumatol 1994; 21:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/39\">",
"      Lawn SD, Bicanic TA, Macallan DC. Pyomyositis and cutaneous abscesses due to Mycobacterium avium: an immune reconstitution manifestation in a patient with AIDS. Clin Infect Dis 2004; 38:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/40\">",
"      Vigil KJ, Johnson JR, Johnston BD, et al. Escherichia coli Pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis 2010; 50:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/41\">",
"      Chu CK, Yang TL, Tan CT. Tuberculous pyomyositis of the temporal muscle in a nonimmunocompromised woman: diagnosis by sonography. J Laryngol Otol 2004; 118:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/42\">",
"      Wang JY, Lee LN, Hsueh PR, et al. Tuberculous myositis: a rare but existing clinical entity. Rheumatology (Oxford) 2003; 42:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/43\">",
"      Ahmed J, Homans J. Tuberculosis pyomyosits of the soleus muscle in a fifteen-year-old boy. Pediatr Infect Dis J 2002; 21:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/44\">",
"      Johnson DW, Herzig KA. Isolated tuberculous pyomyositis in a renal transplant patient. Nephrol Dial Transplant 2000; 15:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/45\">",
"      Shih JY, Hsueh PR, Chang YL, et al. Pyomyositis due to Mycobacterium haemophilum in a patient with polymyositis and long-term steroid use. Clin Infect Dis 1998; 26:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/46\">",
"      Shepherd JJ. Tropical myositis: is it an entity and what is its cause? Lancet 1983; 2:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/47\">",
"      Niamane R, Jalal O, El Ghazi M, et al. Multifocal pyomyositis in an immunocompetent patient. Joint Bone Spine 2004; 71:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/48\">",
"      Peckett WR, Butler-Manuel A, Apthorp LA. Pyomyositis of the iliacus muscle in a child. J Bone Joint Surg Br 2001; 83:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/49\">",
"      Nourse C, Starr M, Munckhof W. Community-acquired methicillin-resistant Staphylococcus aureus causes severe disseminated infection and deep venous thrombosis in children: literature review and recommendations for management. J Paediatr Child Health 2007; 43:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/50\">",
"      Lin MY, Rezai K, Schwartz DN. Septic pulmonary emboli and bacteremia associated with deep tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2008; 46:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/51\">",
"      Sharma A, Kumar S, Wanchu A, et al. Clinical characteristics and predictors of mortality in 67 patients with primary pyomyositis: a study from North India. Clin Rheumatol 2010; 29:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/52\">",
"      Struk DW, Munk PL, Lee MJ, et al. Imaging of soft tissue infections. Radiol Clin North Am 2001; 39:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/53\">",
"      Quillin SP, McAlister WH. Rapidly progressive pyomyositis. Diagnosis by repeat sonography. J Ultrasound Med 1991; 10:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/54\">",
"      Yuh WT, Schreiber AE, Montgomery WJ, Ehara S. Magnetic resonance imaging of pyomyositis. Skeletal Radiol 1988; 17:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32950/abstract/55\">",
"      Scharschmidt TJ, Weiner SD, Myers JP. Bacterial Pyomyositis. Curr Infect Dis Rep 2004; 6:393.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7669 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-33CB703E27-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32950=[""].join("\n");
var outline_f32_11_32950=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Predisposing factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Injection drug use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Concurrent infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laboratory data",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7669\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7669|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/53/31580\" title=\"table 1\">",
"      Differential diagnosis myositis and fasciitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/9/5275\" title=\"table 2\">",
"      Risk factors for MRSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/55/41851\" title=\"table 3\">",
"      Abx therapy pyomyositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/61/35803\" title=\"table 4\">",
"      Immunocompromised pyo rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12264?source=related_link\">",
"      Clostridial myonecrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26649?source=related_link\">",
"      Complications of Staphylococcus aureus bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1526?source=related_link\">",
"      Diabetic muscle infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_11_32951="Rectovaginal, anovaginal, and colovesical fistulas";
var content_f32_11_32951=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rectovaginal, anovaginal, and colovesical fistulas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32951/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32951/contributors\">",
"     Marc R Toglia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32951/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32951/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32951/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32951/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/11/32951/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectovaginal and anovaginal fistulas frequently result from obstetric trauma. These fistulas are often seen in undeveloped countries where prolonged obstructed labor leading to pressure necrosis is more common. They also occur following an unsuccessful primary repair of a third or fourth degree laceration, from unrecognized injury at the time of vaginal delivery, and from episiotomy infection with formation of a fistulous tract.",
"   </p>",
"   <p>",
"    Rectovaginal fistulas may also result from difficult hysterectomies, especially those performed for severe endometriosis with involvement or obliteration of the posterior cul-de-sac (pouch of Douglas), and from surgical procedures involving the posterior vaginal wall, perineum, anus, and rectum. Inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, is another important cause of rectovaginal fistulas in women. In elderly women, rectovaginal fistulas can occur as the result of diverticulitis, colon cancer, or fecal impaction.",
"   </p>",
"   <p>",
"    Fistula-in-ano describes a communication between the anal canal and the perianal skin or perineum. These fistulas are typically initiated by an infection such as an anal abscess, trauma, anal fissure, or Crohn's disease, or as a complication of episiotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32951/abstract/1\">",
"     1",
"    </a>",
"    ]. Anatomically, the fistula may originate anywhere below the dentate line internally and exists externally along the perianal skin or perineum. Histologically, fistula-in-ano differs from anovaginal fistulas in that the fistulous tract is typically lined with chronically inflamed granulation tissue, rather than the epithelialized tract typical of anovaginal and rectovaginal fistulas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women suffering from anovaginal or rectovaginal fistulas present with complaints of uncontrollable passage of gas or feces from the vagina. A malodorous vaginal discharge and fecal soiling of the undergarments are also common complaints. Symptoms may be more pronounced when bowel movements are loose. Occasionally, a small fistula may be asymptomatic. It is important to inquire about fecal urgency and fecal incontinence associated with urgency as this often suggests that the external anal sphincter is also disrupted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/29/34263?source=see_link\">",
"     \"Delayed surgical management of the disrupted anal sphincter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinically, fistula-in-ano differs from anovaginal and rectovaginal fistulas in that rectal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vaginal pain is a prominent symptom with fistula-in-ano, which may reflect its chronic inflammatory etiology. Palpation of the fistulous tract is very uncomfortable for the patient with a fistula-in-ano, in contrast to the relatively painless tract of a rectovaginal or anovaginal fistula. The course of a fistula-in-ano can be complex and circuitous with one or more blind sinus tracts. Their location is usually lateral from the midline, whereas most anovaginal and rectovaginal fistulas are located close to the midline (related to their obstetric origin).",
"   </p>",
"   <p>",
"    Most anovaginal and rectovaginal fistulas of obstetric origin are located in the lower third of the vagina, just inside the introitus. They are readily apparent on physical examination as a red velvety indented area along the posterior vaginal wall. There is often thinning of the rectovaginal septum and tenting of the anal mucosa, which are palpable on rectal examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is critical that the clinician evaluate the entire sphincteric mechanism in women with rectovaginal fistulas to exclude coexisting causes for incontinence, such as a disrupted anal sphincter. Although concomitant sphincter injury has been reported to exist in up to one-third of women presenting with rectovaginal fistulas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32951/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], concomitant internal or external sphincter injuries (or both) are probably more frequent when the location of the fistula is within the distal 3 cm of the anal canal. Anatomic and physiologic studies have shown that this is the normal length of the sphincter complex. Failure to recognize and repair such a sphincter injury may result in continued incontinence following a successful fistulectomy.",
"   </p>",
"   <p>",
"    Pinpoint fistulas can be difficult to locate. The use of magnification, such as a colposcope, may be helpful. Lacrimal duct or silver wire probes can also be used to assist in identifying the fistula tract. A few drops of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    dye can be mixed with lubricating gel and massaged into the anterior rectal wall. Alternatively, an enema consisting of warmed saline and a few drops of methylene blue dye can be instilled into the rectum using a genitourinary syringe. Using a peroxide solution will avoid staining the tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32951/abstract/3\">",
"     3",
"    </a>",
"    ]. Proctoscopy may also be useful in visualizing the fistulous tract from the rectal side. The role of imaging tests in the diagnosis of fistulas is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39319?source=see_link\">",
"     \"The role of imaging tests in the evaluation of anal abscesses and fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF ANTERIOR PERINEAL AND RECTOVAGINAL DEFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"rectovaginal fistula\" is commonly used in clinical practice to describe all fistulas that involve the bowel and vagina. However, it is preferable to describe these fistulas based upon the anatomic site of the communication.",
"   </p>",
"   <p>",
"    Fistulas that occur within the first 3 cm from the anal orifice and below the dentate line are called anovaginal fistulas. Fistulas cephalad to the dentate line are truly rectovaginal. In 1980, Rosenshein and associates proposed an anatomic classification of perineal and rectovaginal defects designed to assist clinical management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32951/abstract/4\">",
"     4",
"    </a>",
"    ], modifications have subsequently been proposed (",
"    <a class=\"graphic graphic_figure graphicRef52917 \" href=\"mobipreview.htm?35/43/36534\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32951/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The distinction between an anovaginal fistulas and rectovaginal fistula is important, as the anal sphincter complex is invariably involved with an anovaginal fistula. Fistulas of the colon above the rectum are referred to as colovaginal fistulas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TIMING OF REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most rectovaginal and anovaginal fistulas are amenable to early repair. The decision of when to operate should depend upon the status of the involved tissue rather than an arbitrary period of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32951/abstract/1\">",
"     1",
"    </a>",
"    ]. Surgical repair should be deferred until there is resolution of any local cellulitis, inflammation, or induration. If wound infection is present, aggressive wound care (eg, sitz baths, debridement) and a 10 to 14-day course of broad-spectrum oral antibiotics should be undertaken. Institution of a low residue diet will decrease the frequency of bowel movements and possibly prevent continuous seeding of the wound with liquid stool. In addition, this may restore some degree of fecal continence. These women should be examined frequently and repair should be performed when all gross evidence of infection, induration, and inflammation has subsided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is neither data nor universal agreement regarding the best preoperative regimen for women undergoing rectal surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary manipulation should be considered in all women undergoing sphincteroplasty or rectovaginal fistula repair. The ultimate goal is to avoid fecal seeding of the wound during the procedure and to decrease the amount of stool that will pass over the repair in the first few weeks of healing. In most cases, a liquid diet should be followed for 24 to 48 hours prior to surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mechanical bowel cleansing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical bowel cleansing is routinely recommended. The authors prefer to give oral agents 48 hours preoperatively because giving them closer to the procedure often results in a thin fecal effluent being present at the time of the repair. Either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    (32 ounces) or Golytely (4 to 6 liters) can be administered at home.",
"   </p>",
"   <p>",
"    Tap water or Fleet enemas should be given the night before surgery to complete the emptying of the lower colon and rectum. Alternatively, a fleet enema can be given an hour prior to surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We administer a single dose of a broad spectrum antibiotic, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    , intravenously 30 minutes before the procedure. For patients with a Beta lactam allergy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    can be used as an alternative regimen. Additional antibiotic therapy is typically not indicated, unless there is fecal soiling during the procedure. In all cases, prophylactic antibiotics should be discontinued within 24 hours of the surgical procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SURGICAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic principles essential for successful fistula repair include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wide mobilization of the adjacent tissue planes",
"     </li>",
"     <li>",
"      Complete excision of the fistula tract",
"     </li>",
"     <li>",
"      Multilayered closure, which reapproximates broad tissue surfaces without tension",
"     </li>",
"     <li>",
"      Proper timing of the repair.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Choice of suture",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer to use delayed absorbable sutures, such as polyglactin or polyglycolic acid, instead of chromic catgut in the repair of these fistulas. The tensile strength is maintained longer and the knot is more secure and smaller in size than with catgut. Tissue reaction is also less with delayed absorbable suture. There may also be a role for small diameter monofilament delayed absorbable and permanent sutures in these repairs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adjuvant techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Modified Martius graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of a modified Martius bulbocavernosus muscle or labial fat pad graft has improved the success rate in closure of large or difficult vesicovaginal and rectovaginal fistulas. The procedure involves transplanting a vascular graft with healthy tissue to the repair site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32951/abstract/8\">",
"     8",
"    </a>",
"    ]. A vertical incision is made over the labia majora (",
"    <a class=\"graphic graphic_figure graphicRef64244 \" href=\"mobipreview.htm?17/38/18017\">",
"     figure 2",
"    </a>",
"    ). The superficial fibroadipose tissue is sharply mobilized with care taken to preserve the blood supply of the graft either superiorly or inferiorly (",
"    <a class=\"graphic graphic_figure graphicRef74982 \" href=\"mobipreview.htm?14/40/14979\">",
"     figure 3",
"    </a>",
"    ). For most rectovaginal fistulas, the base of the pedicle should be on the inferior border of the graft, thus allowing the graft to be rotated medially without significant tension. The graft is tunneled subcutaneously beneath the vaginal mucosa and labia minora to overlay the repaired fistula site (",
"    <a class=\"graphic graphic_figure graphicRef50922 \" href=\"mobipreview.htm?19/56/20355\">",
"     figure 4",
"    </a>",
"    ) and secured at its edges with interrupted sutures of 3-0 chromic or delayed absorbable suture (",
"    <a class=\"graphic graphic_figure graphicRef65715 \" href=\"mobipreview.htm?24/12/24770\">",
"     figure 5",
"    </a>",
"    ). The labial incision is repaired in two layers (",
"    <a class=\"graphic graphic_figure graphicRef78486 \" href=\"mobipreview.htm?7/43/7857\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A modified Martius graft should be considered in patients with inflammatory bowel disease, irradiation-induced fistulas, and those who have failed previous attempts at closure. It should also be considered in the repair of rectovaginal fistulas located in the middle to upper third of the vaginal vault, where there may not be sufficient tissue to transpose between the vagina and the rectum. The labial fat pad graft provides neovascularity, fills in dead space, and enhances granulation tissue formation. It is doubtful, however, that it provides any significant structural support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Diverting colostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There continues to be a role for diverting colostomy in the management of radiation-induced fistulas, large rectovaginal defects (greater than 4 cm in diameter), and some fistulas secondary to inflammatory bowel disease, in which diversion of the fecal stream is felt to be critical to the success of the repair. A diverting colostomy is typically not indicated in the management of most anovaginal and rectovaginal fistulas.",
"   </p>",
"   <p>",
"    Surgical repair of the fistula should be delayed until all evidence of inflammation and cellulitis has resolved, typically 8 to 12 weeks after the colostomy. Take down of the colostomy is usually performed three to four months after the fistula repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     REPAIR TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair techniques vary significantly by fistula type and etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Small rectovaginal fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are often related to obstetric delivery or trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Simple fistulectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small rectovaginal fistulas can often be repaired by simple fistulectomy via a transvaginal or transrectal approach. An incision is made around the fistula, which completely excises the fistulous tract and allows mobilization of the vagina, rectum, and rectovaginal septum to create a tension-free closure (",
"    <a class=\"graphic graphic_figure graphicRef77833 \" href=\"mobipreview.htm?16/10/16545\">",
"     figure 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81075 \" href=\"mobipreview.htm?8/61/9169\">",
"     figure 8",
"    </a>",
"    ). The surgeon's nondominant index finger can be inserted into the rectum during the procedure to assist the repair. Sharp mobilization of the vagina and rectum in a circumferential fashion should be accomplished first, by providing traction and countertraction on the edges of the fistula (",
"    <a class=\"graphic graphic_figure graphicRef73114 \" href=\"mobipreview.htm?28/45/29392\">",
"     figure 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    After the tissue planes are widely mobilized, the entire fistulous tract and any adjacent scar tissue are excised (",
"    <a class=\"graphic graphic_figure graphicRef56251 \" href=\"mobipreview.htm?13/24/13696\">",
"     figure 10",
"    </a>",
"    ). The edges of the \"new\" surgical fistula should contain fresh, viable tissue. The edges of the anterior rectal wall are then inverted, either by placing interrupted submucosal stitches of 3-0 or 4-0 delayed absorbable sutures (",
"    <a class=\"graphic graphic_figure graphicRef52097 \" href=\"mobipreview.htm?2/4/2113\">",
"     figure 11",
"    </a>",
"    ) or by placing a pursestring suture. The most cephalad and most distal sutures should be placed at least 5 mm above and below the fistula. A second layer of suture (2-0 delayed absorbable) is then placed in the muscularis of the anterior rectal wall to invert and take tension off of the first suture line (",
"    <a class=\"graphic graphic_figure graphicRef63815 \" href=\"mobipreview.htm?5/20/5442\">",
"     figure 12",
"    </a>",
"    ). This layer should begin and end approximately 5 mm above and below the initial suture line.",
"   </p>",
"   <p>",
"    The pararectal fascia or puborectalis muscle is then approximated to provide a third layer of closure (",
"    <a class=\"graphic graphic_figure graphicRef75611 \" href=\"mobipreview.htm?40/4/41024\">",
"     figure 13",
"    </a>",
"    ). If deemed necessary, a modified Martius graft can be interposed before this step. Finally, the vaginal mucosa is approximated with a continuous 3-0 suture (",
"    <a class=\"graphic graphic_figure graphicRef55071 \" href=\"mobipreview.htm?10/39/10867\">",
"     figure 14",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Meticulous care must be taken to ensure complete hemostasis and closure of all potential dead space. A small pack soaked in a very dilute Betadine solution, or a petroleum impregnated gauze, may be placed in the vagina loosely and serves as a wick to absorb any seepage from the wound during the first 18 to 24 hours postoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Transsphincteric approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anovaginal and low rectovaginal fistulas resulting from obstetric trauma frequently require reanastomosis of the external and internal anal sphincters and reconstruction of the perineal body and rectovaginal septum. A small bridge of perineal skin is often the only intact tissue in these women. The preferred approach in these cases is a midline perineal incision (transsphincteric or perineoproctomy) with wide mobilization of the posterior vaginal wall followed by a multilayered closure as described for a chronic third-or fourth-degree laceration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/29/34263?source=see_link\">",
"     \"Delayed surgical management of the disrupted anal sphincter\"",
"    </a>",
"    .) It is important that the fistula tract be excised in its entirety, as discussed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Transverse transperineal approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectovaginal fistulas located above the sphincter complex can also be approached with a transverse transperineal incision. This approach allows the surgeon to preserve the intact internal and external anal sphincter and allows wide mobilization of the rectal and vaginal tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32951/abstract/9\">",
"     9",
"    </a>",
"    ]. A transverse incision is made across the perineal body above the sphincter complex and dissection is carried out between the anterior rectal wall and the posterior vaginal wall to mobilize the tissues widely laterally and cephalad to the fistula tract (",
"    <a class=\"graphic graphic_figure graphicRef62973 \" href=\"mobipreview.htm?30/59/31666\">",
"     figure 15",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef77809 \" href=\"mobipreview.htm?30/38/31330\">",
"     figure 16",
"    </a>",
"    ). Dissection above the fistula tract is usually easy because the vagina and rectum are only loosely connected above this point.",
"   </p>",
"   <p>",
"    The fistula tract and any adjacent scar tissue are then excised (",
"    <a class=\"graphic graphic_figure graphicRef57814 \" href=\"mobipreview.htm?9/9/9362\">",
"     figure 17",
"    </a>",
"    ) with Metzenbaum scissors. The rectal wall defect can be closed either longitudinally or transversely with interrupted 3-0 or 4-0 delayed absorbable suture to invert the rectal mucosa without tension. We prefer to close the layers longitudinally in all but the smallest fistulas (",
"    <a class=\"graphic graphic_figure graphicRef64462 \" href=\"mobipreview.htm?9/30/9700\">",
"     figure 18",
"    </a>",
"    ). By closing the rectal mucosal and perirectal fascial layers longitudinally, the anal canal is lengthened, which may help to reestablish the high-pressure zone of the anal canal. Closing the vaginal mucosa and perineal body longitudinally helps to avoid narrowing the vaginal introitus and also lengthens the perineal body.",
"   </p>",
"   <p>",
"    Alternatively, the rectal and vaginal defects may be closed in perpendicular directions to avoid overlying suture lines. With this approach, the rectal defect should be closed transversely and the vaginal mucosa closed longitudinally to minimize narrowing of the vaginal introitus or creation of a transverse ridge across the posterior vaginal wall, which can cause dyspareunia.",
"   </p>",
"   <p>",
"    The second layer of closure is placed into the muscularis of the rectum in the same direction as the first layer, thus imbricating the first layer and reinforcing the closure (",
"    <a class=\"graphic graphic_figure graphicRef77342 \" href=\"mobipreview.htm?41/10/42148\">",
"     figure 19",
"    </a>",
"    ). The puborectalis muscles are approximated in the midline, providing an additional reinforcing layer between the anterior rectal and posterior vaginal walls (",
"    <a class=\"graphic graphic_figure graphicRef55330 \" href=\"mobipreview.htm?29/42/30371\">",
"     figure 20",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The subcutaneous tissues and skin of the perineal body can be approximated with a running nonlocking closure. The skin is closed with interrupted mattress sutures or a running closure of 4-0 delayed absorbable suture (",
"    <a class=\"graphic graphic_figure graphicRef64822 \" href=\"mobipreview.htm?0/46/739\">",
"     figure 21",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     High rectovaginal fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;This type of fistula occurs after pelvic radiation; as a complication following pelvic surgery for endometriosis or diverticular disease; or associated with a pelvic or rectal malignancy. Less commonly, it can be seen with inflammatory bowel disease. In third world nations, high rectovaginal fistulas due to extended tissue ischemia and subsequent necrosis are observed following prolonged, obstructed labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Transabdominal approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abdominal approach with sharp dissection of the rectum from the vagina is occasionally needed to repair a high rectovaginal fistula located near the vaginal apex. The transabdominal approach is facilitated by use of long instruments and retractors, such as those used in thoracic or deep pelvic surgery.",
"   </p>",
"   <p>",
"    It is imperative that the rectum and vagina be widely mobilized from the fistulous communication. Serosal dissection on the colonic side of the fistula site can be extensive, especially when the defect is large. However, excessive dissection can disrupt a significant portion of the blood supply to the bowel, thereby interfering with successful closure and healing of the fistula. The fistula should be excised or inverted, followed by multilayered closure of the rectum and vagina. If extensive bowel ischemia is present, complete transection of the compromised segment of bowel with a colorectal reanastomosis is often preferable to a layered closure of the fistula. Occasionally, extensive bowel ischemia (eg, radiation induced) may necessitate using a permanent diverting colostomy as the primary procedure.",
"   </p>",
"   <p>",
"    Adjuvant procedures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An omental J-flap can be created by dissecting the omentum from its attachment to the transverse colon, while leaving it attached to the stomach. A J-shaped incision is then made approximately 4 cm inside the lateral border of the omentum adjacent to the edge of the stomach, down past the most distal and lateral termination of the mesenteric vessels within the omental apron. This partially detached flap is rotated down to the fistula site and sutured in place between the rectum and the vagina.",
"     </li>",
"     <li>",
"      A segment of the rectus abdominis muscle can be interposed between the rectum and vagina. This provides excellent neovascularity and tissue support to the fistula repair site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Colovesical fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colovesical fistulas are rare. They are usually associated with the same conditions and disease processes that cause the high rectovaginal fistulas discussed above. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42819?source=see_link\">",
"     \"Acute diverticulitis complicated by fistula formation\"",
"    </a>",
"    .) In some instances, a diverting colostomy may be necessary to divert the fecal stream and minimize the risks of ascending urinary tract infection and renal damage while tissue inflammation subsides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Abdominal approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abdominal approach may take one of two routes. The posterior bladder can be dissected completely off of the rectum. A multilayered closure of each organ, followed by an omental or muscle interpositional flap (see above, omental j flap or rectus abdominis flap), will usually be successful.",
"   </p>",
"   <p>",
"    Alternatively, a transvesical approach may be attempted. The dome of the bladder is opened and the fistula tract and ureteral orifices are identified. The bladder serosa is dissected from the vagina and colon through the fistula tract within the bladder mucosa. Even with careful dissection and a multilayered closure, the failure rate is significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Complicated fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fistulas may be complicated because of their size, location, associated pathology, or recurrence. Complicated fistulas often need a different surgical approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Radiation-induced fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fistula formation following radiotherapy is believed to be the result of progressive endarteritis obliterans and tissue hypoxia. These fistulas may occur years after the completion of radiotherapy, can be large, and are located high in the posterior vaginal wall. They are often associated with rectal stricture due to perirectal fibrosis. Refinements in modern radiotherapy have led to a decline in radiation-induced fistulas.",
"   </p>",
"   <p>",
"    Successful closure frequently necessitates extensive excision of the surrounding damaged tissue. One series of 10 women with radiation induced fistulas reported good success with a layered closure and interposition of a modified Martius graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32951/abstract/10\">",
"     10",
"    </a>",
"    ]. The author described five steps essential to the successful closure of these fistulas:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The margins should be biopsied to exclude recurrent or persistent malignancy.",
"     </li>",
"     <li>",
"      A diverting colostomy should be done before the repair.",
"     </li>",
"     <li>",
"      Surgical repair should be delayed at least six months to allow the radiation-induced damage to come to a halt.",
"     </li>",
"     <li>",
"      The repair should include interposition of tissue with a new blood supply (eg, Martius graft).",
"     </li>",
"     <li>",
"      The closure should be carefully layered without tension on the suture lines.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, another study describing successful closure of 14 radiation-induced fistulas using a Martius graft noted that fistula recurred in eight of these women during 10 years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32951/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High rectovaginal fistulas caused by radiation therapy occasionally need to be approached abdominally. After mobilizing the rectum from the vagina, all of the scarred, fibrous, and nonviable tissue should be resected from around the fistulous site. The rectosigmoid can be divided and interposed over the fistula site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32951/abstract/12\">",
"     12",
"    </a>",
"    ]. The advantage of this technique is the interpositioning flap retains its original vascular supply.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Fistulas due to inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectovaginal fistulas associated with inflammatory bowel disease (Crohn's disease, ulcerative colitis) pose a challenging problem for both gynecologists and colorectal surgeons. Successful repair is dependent upon controlling the disease process itself and timing the repair during periods of remission. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26246?source=see_link\">",
"     \"Perianal abscess: Clinical manifestations, diagnosis, treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rectovaginal fistulas are not uncommon with Crohn's disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    .) These fistulas may be single or multiple and a single vaginal orifice may lead to several tracts leading to the anus with microabscesses along the tracts. Determining the optimal time to attempt local repair should be done in conjunction with a gastroenterologist. Not only should the woman's symptoms be quiescent, but there should also be no evidence of active rectal disease on proctoscopy. These women should be counseled that they are at high risk for recurrence or development of a new fistula.",
"   </p>",
"   <p>",
"    A transverse, transperineal approach is often ideal in these women as the sphincter complex tends to be uninvolved. All branches of the fistulous tract should be resected. A modified Martius graft should be considered to bring in additional tissue and blood supply, and to fill in large tissue defects, which may result from complete excision of the affected area. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25273?source=see_link\">",
"     \"Perianal complications of Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no universal agreement on how women should be treated postoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary manipulation should be considered to decrease the amount of stool that will pass over the repair in the first few weeks of healing. A clear liquid diet is prescribed for the first 24 to 72 postoperative hours. A low residue diet should then be instituted for at least three to four weeks. The low residue diet should be discontinued if constipation develops.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Bowel regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stool softener should be given for one month to lubricate the stool. If the patient complains of constipation, milk of magnesia (or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    ) can be given to encourage a looser stool. Enemas should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     General care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulation should not be discouraged. Women should be instructed in wound care and taught how to perform Sitz baths starting two to three days following the procedure. A heat lamp or a blow dryer on a cool setting can also be used to keep the area dry. It is probably unnecessary to keep these women in the hospital until their first bowel movement. Most can be discharged home on the first postoperative day, as long as they are seen within a week to have the incision examined. While on a low residue diet, it is common to have a bowel movement as infrequently as twice weekly.",
"   </p>",
"   <p>",
"    Urinary retention is not an uncommon complication following fistula repair. It is reasonable to place a Foley catheter and a vaginal pack at the end of the surgical procedure and to remove them both on the evening of the surgery, or alternatively, the morning of the first postoperative day. Antibiotics in the postoperative period are probably unnecessary in the absence of clinical infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/2/15393?source=see_link\">",
"       \"Patient information: Rectovaginal fistula (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most anovaginal and rectovaginal fistulas seen in the United States are obstetrical in origin and are frequently associated with an underlying sphincter defect. We suggest that women with these types of fistulas be evaluated for the intactness of the anal sphincter complex prior to planning surgical repair. Transanal or transperineal ultrasound can be helpful in visualizing the sphincter complex.",
"     </li>",
"     <li>",
"      Women with Crohn's disease pose a particular challenge in the management of anovaginal and rectovaginal fistulas, as recurrences, wound breakdown and occurrence of new fistulas are high. We suggest managing these patients in coordination with a colorectal or gastrointestinal specialist.",
"     </li>",
"     <li>",
"      The basic principles for surgical repairs include wide mobilization of adjacent tissue planes, complete excision of the fistulous tract and multi-layered closure.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32951/abstract/1\">",
"      Hibbard LT. Surgical management of rectovaginal fistulas and complete perineal tears. Am J Obstet Gynecol 1978; 130:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32951/abstract/2\">",
"      Corman ML. Anal incontinence following obstetrical injury. Dis Colon Rectum 1985; 28:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32951/abstract/3\">",
"      Shieh CJ, Gennaro AR. Rectovaginal fistula: a review of 11 years experience. Int Surg 1984; 69:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32951/abstract/4\">",
"      Rosenshein NB, Genadry RR, Woodruff JD. An anatomic classification of rectovaginal septal defects. Am J Obstet Gynecol 1980; 137:439.",
"     </a>",
"    </li>",
"    <li>",
"     Thompson, JD. Relaxed vaginal outlet, rectocele, fecal incontinence, and rectovaginal fistula. p. 941. In Thompson JD, Rock JA (eds): TeLinde's Operative Gynecology. 7th Ed. JB Lippincott, Philadelphia, 1992.",
"    </li>",
"    <li>",
"     Baden, WF, Walker, T (eds). Fundamentals, symptoms, and classification. p. 9. In Surgical Repair of Vaginal Defects. JB Lippincott, Philadelphia, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32951/abstract/7\">",
"      Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg 1976; 63:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32951/abstract/8\">",
"      Elkins TE, DeLancey JO, McGuire EJ. The use of modified Martius graft as an adjunctive technique in vesicovaginal and rectovaginal fistula repair. Obstet Gynecol 1990; 75:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32951/abstract/9\">",
"      Wiskind AK, Thompson JD. Transverse transperineal repair of rectovaginal fistulas in the lower vagina. Am J Obstet Gynecol 1992; 167:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32951/abstract/10\">",
"      Boronow RC. Repair of the radiation-induced vaginal fistula utilizing the Martius technique. World J Surg 1986; 10:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32951/abstract/11\">",
"      Aartsen EJ, Sindram IS. Repair of the radiation induced rectovaginal fistulas without or with interposition of the bulbocavernosus muscle (Martius procedure). Eur J Surg Oncol 1988; 14:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32951/abstract/12\">",
"      Bricker EM, Johnston WD, Patwardhan RV. Repair of postirradiation damage to colorectum: a progress report. Ann Surg 1981; 193:555.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1385 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32951=[""].join("\n");
var outline_f32_11_32951=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASSIFICATION OF ANTERIOR PERINEAL AND RECTOVAGINAL DEFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TIMING OF REPAIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mechanical bowel cleansing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SURGICAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Choice of suture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adjuvant techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Modified Martius graft",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Diverting colostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      REPAIR TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Small rectovaginal fistulas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Simple fistulectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Transsphincteric approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Transverse transperineal approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      High rectovaginal fistulas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Transabdominal approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Colovesical fistula",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Abdominal approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Complicated fistulas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Radiation-induced fistulas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Fistulas due to inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Bowel regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      General care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/1385\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1385|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/43/36534\" title=\"figure 1\">",
"      Anal Rectal Fistulas Parks classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/38/18017\" title=\"figure 2\">",
"      Modified Martius fat pad graft",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/40/14979\" title=\"figure 3\">",
"      Modified Martius fat pad graft2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/56/20355\" title=\"figure 4\">",
"      Modified Martius fat pad graft3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/12/24770\" title=\"figure 5\">",
"      Modified Martius fat pad graft4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/43/7857\" title=\"figure 6\">",
"      Modified Martius fat pad graft5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/10/16545\" title=\"figure 7\">",
"      Exposing rectovaginal fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/61/9169\" title=\"figure 8\">",
"      Incision rectovaginal fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/45/29392\" title=\"figure 9\">",
"      Mobilizing vagina and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/24/13696\" title=\"figure 10\">",
"      Excision rectovaginal fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/4/2113\" title=\"figure 11\">",
"      Closure rectovaginal fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/20/5442\" title=\"figure 12\">",
"      Closure rectovaginal fistula2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/4/41024\" title=\"figure 13\">",
"      Closure rectovaginal fistula3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/39/10867\" title=\"figure 14\">",
"      Closure rectovaginal fistula4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/59/31666\" title=\"figure 15\">",
"      Transperineal fistula repair1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/38/31330\" title=\"figure 16\">",
"      Transperineal fistula repair2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/9/9362\" title=\"figure 17\">",
"      Transperineal fistula repair3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/30/9700\" title=\"figure 18\">",
"      Transperineal fistula repair4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/10/42148\" title=\"figure 19\">",
"      Transperineal fistula repair5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/42/30371\" title=\"figure 20\">",
"      Transperineal fistula repair6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/46/739\" title=\"figure 21\">",
"      Reapproximation perineal body",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42819?source=related_link\">",
"      Acute diverticulitis complicated by fistula formation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/29/34263?source=related_link\">",
"      Delayed surgical management of the disrupted anal sphincter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/2/15393?source=related_link\">",
"      Patient information: Rectovaginal fistula (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26246?source=related_link\">",
"      Perianal abscess: Clinical manifestations, diagnosis, treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25273?source=related_link\">",
"      Perianal complications of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39319?source=related_link\">",
"      The role of imaging tests in the evaluation of anal abscesses and fistulas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_11_32952="Vulvar intraepithelial neoplasia";
var content_f32_11_32952=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vulvar intraepithelial neoplasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32952/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32952/contributors\">",
"     Christine H Holschneider, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32952/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32952/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32952/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32952/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/11/32952/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2004, the Vulvar Oncology Subcommittee of the International Society for the Study of Vulvar Diseases (ISSVD) developed the current classification system for vulvar intraepithelial neoplasia (VIN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/1\">",
"     1",
"    </a>",
"    ]. This disorder is classified into two main groups:",
"   </p>",
"   <p>",
"    &nbsp;(1) VIN, usual type, which encompasses the former subcategories of VIN, warty type; VIN, basaloid type; and VIN, mixed (warty, basaloid) type",
"   </p>",
"   <p>",
"    &nbsp;(2) VIN, differentiated type, which encompasses the former category simplex type",
"   </p>",
"   <p>",
"    Rare cases that do not fit into these categories are termed \"unclassified type.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously, VIN was categorized as VIN 1, 2 and 3, according to the degree of abnormality (",
"    <a class=\"graphic graphic_table graphicRef67918 \" href=\"mobipreview.htm?6/23/6523\">",
"     table 1",
"    </a>",
"    ). Since there is no evidence that what had been termed VIN 1 is a cancer precursor requiring treatment, the ISSVD committee recommended that the term VIN be limited to histologically high-grade squamous lesions (formerly termed VIN 2 and VIN 3) for which treatment is indicated to prevent progression to cancer. This topic review will adhere to the 2004 ISSVD nomenclature whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of VIN is increasing worldwide, primarily due to the increasing occurrence of this disease in young women, who account for 75 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In a study based on data from a United States national cancer database, in 2000 the incidence of VIN 3 was 2.86 per 100,000 women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence of vulvar cancer is also increasing, but at a slower rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     VIN, USUAL TYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;VIN lesions can be subdivided based on their morphologic and histological features (",
"    <a class=\"graphic graphic_picture graphicRef67283 \" href=\"mobipreview.htm?35/35/36409\">",
"     picture 1",
"    </a>",
"    ). Although each of these types of VIN exist in pure form, mixtures of warty and basaloid VIN are common and are now classified together as usual type.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The basaloid subtype has a thickened epithelium with a relatively flat, smooth surface. Histologically, it consists of atypical immature parabasal type cells with numerous mitotic figures and enlarged hyperchromatic nuclei.",
"     </li>",
"     <li>",
"      The warty (condylomatous) subtype is characterized by a surface that is undulating or spiking, giving it a condylomatous appearance. Histologically, it consists of marked cellular proliferation with numerous mitotic figures and abnormal maturation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    VIN, usual type typically occurs in younger, premenopausal women. Risk factors are similar to those for vulvar cancer of the warty or basaloid type, and include human papillomavirus (HPV) infection, cigarette smoking, and immunodeficiency or immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human papillomavirus &mdash; Almost 90 percent of all VIN lesions test positive for HPV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/8\">",
"       8",
"      </a>",
"      ]. HPV has been associated with both VIN and vulvar cancer of the warty and basaloid subtypes. Multifocal VIN and multicentric VIN are most often associated with high oncogenic risk HPV subtypes 16, 18, and 31 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/9-12\">",
"       9-12",
"      </a>",
"      ], and should be considered premalignant lesions. In contrast, vulvar condyloma acuminata and the former VIN 1 are usually, but not exclusively, associated with low oncogenic risk HPV subtypes 6 and 11. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=see_link&amp;anchor=H3#H3\">",
"       \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\", section on 'Role of human papillomavirus'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23144?source=see_link\">",
"       \"Condylomata acuminata (anogenital warts)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cigarette smoking &mdash; Cigarette smoking has been consistently associated with development of VIN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. As an example, one series reported 27 of 40 women with VIN were cigarette smokers compared to 5 of 40 age-matched women with nonneoplastic vulvar disease (68 versus 13 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/16\">",
"       16",
"      </a>",
"      ]. The mechanism for the association is unknown.",
"     </li>",
"     <li>",
"      Immunodeficiency &mdash;",
"      <span class=\"nowrap\">",
"       Vulvar/perianal",
"      </span>",
"      intraepithelial neoplasia is more common in women infected with human immunodeficiency virus (HIV) than in uninfected controls. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/19/6455?source=see_link\">",
"       \"Vulvar and vaginal intraepithelial neoplasia in HIV-infected women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anogenital epithelium is derived from the embryonic cloaca and includes the cervix, vagina, vulva, anus, and lower three centimeters of rectal mucosa up to the dentate line. Since the entire region shares the same embryological origin and is susceptible to similar exogenous agents (eg, HPV infection), squamous intraepithelial lesions in this area are often both multifocal (ie, multiple foci of disease within the same organ) and multicentric (ie, foci of disease involving more than one organ).",
"   </p>",
"   <p>",
"    VIN, usual type is often multifocal and multicentric. The interlabial grooves, posterior fourchette, and perineum are most frequently affected by multifocal lesions; more extensive disease is often confluent, involving the labia majora, minora, and perianal skin. Confluent or multifocal lesions exist in up to two-thirds of women with VIN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 60 percent of women with vaginal intraepithelial neoplasia (VAIN) 3 or VIN have preexisting or synchronous cervical intraepithelial neoplasia (CIN), and close to 10 percent of women with CIN 3 have concomitant preinvasive disease at other sites (eg, 3 percent have VAIN 3 and 7 percent have VIN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/9,18,19\">",
"     9,18,19",
"    </a>",
"    ]. There is also evidence that some cases of high grade VIN and VAIN represent a monoclonal lesion derived from high grade or malignant cervical lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     VIN, DIFFERENTIATED TYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiated VIN comprises less than 5 percent of VIN and typically occurs in postmenopausal women. It is usually unifocal and unicentric and often associated with lichen sclerosus, but not with HPV infection.",
"   </p>",
"   <p>",
"    Differentiated VIN is commonly found adjacent to keratinizing squamous cell carcinoma or in patients with a history of vulvar cancer. The differentiated (simplex) type refers to lesions in which the epithelium is thickened and parakeratotic with elongated and anastomosing rete ridges. The abnormal cells are confined to the parabasal and basal portion of the rete pegs with little or no atypia above the basal or parabasal layers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/21\">",
"     21",
"    </a>",
"    ]. The basal cells usually stain positively for p53, and p53 positive cells extend above the basal layers into the upper layers of the epidermis. Differentiated VIN is probably a precursor of HPV-negative vulvar cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus is the most common complaint among symptomatic women. Other presentations include a visible lesion (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Physical examination'",
"    </a>",
"    below), a palpable abnormality, perineal pain or burning, or dysuria. Approximately 50 percent of women are asymptomatic and are diagnosed either when a lesion is observed during a routine gynecological examination or at colposcopy for abnormal cervical cytology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue biopsy is necessary for a definitive diagnosis. Appropriate sites for biopsy are identified by physical examination and colposcopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gynecological examination should include thorough inspection and palpation of the vulva and groin for masses, ulceration, or color changes. Most VIN lesions are multifocal and located in the nonhairy part of the vulva [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/24\">",
"     24",
"    </a>",
"    ]. The lesions are often raised or verrucous and white (",
"    <a class=\"graphic graphic_picture graphicRef72661 \" href=\"mobipreview.htm?17/26/17827\">",
"     picture 2",
"    </a>",
"    ), but the color may be red (",
"    <a class=\"graphic graphic_picture graphicRef74997 \" href=\"mobipreview.htm?31/0/31745\">",
"     picture 3",
"    </a>",
"    ), pink, gray, or brown (",
"    <a class=\"graphic graphic_picture graphicRef75216 \" href=\"mobipreview.htm?20/15/20725\">",
"     picture 4",
"    </a>",
"    ). Macular lesions mostly occur on adjacent mucosal surfaces. There is no pathognomonic clinical appearance, and more than one of these patterns may be seen in the same patient. Suspicious lesions should be biopsied.",
"   </p>",
"   <p>",
"    Lichen sclerosus or lichen planus, condylomata acuminata, and condyloma lata can mimic VIN. If one of these disorders is suspected clinically but the lesion does not completely resolve or is refractory to therapy, then it should be biopsied to obtain a definitive diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Colposcopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colposcopy may identify subclinical lesions not appreciated on physical examination and helps to define the extent of disease and guide biopsy. Because of the high prevalence of multicentric synchronous or metachronous intraepithelial lesions, comprehensive colposcopic evaluation of the entire lower genital tract and perianal area is indicated in any patient with VIN. If colposcopy is not available, a hand lens provides similar magnification and is easy to use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=see_link\">",
"     \"Colposcopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cotton balls containing 2 to 5 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    are applied to the vulva for several minutes prior to the procedure. Intraepithelial neoplasia produces well-demarcated, dense acetowhite lesions with or without punctation. Vascular abnormalities are a sign of invasive cancer, although high-grade preinvasive lesions may have subtle or absent vascular patterns. Some clinicians then paint the vulva with 1 percent toluidine blue, which is washed off with 1 percent acetic acid after two minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Any abnormal areas will retain the blue dye and should be biopsied. However, false positives may occur due to infection or nonneoplastic ulceration, while false negatives may occur in thick hyperkeratotic lesions, ulcers, and abraded areas, which absorb only a small amount of dye.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biopsy site is infiltrated with a local anesthetic. For punch biopsies, the Keys dermatologic biopsy instrument enables accurate orientation of the specimen and evaluation of its full thickness for microinvasion. Disposable instruments for this purpose are available. Multiple biopsies may be required when there are multifocal lesions.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/18/19747?source=see_link\">",
"     Ferric subsulfate",
"    </a>",
"    (Monsel's solution) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    can be used for hemostasis; a suture is rarely needed.",
"   </p>",
"   <p>",
"    Excisional biopsies should be performed if a punch biopsy does not yield a satisfactory pathological specimen or for select cases with extensive ulceration or induration. Lesions potentially suspicious for melanoma should always be evaluated with an excisional biopsy to provide a specimen that is appropriate for microstaging (ie, skin specimen is examined microscopically to determine tumor thickness and depth).",
"   </p>",
"   <p>",
"    VIN is frequently found in association with invasive squamous cell cancer (",
"    <a class=\"graphic graphic_picture graphicRef67283 \" href=\"mobipreview.htm?35/35/36409\">",
"     picture 1",
"    </a>",
"    ) or lichen sclerosus or lichen planus. These disorders can be difficult to distinguish from one another, especially when they occur concurrently. Therefore, any lesion on the vulva that is not known to be benign warrants biopsy. A vulva with multiple areas of abnormalities warrants multiple biopsies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/45/6874?source=see_link\">",
"     \"Vulvar lichen sclerosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/5/36952?source=see_link\">",
"     \"Vulvar lichen planus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment are to prevent development of invasive vulvar cancer and relieve symptoms, while preserving normal vulvar anatomy and function. Treatment of VIN must be individualized based upon biopsy results, location and extent of disease, and the woman's symptoms. Management options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wide local excision",
"     </li>",
"     <li>",
"      Skinning vulvectomy",
"     </li>",
"     <li>",
"      Laser ablation",
"     </li>",
"     <li>",
"      Topical treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Excisional treatment has a diagnostic advantage over ablative or medical management modalities in women with VIN since an occult invasive squamous cell carcinoma is present in many of these women; the risk is particularly high in women over age 50 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. Removing the entire lesion for histopathological examination facilitates diagnosis of these cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Surgical",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major surgical interventions for VIN appear to be similarly effective. In a literature review of 1905 surgically treated patients, the frequency of recurrence after vulvectomy, partial vulvectomy, local excision, and laser ablation was 19, 18, 22, and 23 percent, respectively, within 12 to 75 months (mean 39 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The immediate precursor of HPV-negative vulvar squamous cell carcinoma is differentiated VIN. Due to its unifocal nature and high malignant potential, wide local excision is preferred for treatment of differentiated VIN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Wide local excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local excision of an individual lesion with a one centimeter margin followed by reapproximation of the defect generally provides satisfactory cosmetic results. While the gross surgical margin after vulvar resection is reduced by 15 percent when measured in the final fixed specimen, a grossly negative 1 cm margin will rarely harbor significant disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/28\">",
"     28",
"    </a>",
"    ]. Removal of the epidermis provides sufficient depth for treatment of VIN as long as the margins are clear. Removing a small amount of underlying dermis helps to insure the absence of early invasive disease. Excision can be performed with a knife, electrosurgery, or carbon dioxide laser. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/12/14535?source=see_link&amp;anchor=H7472483#H7472483\">",
"     \"Vulvar wide local excision, simple vulvectomy, and skinning vulvectomy\", section on 'Wide local excision'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Laser ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser vaporization was introduced as an alternative to excisional therapy, especially for women with multifocal and extensive lesions. Only one laser treatment is required in 75 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. It is most advantageous when there are multiple small lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Since tissue is ablated rather than excised, the coexistence of invasive cancer must be carefully excluded by liberal use of colposcopically directed biopsies prior to the procedure.",
"   </p>",
"   <p>",
"    The goal of laser vaporization is to treat the entire area of intraepithelial abnormality. Colposcopy is used to control the depth of tissue destruction to less than 1 mm, which will ablate the intraepithelial lesion and allow for rapid healing. While 1 mm depth is sufficient ablation for hair free epithelium, 3 mm depth is required in hairy areas of the vulva because the hair root sheet tends to extend as deep as 2.5 mm and is at significant risk for harboring VIN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Superficial laser vaporization may offer cosmetic advantages over skinning vulvectomy. In contrast, deep laser vaporization results in destruction of the skin appendage, which leads to hypertrophic scar formation, thus negating the cosmetic advantages of laser over excisional surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1062486\">",
"    <span class=\"h3\">",
"     Simple vulvectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple, or total, vulvectomy refers to removal of the entire vulva together with perineal tissues, as indicated, and usually including some subcutaneous tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/35\">",
"     35",
"    </a>",
"    ]. It may be performed for benign and premalignant conditions of the vulva that are extensive or multifocal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/12/14535?source=see_link&amp;anchor=H1063525#H1063525\">",
"     \"Vulvar wide local excision, simple vulvectomy, and skinning vulvectomy\", section on 'Simple vulvectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1062447\">",
"    <span class=\"h3\">",
"     Skinning vulvectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skinning vulvectomy is rarely indicated and is reserved for extensive VIN lesions that are either multifocal or large and confluent. It is used in the small proportion of patients in whom prior treatments such as topical treatments, laser ablation, or smaller excisions have failed to control disease. The procedure requires removing the vulvar skin along a relatively avascular plane beneath the epidermis, while preserving the subcutaneous tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Primary closure can be achieved by either reapproximation or by using a split thickness skin graft. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/12/14535?source=see_link&amp;anchor=H1#H1\">",
"     \"Vulvar wide local excision, simple vulvectomy, and skinning vulvectomy\", section on 'Skinning vulvectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Medical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative therapies aimed at preserving the vulvar anatomy have been attempted, particularly in younger patients. Careful colposcopic examination with biopsies to exclude invasive disease is mandatory prior to beginning treatment with any of these drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Imiquimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    cream (Aldara&reg;) is a topical immune response modifier; its antiviral and antitumor effects are mediated through the stimulation of local cytokine production and cell-mediated immunity. Imiquimod appears to be effective therapy for high-grade VIN; however further high quality data are needed. In particular, studies comparing imiquimod with other therapies are needed.",
"   </p>",
"   <p>",
"    A systematic review of treatment of high-grade VIN that included the two randomized trials and eight observational studies (total n=162) reported a complete response rate of 51 percent, partial response rate of 25 percent, and a recurrence rate of 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/38\">",
"     38",
"    </a>",
"    ]. The two randomized trials (n = 52 and 31) found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    was significantly more effective than placebo (response rate for placebo was zero in both trials) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one randomized trial, at 12 months after initiation of therapy, vulvar carcinoma had developed in one of 26 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    (the patient had a partial response to therapy; the malignancy developed at a new site) compared with two of 26 patients in the placebo group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/39\">",
"     39",
"    </a>",
"    ]. At seven-year follow-up, there were two additional vulvar cancers, both in women with a partial or no response to initial therapy. Long-term follow-up data were not reported for the placebo group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    is applied topically to individual lesions, not to the entire vulva. A typical course of therapy is 16 weeks. Side effects of imiquimod are common; up to two-thirds of patients reduce the number of applications due to local side-effects, mostly from three to two times per week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Side effects of imiquimod consist mostly of inflammation at the application site, including mild to moderate erythema or erosions.",
"   </p>",
"   <p>",
"    To reduce the incidence of local inflammation, some experts suggest an escalating dose regimen starting with an application once a week for two weeks, then twice a week for two weeks, then, if tolerated well, three times a week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/40,42\">",
"     40,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Topical 5-fluorouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Application of 5-fluorouracil cream causes a chemical desquamation of the VIN lesion; response rates as high as 75 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. A disadvantage of this approach is that often it is poorly tolerated because of significant burning, pain, inflammation, edema, or painful ulcerations. For this reason, topical 5-FU has a limited role in the primary therapy of VIN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Investigational therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodynamic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/45\">",
"     45",
"    </a>",
"    ], ultrasonic surgical aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], and the use of chemopreventive agents, such as retinyl acetate gel, are also being investigated. A pilot study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    , a potent antiviral agent, showed promising results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/48\">",
"     48",
"    </a>",
"    ]. There have been preliminary investigations regarding treatment of women with established VIN benefit with HPV vaccination with vaccines designed to elicit a cellular immune response (commercially available vaccines elicit only a humoral response) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/8,49-52\">",
"     8,49-52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Management of VIN in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding VIN and pregnancy are extremely limited. Approximately 15 percent of vulvar carcinomas have been reported to occur in women under the age of 40 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/53\">",
"     53",
"    </a>",
"    ]. Thus, any vulvar lesion noted during pregnancy should be biopsied as outlined above for the non-pregnant patient. Management options for the pregnant patient with VIN fall principally into two main categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical therapy with either local excision or ablative therapy should follow the same general principles as for the non-pregnant patient. This is the preferred treatment option for VIN in pregnancy, especially for the patient remote from delivery.",
"     </li>",
"     <li>",
"      Expectant management until after delivery. Once invasive cancer has been ruled out histologically, clinicians may consider deferring treatment of VIN to the postpartum period especially in patients who are diagnosed in the third trimester. Small series suggest a possibility for spontaneous regression particularly in asymptomatic women who are younger than 30 years of age and who present with multifocal pigmented VIN 2-3 lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/54\">",
"       54",
"      </a>",
"      ]. While several of these spontaneous regressions were associated with pregnancy, there are no data regarding the incidence of regression in this patient population.",
"     </li>",
"     <li>",
"      Medical therapy is generally not recommended:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"       Imiquimod",
"      </a>",
"      is classified as a category C drug by the FDA and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/55\">",
"       55",
"      </a>",
"      ]. The safety of topical therapy with imiquimod during pregnancy has not been clearly established [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/56,57\">",
"       56,57",
"      </a>",
"      ], nor are there efficacy data on the use of imiquimod for the treatment of VIN in pregnancy. 5-FU is a category D drug and should not be used for the treatment of VIN in pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Management of VIN in HIV-infected women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals infected with HIV are at greater risk of HPV-related cancers. Vulvar intraepithelial neoplasia occurs commonly among women infected with HIV. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/19/6455?source=see_link\">",
"     \"Vulvar and vaginal intraepithelial neoplasia in HIV-infected women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;If left untreated, VIN may persist, progress, or resolve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/27,58\">",
"     27,58",
"    </a>",
"    ]. A literature review of patients with VIN included 10 studies involving 61 untreated patients and 27 patients in whom macroscopic VIN was left behind after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/27\">",
"     27",
"    </a>",
"    ]. Eight of the 88 patients (9 percent) progressed to invasive vulvar cancer over one to eight years; four of these women had had previous radiation therapy to the lower genital tract and one was immunosuppressed. In addition, 13 studies reported complete spontaneous regression in a total of 41 patients. All of these women were under age 35 years (mean age 20 years); regression was related to pregnancy in 17 cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Recurrence after treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;With prolonged follow-up, at least one-third of women develop recurrent VIN, regardless of the treatment modality employed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/4,9,27,32,33,36,59,60\">",
"     4,9,27,32,33,36,59,60",
"    </a>",
"    ]. Risk factors for recurrent disease include immunosuppression, the presence of multifocal or multicentric disease, or positive margins on the biopsy specimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/4,9,32\">",
"     4,9,32",
"    </a>",
"    ]. In two series, the risk of recurrent VIN was almost threefold higher among women with positive compared to negative margins on the excisional biopsy (46 to 50 versus 15 to 17 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/4,60\">",
"     4,60",
"    </a>",
"    ]. Therefore, long-term surveillance of the entire lower genital tract is mandatory. We suggest follow-up every six months for five years after the last treatment and then annually.",
"   </p>",
"   <p>",
"    Cigarette smoking is also a risk factor for recurrence. Patients should be encouraged to stop using tobacco to reduce their recurrence risk and for the general health benefits of not smoking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Carcinoma in patients with treated VIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple small studies have reported that 4 to 8 percent of patients develop locally invasive cancer following initial treatment of VIN 3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/9,32,33,60-62\">",
"     9,32,33,60-62",
"    </a>",
"    ]. A systematic review of 3322 patients with VIN 3 found that 6.5 percent developed invasive vulvar cancer, one-half of these were occult carcinomas detected during diagnostic evaluation and therapy and the other one-half were discovered during follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appear to be two distinct patterns of invasive vulvar cancer in women treated for VIN. One pattern is development of invasive carcinoma at a prior site of frequently incompletely treated VIN and reflects disease progression. In these cases, cancer is observed after a median of 2.4 years following VIN treatment. In the other pattern, an invasive carcinoma develops several years later at a site distinct from the previously treated VIN and represents a new neoplastic change in the area at risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A policy of prophylactic HPV vaccination could prevent two-thirds of vulvar, vaginal, and perianal intraepithelial neoplasia in younger women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32952/abstract/12,63,64\">",
"     12,63,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 2004, the Vulvar Oncology Subcommittee of the International Society for the Study of Vulvar Diseases (ISSVD) recommended that the term vulvar intraepithelial neoplasia (VIN) be used exclusively for describing high grade lesions and that it take the place of the former terms VIN 2 and 3. The term VIN 1 was dropped, as it is not a premalignant lesion. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of VIN is higher in premenopausal women than postmenopausal women. In premenopausal women, VIN is often associated with HPV infection, immunosuppression, or cigarette smoking, and is multifocal. Postmenopausal women are more likely to have non-HPV associated VIN and unifocal lesions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'VIN, usual type'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'VIN, differentiated type'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pruritus is the most common symptom of VIN. Other presentations include a visible lesion, a palpable abnormality, pain, or dysuria; but many women are asymptomatic. Squamous intraepithelial neoplasia in more than one location (vulva, vagina, cervix, or perianal area) is relatively common. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tissue biopsy is necessary for a definitive diagnosis. VIN is frequently found in association with invasive squamous cell cancer or lichen sclerosus or lichen planus. These three disorders can be difficult to distinguish from one another, especially when they occur concurrently. Therefore, any lesion on the vulva that is not known to be benign warrants biopsy. Appropriate sites for biopsy are identified by physical examination and colposcopy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of treatment are to prevent development of invasive vulvar cancer and relieve symptoms, while preserving normal vulvar anatomy and function. Treatment is individualized based upon biopsy results, extent of disease, and the woman's symptoms. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with VIN, we suggest surgery rather than medical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We recommend wide local excision if there is a significant risk of invasion based on patient age or the characteristics of the lesion. We suggest laser ablation or topical therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      for patients whose lesions are located such that excision with negative margins is not feasible without significant vulvar mutilation, such as clitoral, periurethral or perianal lesions. A combination of these approaches may be indicated in some patients with extensive disease. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Surgical'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite treatment, VIN recurs in one-third of women and 4 to 8 percent develop locally invasive cancer. Therefore, long-term surveillance of the entire lower genital tract is mandatory. We suggest follow-up every six months for five years after the last treatment and then annually. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/1\">",
"      Sideri M, Jones RW, Wilkinson EJ, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med 2005; 50:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/2\">",
"      Judson PL, Habermann EB, Baxter NN, et al. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006; 107:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/3\">",
"      Joura EA, L&ouml;sch A, Haider-Angeler MG, et al. Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med 2000; 45:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/4\">",
"      Modesitt SC, Waters AB, Walton L, et al. Vulvar intraepithelial neoplasia III: occult cancer and the impact of margin status on recurrence. Obstet Gynecol 1998; 92:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/5\">",
"      Jones RW, Baranyai J, Stables S. Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol 1997; 90:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/6\">",
"      Wright TC, Koulos JP, Liu P, Sun XW. Invasive vulvar carcinoma in two women infected with human immunodeficiency virus. Gynecol Oncol 1996; 60:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/7\">",
"      Conley LJ, Ellerbrock TV, Bush TJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/8\">",
"      van de Nieuwenhof HP, van der Avoort IA, de Hullu JA. Review of squamous premalignant vulvar lesions. Crit Rev Oncol Hematol 2008; 68:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/9\">",
"      H&oslash;rding U, Junge J, Poulsen H, Lundvall F. Vulvar intraepithelial neoplasia III: a viral disease of undetermined progressive potential. Gynecol Oncol 1995; 56:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/10\">",
"      Ogunbiyi OA, Scholefield JH, Robertson G, et al. Anal human papillomavirus infection and squamous neoplasia in patients with invasive vulvar cancer. Obstet Gynecol 1994; 83:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/11\">",
"      Almeida G, do Val I, Gondim C, et al. Human papillomavirus, Epstein-Barr virus and p53 mutation in vulvar intraepithelial neoplasia. J Reprod Med 2004; 49:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/12\">",
"      Srodon M, Stoler MH, Baber GB, Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol 2006; 30:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/13\">",
"      Edwards CL, Tortolero-Luna G, Linares AC, et al. Vulvar intraepithelial neoplasia and vulvar cancer. Obstet Gynecol Clin North Am 1996; 23:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/14\">",
"      Jones RW. Vulval intraepithelial neoplasia: current perspectives. Eur J Gynaecol Oncol 2001; 22:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/15\">",
"      Newcomb PA, Weiss NS, Daling JR. Incidence of vulvar carcinoma in relation to menstrual, reproductive, and medical factors. J Natl Cancer Inst 1984; 73:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/16\">",
"      Thuis YN, Campion M, Fox H, Hacker NF. Contemporary experience with the management of vulvar intraepithelial neoplasia. Int J Gynecol Cancer 2000; 10:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/17\">",
"      Friedrich EG Jr, Wilkinson EJ, Fu YS. Carcinoma in situ of the vulva: a continuing challenge. Am J Obstet Gynecol 1980; 136:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/18\">",
"      Campion MJ. Clinical manifestations and natural history of genital human papillomavirus infection. Obstet Gynecol Clin North Am 1987; 14:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/19\">",
"      Hummer WK, Mussey E, Decker DG, Dockerty MB. Carcinoma in situ of the vagina. Am J Obstet Gynecol 1970; 108:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/20\">",
"      Vinokurova S, Wentzensen N, Einenkel J, et al. Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. J Natl Cancer Inst 2005; 97:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/21\">",
"      Fox H, Wells M. Recent advances in the pathology of the vulva. Histopathology 2003; 42:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/22\">",
"      Yang B, Hart WR. Vulvar intraepithelial neoplasia of the simplex (differentiated) type: a clinicopathologic study including analysis of HPV and p53 expression. Am J Surg Pathol 2000; 24:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/23\">",
"      Roma AA, Hart WR. Progression of simplex (differentiated) vulvar intraepithelial neoplasia to invasive squamous cell carcinoma: a prospective case study confirming its precursor role in the pathogenesis of vulvar cancer. Int J Gynecol Pathol 2007; 26:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/24\">",
"      Rodolakis A, Diakomanolis E, Vlachos G, et al. Vulvar intraepithelial neoplasia (VIN)--diagnostic and therapeutic challenges. Eur J Gynaecol Oncol 2003; 24:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/25\">",
"      Collins CG, Hansen LH, Theriot E. A clinical stain for use in selecting biopsy sites in patients with vulvar disease. Obstet Gynecol 1966; 28:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/26\">",
"      Joura EA, Zeisler H, L&ouml;sch A, et al. Differentiating vulvar intraepithelial neoplasia from nonneoplastic epithelial disorders. The toluidine blue test. J Reprod Med 1998; 43:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/27\">",
"      van Seters M, van Beurden M, de Craen AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 2005; 97:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/28\">",
"      DeSimone CP, Crisp MP, Ueland FR, et al. Concordance of gross surgical and final fixed margins in vulvar intraepithelial neoplasia 3 and vulvar cancer. J Reprod Med 2006; 51:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/29\">",
"      Sideri M, Spinaci L, Spolti N, Schettino F. Evaluation of CO(2) laser excision or vaporization for the treatment of vulvar intraepithelial neoplasia. Gynecol Oncol 1999; 75:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/30\">",
"      Penna C, Fallani MG, Fambrini M, et al. CO2 laser surgery for vulvar intraepithelial neoplasia. Excisional, destructive and combined techniques. J Reprod Med 2002; 47:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/31\">",
"      Hoffman MS, Pinelli DM, Finan M, et al. Laser vaporization for vulvar intraepithelial neoplasia III. J Reprod Med 1992; 37:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/32\">",
"      K&uuml;ppers V, Stiller M, Somville T, Bender HG. Risk factors for recurrent VIN. Role of multifocality and grade of disease. J Reprod Med 1997; 42:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/33\">",
"      Buscema J, Woodruff JD, Parmley TH, Genadry R. Carcinoma in situ of the vulva. Obstet Gynecol 1980; 55:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/34\">",
"      Wright VC, Davies E. Laser surgery for vulvar intraepithelial neoplasia: principles and results. Am J Obstet Gynecol 1987; 156:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/35\">",
"      Abell DA. Simple vulvectomy--a 10-year review. Aust N Z J Obstet Gynaecol 1973; 13:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/36\">",
"      Di Saia PJ, Rich WM. Surgical approach to multifocal carcinoma in situ of the vulva. Am J Obstet Gynecol 1981; 140:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/37\">",
"      Rutledge F, Sinclair M. Treatment of intraepithelial carcinoma of the vulva by skin excision and graft. Am J Obstet Gynecol 1968; 102:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/38\">",
"      Mahto M, Nathan M, O'Mahony C. More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia. Int J STD AIDS 2010; 21:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/39\">",
"      van Seters M, van Beurden M, ten Kate FJ, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008; 358:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/40\">",
"      Mathiesen O, Buus SK, Cramers M. Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study. Gynecol Oncol 2007; 107:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/41\">",
"      Terlou A, van Seters M, Ewing PC, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. Gynecol Oncol 2011; 121:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/42\">",
"      Le T, Menard C, Hicks-Boucher W, et al. Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. Gynecol Oncol 2007; 106:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/43\">",
"      Sillman FH, Sedlis A, Boyce JG. A review of lower genital intraepithelial neoplasia and the use of topical 5-fluorouracil. Obstet Gynecol Surv 1985; 40:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/44\">",
"      Krupp PJ, Bohm JW. 5-fluorouracil topical treatment of in situ vulvar cancer. A preliminary report. Obstet Gynecol 1978; 51:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/45\">",
"      Hillemanns P, Wang X, Staehle S, et al. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol Oncol 2006; 100:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/46\">",
"      Miller BE. Vulvar intraepithelial neoplasia treated with cavitational ultrasonic surgical aspiration. Gynecol Oncol 2002; 85:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/47\">",
"      von Gruenigen VE, Gibbons HE, Gibbins K, et al. Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstet Gynecol 2007; 109:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/48\">",
"      Tristram A, Fiander A. Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithelial neoplasia. Gynecol Oncol 2005; 99:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/49\">",
"      Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/50\">",
"      Baldwin PJ, van der Burg SH, Boswell CM, et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 2003; 9:5205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/51\">",
"      Davidson EJ, Boswell CM, Sehr P, et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003; 63:6032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/52\">",
"      van Poelgeest MI, van Seters M, van Beurden M, et al. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 2005; 11:5273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/53\">",
"      Ogunleye D, Lewin SN, Huettner P, Herzog TJ. Recurrent vulvar carcinoma in pregnancy. Gynecol Oncol 2004; 95:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/54\">",
"      Jones RW, Rowan DM. Spontaneous regression of vulvar intraepithelial neoplasia 2-3. Obstet Gynecol 2000; 96:470.",
"     </a>",
"    </li>",
"    <li>",
"     .S. Food and Drug Administration. Highlights of Prescribing information: Aldara&trade; (imiquimod) Cream At: file://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4399b1-34%20(Aldara%20(imiquimod)%20Labeling).pdf (Accessed on June 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/56\">",
"      Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Sexually Transmitted Disease Treatment Guidelines 2006 file://www.cdc.gov/std/treatment/2006/genital-warts.htm (Accessed on June 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/58\">",
"      Jones RW, McLean MR. Carcinoma in situ of the vulva: a review of 31 treated and five untreated cases. Obstet Gynecol 1986; 68:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/59\">",
"      Rettenmaier MA, Berman ML, DiSaia PJ. Skinning vulvectomy for the treatment of multifocal vulvar intraepithelial neoplasia. Obstet Gynecol 1987; 69:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/60\">",
"      Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 2005; 106:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/61\">",
"      Jones RW, Rowan DM. Vulvar intraepithelial neoplasia III: a clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinoma. Obstet Gynecol 1994; 84:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/62\">",
"      Herod JJ, Shafi MI, Rollason TP, et al. Vulvar intraepithelial neoplasia: long term follow up of treated and untreated women. Br J Obstet Gynaecol 1996; 103:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/63\">",
"      Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32952/abstract/64\">",
"      Hampl M, Sarajuuri H, Wentzensen N, et al. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 2006; 108:1361.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3235 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-219.243.220.100-CF9D26F5DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32952=[""].join("\n");
var outline_f32_11_32952=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      VIN, USUAL TYPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      VIN, DIFFERENTIATED TYPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Surgical",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Wide local excision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Laser ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1062486\">",
"      - Simple vulvectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1062447\">",
"      - Skinning vulvectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Medical",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Imiquimod",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Topical 5-fluorouracil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Management of VIN in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Management of VIN in HIV-infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Recurrence after treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Carcinoma in patients with treated VIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3235\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3235|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/35/36409\" title=\"picture 1\">",
"      VIN histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/26/17827\" title=\"picture 2\">",
"      White plaques of VIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/0/31745\" title=\"picture 3\">",
"      Red macular lesion of VIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/15/20725\" title=\"picture 4\">",
"      Brown macular lesion of VIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3235|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/23/6523\" title=\"table 1\">",
"      VIN grading",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/19/6455?source=related_link\">",
"      Vulvar and vaginal intraepithelial neoplasia in HIV-infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9303?source=related_link\">",
"      Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/5/36952?source=related_link\">",
"      Vulvar lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/45/6874?source=related_link\">",
"      Vulvar lichen sclerosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/12/14535?source=related_link\">",
"      Vulvar wide local excision, simple vulvectomy, and skinning vulvectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_11_32953="Headache, migraine, and stroke";
var content_f32_11_32953=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Headache, migraine, and stroke",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32953/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32953/contributors\">",
"     Muhammad Ramzan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32953/contributors\">",
"     Marc Fisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32953/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32953/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32953/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32953/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32953/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/11/32953/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     POSSIBLE RELATIONSHIPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between headache, migraine, and stroke is complex. All of these conditions are common and can be temporally related, but whether the association is causal has not been definitively proven in clinical studies. In addition to being causal, a number of additional possible relationships between these entities might exist:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Headache may be coincidental with stroke",
"     </li>",
"     <li>",
"      Headache may be a consequence of stroke",
"     </li>",
"     <li>",
"      Stroke and cerebrovascular lesions may have clinical features of migraine",
"     </li>",
"     <li>",
"      Headache or migraine may increase the risk of stroke",
"     </li>",
"     <li>",
"      Migraine may have clinical features of stroke",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further modifications are likely as knowledge of the epidemiology and pathophysiology of these relationships advances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Headache coincidental with stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache or migraine may occur coincidentally with stroke since both are common conditions. With aging, the prevalence of migraine decreases, while that of stroke increases. In addition, stroke risk factors such as hypertension, diabetes, and heart disease are more common in older age groups. Therefore, younger patients are much more likely than older patients to have migraine as the only stroke risk factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Coexisting stroke and migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coexisting stroke and migraine is defined as a clear clinical stroke syndrome occurring remotely in time from a typical attack of migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/1\">",
"     1",
"    </a>",
"    ]. This definition implies that the two conditions are coincidental.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Headache due to stroke or vascular disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hemorrhagic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache at or near the onset of stroke occurs almost invariably in subarachnoid hemorrhage. Headache is less frequent with other stroke mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/2\">",
"     2",
"    </a>",
"    ]. In intracerebral hemorrhage (ICH), headache may occur acutely at stroke onset, or may occur a bit later (within hours of onset) as the hematoma gradually expands and begins to compress pain sensitive intracranial structures such as larger arteries and the meninges. In some cases of ICH, headache may not be present at all. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link&amp;anchor=H10#H10\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Sentinel headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;A premonitory or sentinel headache may occur before subarachnoid hemorrhage (SAH). Sentinel headache is important to recognize because it may signal an aneurysmal leak days or weeks before a more devastating SAH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=see_link&amp;anchor=H12#H12\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Ischemic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;In ischemic stroke of large vessel origin, headache may occur prior to, during, or after stroke onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/3\">",
"     3",
"    </a>",
"    ]. Although the cause is often unclear, several plausible mechanisms have been postulated including vascular dilation as a homeostatic response to ischemia and direct arterial irritation by thrombus, embolism, or dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/4\">",
"     4",
"    </a>",
"    ]. Headache is uncommon in lacunar stroke syndromes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Reversible cerebral vasoconstriction syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversible cerebral vasoconstriction syndromes (RCVS) encompass a number of diverse conditions that share similar clinical and radiologic features, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thunderclap headache with reversible vasospasm",
"     </li>",
"     <li>",
"      Benign angiopathy of the central nervous system",
"     </li>",
"     <li>",
"      Migrainous vasospasm or crash migraine",
"     </li>",
"     <li>",
"      Call-Fleming syndrome",
"     </li>",
"     <li>",
"      Postpartum angiopathy",
"     </li>",
"     <li>",
"      Drug-induced cerebral vasoconstriction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These syndromes are characterized by thunderclap headache and by diffuse, segmental, reversible cerebral vasospasm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12601?source=see_link&amp;anchor=H13#H13\">",
"     \"Thunderclap headache\", section on 'Reversible cerebral vasoconstriction syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Characteristic features of the Call-Fleming syndrome (or Call syndrome), which occurs more often in women than men, are thunderclap headache, focal neurologic deficits, and sometimes generalized seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/5\">",
"     5",
"    </a>",
"    ]. Neurologic deficits usually resolve within days to weeks. Transient reversible vasoconstriction and dilation prominently involving the arteries around the Circle of Willis is seen at angiography.",
"   </p>",
"   <p>",
"    Serotonergic drugs, including triptans used for treating migraines, have also been implicated in causing reversible cerebral vasoconstriction. Use of these and other serotonergic agents (antidepressants, decongestants, diet pills, amphetamines, St. John's Wort, and certain drugs of abuse such as cocaine, ecstasy, and methamphetamine) alone or in combination have been reported in association with ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. In addition, arterial spasm is a well-known side effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    , which was once commonly used to treat acute migraine headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the data are insufficient to establish a concrete causal relationship between the use of these agents and vasoconstriction or stroke.",
"   </p>",
"   <p>",
"    In most cases, RCVS are self-limiting in terms of clinical features, and vasoconstriction is reversible by definition. However, some patients with RCVS may have fluctuating focal neurologic symptoms and signs, including ischemic or hemorrhagic strokes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of stroke with permanent neurologic deficit due to RCVS is thought to be low, but data are limited.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a literature review that analyzed 152 patients with vasoconstriction in the absence of subarachnoid hemorrhage (SAH), atherosclerosis, infection, or inflammation, stroke was present in 54 percent, and hemorrhagic stroke in 14 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/13\">",
"       13",
"      </a>",
"      ]. Infarcts and edema were commonly located in cortical borderzone regions. Recovery within one month was reported in 75 percent, while death occurred in 3 percent.",
"     </li>",
"     <li>",
"      Another retrospective study of 89 patients with RCVS reported that intracranial hemorrhage occurred in 32 percent, primarily focal cortical SAH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/12\">",
"       12",
"      </a>",
"      ]. Cerebral infarction occurred in 6 percent, accompanied or preceded by intracranial hemorrhage in 4 percent. Independent risk factors for hemorrhage in RCVS were female gender and migraine. At six months follow-up, inability to resume work related to persistent deficits was noted in 9 percent of patients, all with hemorrhagic RCVS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, the attribution of SAH to RCVS is problematic because SAH can be a cause rather than a consequence of cerebral vasoconstriction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=see_link&amp;anchor=H15#H15\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Vasospasm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache is also a frequent clinical symptom of hypertensive encephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], the cerebral hyperperfusion syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/16\">",
"     16",
"    </a>",
"    ], and reversible posterior leukoencephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/17\">",
"     17",
"    </a>",
"    ]. These syndromes may share a common pathophysiology involving failure of cerebral blood flow autoregulation and endothelial dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link\">",
"     \"Reversible posterior leukoencephalopathy syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=see_link\">",
"     \"Neurologic complications of platinum-based chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Symptomatic migraine and migraine mimics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic migraine results from structural brain lesions, vasculopathies, and vascular malformations that cause recurrent symptoms typical of migraine with aura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/18\">",
"     18",
"    </a>",
"    ]. Arteriovenous malformations may be associated with migraine attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. One literature review of case studies found a correlation between the side of the head with the AVM and the side affected by unilateral headache, with a similar correlation for lateralized auras [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/21\">",
"     21",
"    </a>",
"    ]. Migraine attacks have also been associated with the syndrome of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts And Leukoencephalopathy (CADASIL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/16/11530?source=see_link\">",
"     \"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute stroke may be accompanied by headache and neurologic signs and symptoms indistinguishable from migraine, in which case the stroke may be considered a migraine mimic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/18\">",
"     18",
"    </a>",
"    ]. Various stroke subtypes including ischemic stroke, subarachnoid hemorrhage, and cerebral venous thrombosis can mimic migraine attacks.",
"   </p>",
"   <p>",
"    Cervical internal carotid artery dissection may occasionally present as a migraine mimic with visual scintillating scotomata [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. One study of 161 patients found that nearly 70 percent of cervical carotid and vertebral dissections were associated with headache, and headache was the initial symptom in 33 to 47 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/27\">",
"     27",
"    </a>",
"    ]. An earlier study found that 19 of 21 patients with angiographically documented carotid dissection had ipsilateral head pain in one or more regions such as the orbit, frontal region, and side of the head [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/28\">",
"     28",
"    </a>",
"    ]. The head pain was typically acute and severe, and neck pain occurred as well in 12 patients. About three quarters of the 21 patients had ischemic events related to the dissection, with the headache preceding the ischemic symptoms in about half.",
"   </p>",
"   <p>",
"    The relationship of dissection with headache is made even more complicated because about one-half of patients with cervicocephalic dissection have a prior history of migraine. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Interaction of migraine with other stroke risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prolonged aura (complicated migraine)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prolonged aura is characterized by a focal neurologic deficit that lasts beyond the resolution of the migraine attack; prolonged aura was previously considered under the rubric of \"complicated migraine.\" Under the IHS classification revised in 2004, prolonged auras are now divided into three categories based on the duration of aura or presence of infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/1,29\">",
"     1,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Migraine with prolonged aura (if the aura lasts more than one hour but less than one week with normal brain imaging).",
"     </li>",
"     <li>",
"      Persistent aura without infarction (if the aura lasts more than one week with no evidence of infarction).",
"     </li>",
"     <li>",
"      Migrainous infarction (if the deficit lasts more than one hour and the neuroimaging shows infarction).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other migraine types include ophthalmoplegic migraine, retinal migraine (ocular migraine), confusional migraine, basilar-type migraine, and hemiplegic migraine. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Migraine with clinical features of stroke'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Migrainous stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is as yet no universal agreement on the definition of migraine associated stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/1,18,29-34\">",
"     1,18,29-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Migrainous infarction definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IHS classification as revised in 2004 defines migrainous infarction by the following features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/1,29\">",
"     1,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient has previously fulfilled criteria for migraine with aura.",
"     </li>",
"     <li>",
"      The neurologic deficit develops during the course of an apparently typical attack of migraine with aura.",
"     </li>",
"     <li>",
"      The aura exactly mimics the auras of previous attacks.",
"     </li>",
"     <li>",
"      One or more otherwise typical aura symptoms persist beyond one hour.",
"     </li>",
"     <li>",
"      Neuroimaging confirms ischemic infarction in the relevant area.",
"     </li>",
"     <li>",
"      All other known causes of stroke have been excluded by appropriate investigations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The definition of migrainous infarction, also called migraine-induced stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/18\">",
"     18",
"    </a>",
"    ], has been criticized because it does not allow for the possibility of migraine-related stroke in migraine attacks without aura. However, several reports have noted the occurrence of migrainous infarction associated with attacks of migraine without aura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Migraine-related stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some experts have used the term migraine-related stroke to expand the definition of migrainous infarction and allow inclusion of patients who have migraine without aura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/33\">",
"     33",
"    </a>",
"    ]. Others use migraine-related stroke for cases when additional stroke mechanisms coexist with migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Migraine with clinical features of stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine with aura occurs in about 15 to 20 percent or more of migraine patients and may mimic stroke. Typical migraine auras develop gradually over 5 to 20 minutes and last less than one hour; the most common types involve homonymous visual disturbances. There is usually little clinical difficulty recognizing these auras as manifestations of migraine when the aura is brief and precedes a headache. In the IHS classification, typical auras may manifest as ophthalmic, hemiparesthetic, hemiparetic, hemiplegic, or aphasic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link&amp;anchor=H203275055#H203275055\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Migraine aura'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prolonged or atypical auras may be difficult to distinguish from stroke or transient ischemic attacks (TIAs). In particular, motor auras of hemiplegic migraine are more likely than others to last longer than one hour (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/60/17354?source=see_link&amp;anchor=H181715005#H181715005\">",
"     \"Hemiplegic migraine\", section on 'Auras'",
"    </a>",
"    ). Additionally, migraine aura without headache may be confused with TIA or stroke in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Migraine or migraine variants that may mimic TIA or stroke include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemiplegic migraine and familial hemiplegic migraine (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/60/17354?source=see_link\">",
"       \"Hemiplegic migraine\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Basilar-type migraine (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/44/44743?source=see_link\">",
"       \"Basilar-type migraine\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ophthalmoplegic migraine",
"     </li>",
"     <li>",
"      Retinal or ocular migraine",
"     </li>",
"     <li>",
"      Migraine aura without headache",
"     </li>",
"     <li>",
"      Migraine with acute-onset aura",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These migraine variants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link&amp;anchor=H222097293#H222097293\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Migraine variants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Migrainous stroke prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the prevalence of migraine in stroke patients varies in different retrospective studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A French study found that the prevalence of migraine in ischemic stroke patients was double that of controls (60 versus 30 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the European WHO collaborative study, the prevalence of migraine in patients with all types of stroke compared with controls was 25 versus 13 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/37\">",
"       37",
"      </a>",
"      ]. This study has been criticized on several grounds, including the high proportion of migraine with aura patients compared with those without aura and the high incidence of migrainous stroke (between 20 to 40 percent) among the study participants, a finding that does not concur with clinical experience [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Collaborative Group for the Study of Stroke in Young Women found that the prevalence of migraine in women with stroke, hospitalized controls, and neighborhood controls was 34, 33, and 24 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Migrainous stroke incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partly because of the ambiguity of the operational definitions, the true incidence of migrainous stroke is unknown. In a French case-control study, the calculated absolute risk of ischemic stroke in women with migraine was 19 per 100,000 per year, which is a relatively low rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/36\">",
"     36",
"    </a>",
"    ]. For comparison, the overall incidence of ischemic stroke under age 50 ranges from 6.5 to 22.8 per 100,000 per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In studies that have looked at women and men with migraine, the migrainous stroke incidence has varied from 0.8 per 100,000 per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/41\">",
"     41",
"    </a>",
"    ] to 3.4 per 100,000 per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/42\">",
"     42",
"    </a>",
"    ]. In a study that used a strict IHS definition of migrainous infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/1\">",
"     1",
"    </a>",
"    ], migraine-induced stroke accounted for 13.7 percent of infarcts in young adults and 0.8 percent of all ischemic strokes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/43\">",
"     43",
"    </a>",
"    ]. Similar results (ie, 0.8 percent of all acute strokes) were reported in a separate case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MIGRAINE AND ISCHEMIC STROKE RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating evidence supports an association between migraine, particularly migraine with aura, and ischemic stroke risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/36-38,45-51\">",
"     36-38,45-51",
"    </a>",
"    ]. However, the absolute increase in the risk of stroke is small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/52\">",
"     52",
"    </a>",
"    ]. For other forms of cardiovascular disease such as myocardial infarction, several studies have found an association with migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/53-55\">",
"     53-55",
"    </a>",
"    ], or migraine with aura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/55-59\">",
"     55-59",
"    </a>",
"    ], though not all reports have confirmed the association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/49,60\">",
"     49,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence supporting migraine as an independent risk factor for ischemic stroke comes from a meta-analysis that included 25 studies (13 case-control, 10 cohort, and two cross sectional) published through January 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/49\">",
"     49",
"    </a>",
"    ]. The strength of this meta-analysis is limited mainly by the case-control nature of many of the studies, with their inherent susceptibility to recall bias. In addition, the included studies were heterogeneous with regard to subject characteristics and cardiovascular disease definitions. With these caveats in mind, the following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In nine studies, the pooled relative risk (RR) for ischemic stroke among subjects with any type of migraine was 1.73 (95% CI 1.31-2.29). The increased risk was largely driven by participants who had migraine with aura (pooled RR 2.16, 95% CI 1.53-3.03). In contrast, the increase in risk for those who had migraine without aura was",
"      <strong>",
"       not",
"      </strong>",
"      statistically significant (pooled RR 1.23, 95% CI 0.90-1.69) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/49\">",
"       49",
"      </a>",
"      ]. Another meta-analysis reported similar findings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In studies with available data stratification, the risk of ischemic stroke was significantly increased for the following subgroups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/49\">",
"       49",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Women with migraine (pooled RR 2.08, 95% CI 1.13-3.84) but not men (pooled RR 1.37, 95% CI 0.89-2.11)",
"     </li>",
"     <li>",
"      Subjects with migraine &lt;45 years of age (pooled RR 2.65, 95% CI 1.41-4.97)",
"     </li>",
"     <li>",
"      Smokers who had migraine with aura (pooled RR 9, 95% CI 4.2-19.3)",
"     </li>",
"     <li>",
"      Women currently using oral contraceptives who had migraine with aura (pooled RR 7, 95% CI 1.5-32.7)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In eight studies, there was no significant increase in risk for myocardial infarction among participants with migraine (pooled RR 1.12, 95% CI 0.95-1.32) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/49\">",
"       49",
"      </a>",
"      ]. However, the only study that stratified results by aura status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/58\">",
"       58",
"      </a>",
"      ] found that migraine with aura (but not migraine without aura) was associated with a significantly increased risk of myocardial infarction.",
"     </li>",
"     <li>",
"      In five studies, death due to cardiovascular disease was not increased in subjects with migraine (pooled RR 1.03, 95% CI 0.79-1.34) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, there is evidence that women who have migraine with aura are at increased risk of ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/49\">",
"     49",
"    </a>",
"    ], but the absolute increase in the risk of stroke is small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/61\">",
"     61",
"    </a>",
"    ]. Smoking, estrogen-progestin contraceptive use, and age &lt;45 years appear to confer additional risk in these women.",
"   </p>",
"   <p>",
"    Of note, none of the relevant studies of migraine and stroke risk have distinguished whether the estrogen content of the estrogen-progestin contraceptives was high or low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/62\">",
"     62",
"    </a>",
"    ], which other reports have identified as a critical factor related to stroke risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H10#H10\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Stroke'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H40#H40\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Migraine headaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77337178\">",
"    <span class=\"h2\">",
"     Acute migrainous infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only a few reported patients with acute migrainous infarction who have had a complete stroke evaluation. The largest study with modern neuroimaging is a report of 11 patients, mostly women, with migrainous infarction according to strict IHS criteria (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Migrainous infarction definition'",
"    </a>",
"    above) who were identified from a stroke database of 8137 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/63\">",
"     63",
"    </a>",
"    ]. All patients reported symptoms at onset similar to previous migraine aura without new or atypical symptoms. However, the previously transient aura symptoms persisted. On diffusion-weighted MRI sequences, 4 of the 11 patients had multiple small lesions consistent with infarction, mainly in the posterior circulation, while 3 had isolated lesions in the posterior circulation territory, and 3 had isolated lesions in the middle cerebral artery territory (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57203 \" href=\"mobipreview.htm?32/43/33463\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Subclinical brain lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several prospective population-based studies have found an association between migraine with aura and silent infarct-like lesions on brain MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. However, the etiology, nature, and clinical significance of the MRI lesions reported in these studies remains unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cross-sectional CAMERA study of Dutch adults aged 30 to 60 years randomly selected 161 patients who had migraine with aura, 134 patients who had migraine without aura, and 140 controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/64\">",
"       64",
"      </a>",
"      ]. Migraine with (but not without) aura was associated with an increased risk for subclinical posterior circulation territory infarct-like lesions. In patients with migraine, 32 of the 33 such lesions were in the cerebellum, and one was in the pons. In another CAMERA study report, patients with migraine had a significantly increased prevalence of small infratentorial hyperintense lesions, most located in the mid-pons, on T2 and proton density MRI sequences compared with controls (4.4 versus 0.7 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The population-based AGES-Reykjavik Study reported long-term follow-up of 4689 subjects initially evaluated at a mean age of 51 years and then reevaluated at a mean age of 76 years by interview and brain MRI scan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/66\">",
"       66",
"      </a>",
"      ]. Compared with those not reporting headache once or more per month at baseline, subjects who had migraine with aura at the initial evaluation (n = 361) had an increased risk of infarct-like lesions 25 years later (adjusted odds ratio [OR] 1.4, 95% CI 1.1-1.8). This result was driven mainly by an increased risk of cerebellar infarct-like lesions in the subgroup of woman who had migraine with aura (OR 1.9, 95% CI 1.4-2.6).",
"     </li>",
"     <li>",
"      A meta-analysis of seven case-control studies found a significantly increased risk of white matter lesions on MRI in those with migraine compared with those without migraine (odds ratio 3.9, 95% CI 2.26-6.72) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology underlying migraine as a possible cause of stroke or as a stroke risk factor is not clear. Putative mechanisms include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasospasm and changes in cerebral blood flow; vasospasm historically has received the most attention as a potential mechanism for migraine-induced stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/18,33,70-73\">",
"       18,33,70-73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prolongation of cortical spreading depression and aura [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/74\">",
"       74",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neuronal glutamatergic hyperexcitability resulting in enhanced susceptibility to ischemic depolarizations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/75\">",
"       75",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased platelet aggregability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/76-78\">",
"       76-78",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Release of prothrombotic factors or vasoactive peptides [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/79-84\">",
"       79-84",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Endothelial abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/85-88\">",
"       85-88",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Abnormal activity of serotonergic raphe cells causing excitotoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/89\">",
"       89",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Genetic polymorphisms. As an example, the methylenetetrahydrofolate reductase C677T genotype may be associated with an increased risk of migraine with aura [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/90\">",
"       90",
"      </a>",
"      ] and with mildly elevated homocysteine, a stroke risk factor (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of homocysteine\", section on 'Role in vascular disease'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atrial fibrillation attributed to the autonomic dysfunction associated with migraine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/91,92\">",
"       91,92",
"      </a>",
"      ] and associated with cerebral embolization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of the postulated mechanisms has yet been confirmed as a pathophysiological explanation linking stroke and migraine. However, the CAMERA study investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/65\">",
"     65",
"    </a>",
"    ] suggested that the most likely explanation for posterior circulation border zone lesions in migraine was a combination of low flow (hypoperfusion) and local thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Interaction of migraine with other stroke risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine has been associated with other known or putative risk factors for stroke, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms (MELAS) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7370?source=see_link&amp;anchor=H10#H10\">",
"       \"Mitochondrial myopathies: Clinical features and diagnosis\", section on 'MELAS'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/16/11530?source=see_link&amp;anchor=H9#H9\">",
"       \"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)\", section on 'Migraine with aura'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cervical artery dissection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/94\">",
"       94",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10730?source=see_link&amp;anchor=H163601524#H163601524\">",
"       \"Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis\", section on 'Predisposing conditions'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antiphospholipid antibodies and lupus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/95-98\">",
"       95-98",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Livedo reticularis and Sneddon's syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/99-102\">",
"       99-102",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     NONSPECIFIC HEADACHE AND STROKE RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonmigraine, nonspecific,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic headache may be a predictor of ischemic stroke risk, but the evidence is conflicting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Physician's Health Study did not find any association between nonmigraine headache and subsequent stroke in men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/103\">",
"       103",
"      </a>",
"      ]. Similarly, the Women's Health study reported that headache in general and nonmigraine headache were not associated with stroke risk in women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective cohort study of 35,056 Finnish men and women, men with chronic unspecified headache had a fourfold higher risk of stroke during the first 12 months of follow-up as compared with those without headache [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/104\">",
"       104",
"      </a>",
"      ]. The headache (nonspecific) associated hazard ratio of stroke for men decreased for each interval of follow-up from 4.1 (95% CI 2.1-7.93) at one year to 1.86 at five years and 1.2 at 23 years. In the same study, there was no significant association between chronic headache and the risk of stroke in women; this finding was thought to be due to the higher prevalence and more heterogeneous etiology of nonspecific headaches in women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/104\">",
"       104",
"      </a>",
"      ]. The issue of migraine headache was not discussed directly in this study.",
"     </li>",
"     <li>",
"      The US National Health and Nutrition Examination Survey involved more than 14,000 participants who were followed for 10 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/105\">",
"       105",
"      </a>",
"      ]. The study found a significant association of stroke with severe nonspecific headache and migraine in both women and men. Among participants younger than 45 years of age, there was a fivefold increase in stroke in the headache group compared with those in the no-headache group (3.6 percent versus 0.7 percent for men; 2.2 percent versus 0.4 percent for women). The risk of stroke related to headache decreased with increasing age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment aimed at primary or secondary stroke prevention in patients with migraine or nonspecific headache is not well studied, but an approach combining stroke risk factor control with migraine prophylaxis seems most reasonable. Both of these topics are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with migraine should be educated to recognize the early warning signs of stroke to prevent confusion between migraine aura and TIA, and to seek appropriate intervention. Similarly, physicians should be aware of the potentially increased risk of stroke in the migraine population and should not dismiss focal symptoms in their evaluation of these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Drugs to avoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain medications are best avoided in patients with migraine who have a history of stroke, TIA, or cardiovascular disease. Vasoconstrictive medications in particular are contraindicated in this setting. Agents to avoid include triptans, serotonin agonists (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/15/40181?source=see_link\">",
"     pizotifen",
"    </a>",
"    , methysergide), and ergot alkaloids. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Reversible cerebral vasoconstriction syndromes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest that beta blockers should NOT be used as initial therapy for migraine prophylaxis in patients over age 60 and in smokers. Compared with other antihypertensive drugs in the primary treatment of hypertension, beta blockers may be associated with a higher rate of stroke and other cardiovascular events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link&amp;anchor=H22#H22\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with a history of intracerebral hemorrhage or subarachnoid hemorrhage should avoid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for acute migraine attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/18\">",
"     18",
"    </a>",
"    ]; in addition, non steroidal antiinflammatory agents (NSAIDs) should not be used for migraine prophylaxis in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/18\">",
"     18",
"    </a>",
"    ]. Triptans should not be used for headache therapy in the first one to two months after subarachnoid hemorrhage because of the risk of vasospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/18,106\">",
"     18,106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women younger than 35 years old who have migraine without aura and no other risk factors for stroke may use a contraceptive pill with low-dose estrogen, less than 50 mcg as per the American College of Obstetricians and Gynecologists (ACOG) guidelines or less than 35 mcg as per The World Health Organization (WHO) guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]. However, the frequency and severity of their migraines should be monitored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H10#H10\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Stroke'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H40#H40\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Migraine headaches'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35433?source=see_link&amp;anchor=H13#H13\">",
"     \"Estrogen-associated migraine\", section on 'Hormone-based interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The WHO concluded that the risks of estrogen-progestin contraceptives usually outweigh the benefits for women age 35 and older who have migraine without aura, and for women of any age who have migraine with aura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32953/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who have migraine with aura should be encouraged to stop smoking, control their blood pressure, and use an alternative method of contraception. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H40#H40\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Migraine headaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/51/16179?source=see_link\">",
"       \"Patient information: Headache causes and diagnosis in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/59/42931?source=see_link\">",
"       \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headache or migraine may be a consequence of stroke, and perhaps a cause, although coincidental occurrence is more likely. In addition, migraine may mimic stroke, and stroke may mimic migraine. In any given patient, the co-occurrence of headache with stroke should raise suspicion for a common pathophysiologic mechanism. This is especially true in younger age groups where the prevalence of stroke is low and the prevalence of migraine is high. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Possible relationships'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There appears to be an increased risk of stroke associated with migraine, particularly in women who have migraine with aura. However, the absolute increase in the risk of stroke is small. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Migraine and ischemic stroke risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stroke risk appears to be most increased in women of child bearing age who have migraine with aura and smoke",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      use estrogen-progestin contraceptives. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several studies have found an association between migraine with aura and silent infarct-like lesions on brain MRI located mainly in the posterior circulation white matter or cerebellum. However, the etiology, nature, and clinical significance of these MRI lesions remain unclear. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Subclinical brain lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathophysiology underlying migraine as a possible cause of stroke or as a stroke risk factor is not clear, but vasospasm and changes in cerebral blood flow are biologically plausible mechanisms. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonmigraine, nonspecific,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic headache may be a predictor of ischemic stroke risk, but the evidence is conflicting. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Nonspecific headache and stroke risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment aimed at primary or secondary stroke prevention should combine stroke risk factor control with headache prophylaxis. Patients with frequent migraine and vascular disease should also receive migraine prophylaxis. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vasoconstrictive medications including triptans, serotonin agonists, and ergot alkaloids are relatively contraindicated in patients with vascular disease. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Drugs to avoid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who have migraine without aura and no other risk factors for stroke may use a contraceptive pill with low-dose estrogen (less than 50 mcg). Women who have migraine with aura should be encouraged to stop smoking, control their blood pressure, and use an alternative method of contraception. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Contraception'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/1\">",
"      Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988; 8 Suppl 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/2\">",
"      Gorelick PB, Hier DB, Caplan LR, Langenberg P. Headache in acute cerebrovascular disease. Neurology 1986; 36:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/3\">",
"      Mitsias P, Ramadan NM. Headache in ischemic cerebrovascular disease. Part I: Clinical features. Cephalalgia 1992; 12:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/4\">",
"      Mitsias P, Ramadan NM. Headache in ischemic cerebrovascular disease. Part II: Mechanisms and predictive value. Cephalalgia 1992; 12:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/5\">",
"      Call GK, Fleming MC, Sealfon S, et al. Reversible cerebral segmental vasoconstriction. Stroke 1988; 19:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/6\">",
"      Meschia JF, Malkoff MD, Biller J. Reversible segmental cerebral arterial vasospasm and cerebral infarction: possible association with excessive use of sumatriptan and Midrin. Arch Neurol 1998; 55:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/7\">",
"      Conde L&oacute;pez VJ, Ballesteros Alcalde MC, Blanco Garrote JA, Marco Llorente J. [Cerebral infarction in an adolescent girl following an overdose of paroxetine and caffedrine combined with theodrenaline]. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1998; 26:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/8\">",
"      Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002; 58:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/9\">",
"      Noskin O, Jafarimojarrad E, Libman RB, Nelson JL. Diffuse cerebral vasoconstriction (Call-Fleming syndrome) and stroke associated with antidepressants. Neurology 2006; 67:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/10\">",
"      Lindboe CF, Dahl T, Rostad B. Fatal stroke in migraine: a case report with autopsy findings. Cephalalgia 1989; 9:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/11\">",
"      Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med 2007; 146:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/12\">",
"      Ducros A, Fiedler U, Porcher R, et al. Hemorrhagic manifestations of reversible cerebral vasoconstriction syndrome: frequency, features, and risk factors. Stroke 2010; 41:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/13\">",
"      Singhal, A. Cerebral vasoconstriction without subarachnoid hemorrhage: associated conditions and clinical and neuroimaging characteristics. Ann Neurol 2002; Suppl 1:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/14\">",
"      Pavlakis SG, Frank Y, Chusid R. Hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: three names for an old syndrome. J Child Neurol 1999; 14:277.",
"     </a>",
"    </li>",
"    <li>",
"     Lamy, C, Mas, J-L. Hypertensive encephalopathy. In: Stroke: pathophysiology, diagnosis, and management, Mohr, JP, Choi, DW, Grotta, JC, et al (Eds), Churchill Livingstone, Philadelphia 2004. p.641.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/16\">",
"      Reigel MM, Hollier LH, Sundt TM Jr, et al. Cerebral hyperperfusion syndrome: a cause of neurologic dysfunction after carotid endarterectomy. J Vasc Surg 1987; 5:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/17\">",
"      Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334:494.",
"     </a>",
"    </li>",
"    <li>",
"     Diener, HC, Welch, KMA, Mohr, JP. Migraine and stroke. In: Stroke: pathophysiology, diagnosis, and management, Mohr, JP, Choi, DW, Grotta, JC, et al (Eds), Churchill Livingstone, Philadelphia 2004. p.629.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/19\">",
"      Bruyn GW. Intracranial arteriovenous malformation and migraine. Cephalalgia 1984; 4:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/20\">",
"      Monteiro JM, Rosas MJ, Correia AP, Vaz AR. Migraine and intracranial vascular malformations. Headache 1993; 33:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/21\">",
"      Haas DC. Arteriovenous malformations and migraine: case reports and an analysis of the relationship. Headache 1991; 31:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/22\">",
"      Tournier-Lasserve E, Iba-Zizen MT, Romero N, Bousser MG. Autosomal dominant syndrome with strokelike episodes and leukoencephalopathy. Stroke 1991; 22:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/23\">",
"      Chabriat H, Vahedi K, Iba-Zizen MT, et al. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet 1995; 346:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/24\">",
"      Hutchinson M, O'Riordan J, Javed M, et al. Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL). Ann Neurol 1995; 38:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/25\">",
"      Ramadan NM, Tietjen GE, Levine SR, Welch KM. Scintillating scotomata associated with internal carotid artery dissection: report of three cases. Neurology 1991; 41:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/26\">",
"      Silverman IE, Wityk RJ. Transient migraine-like symptoms with internal carotid artery dissection. Clin Neurol Neurosurg 1998; 100:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/27\">",
"      Silbert PL, Mokri B, Schievink WI. Headache and neck pain in spontaneous internal carotid and vertebral artery dissections. Neurology 1995; 45:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/28\">",
"      Fisher CM. The headache and pain of spontaneous carotid dissection. Headache 1982; 22:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/29\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/30\">",
"      Narbone MC, Leggiadro N, La Spina P, et al. Migraine stroke: a possible complication of both migraine with and without aura. Headache 1996; 36:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/31\">",
"      Rothrock J, North J, Madden K, et al. Migraine and migrainous stroke: risk factors and prognosis. Neurology 1993; 43:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/32\">",
"      Ebinger F, Boor R, Gawehn J, Reitter B. Ischemic stroke and migraine in childhood: coincidence or causal relation? J Child Neurol 1999; 14:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/33\">",
"      Welch KM, Levine SR. Migraine-related stroke in the context of the International Headache Society classification of head pain. Arch Neurol 1990; 47:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/34\">",
"      Dayno JM, Silberstein SD. Migraine-related stroke versus migraine-induced stroke. Headache 1997; 37:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/35\">",
"      Fisher CM. Late-life migraine accompaniments as a cause of unexplained transient ischemic attacks. Can J Neurol Sci 1980; 7:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/36\">",
"      Tzourio C, Tehindrazanarivelo A, Igl&eacute;sias S, et al. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ 1995; 310:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/37\">",
"      Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 1999; 318:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/38\">",
"      Oral contraceptives and stroke in young women. Associated risk factors. JAMA 1975; 231:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/39\">",
"      Kittner SJ, McCarter RJ, Sherwin RW, et al. Black-white differences in stroke risk among young adults. Stroke 1993; 24:I13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/40\">",
"      Marini C, Carolei A, Roberts RS, et al. Focal cerebral ischemia in young adults: a collaborative case-control study. The National Research Council Study Group. Neuroepidemiology 1993; 12:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/41\">",
"      Sochurkova D, Moreau T, Lemesle M, et al. Migraine history and migraine-induced stroke in the Dijon stroke registry. Neuroepidemiology 1999; 18:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/42\">",
"      Henrich JB, Sandercock PA, Warlow CP, Jones LN. Stroke and migraine in the Oxfordshire Community Stroke Project. J Neurol 1986; 233:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/43\">",
"      Arboix A, Massons J, Garc&iacute;a-Eroles L, et al. Migrainous cerebral infarction in the Sagrat Cor Hospital of Barcelona stroke registry. Cephalalgia 2003; 23:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/44\">",
"      Linetsky E, Leker RR, Ben-Hur T. Headache characteristics in patients after migrainous stroke. Neurology 2001; 57:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/45\">",
"      Kurth T, Slomke MA, Kase CS, et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 2005; 64:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/46\">",
"      Carolei A, Marini C, De Matteis G. History of migraine and risk of cerebral ischaemia in young adults. The Italian National Research Council Study Group on Stroke in the Young. Lancet 1996; 347:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/47\">",
"      MacClellan LR, Giles W, Cole J, et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke 2007; 38:2438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/48\">",
"      Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 2005; 330:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/49\">",
"      Sch&uuml;rks M, Rist PM, Bigal ME, et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009; 339:b3914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/50\">",
"      Spector JT, Kahn SR, Jones MR, et al. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 2010; 123:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/51\">",
"      Rist PM, Buring JE, Kase CS, et al. Migraine and functional outcome from ischemic cerebral events in women. Circulation 2010; 122:2551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/52\">",
"      Diener HC, Beck CA. Migraine and risk of cardiovascular disease in women: learning about relative and absolute risk. Neurology 2009; 73:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/53\">",
"      Rose KM, Wong TY, Carson AP, et al. Migraine and retinal microvascular abnormalities: the Atherosclerosis Risk in Communities Study. Neurology 2007; 68:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/54\">",
"      Kurth T, Gaziano JM, Cook NR, et al. Migraine and risk of cardiovascular disease in men. Arch Intern Med 2007; 167:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/55\">",
"      Bigal ME, Kurth T, Santanello N, et al. Migraine and cardiovascular disease: a population-based study. Neurology 2010; 74:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/56\">",
"      Kurth T, Sch&uuml;rks M, Logroscino G, Buring JE. Migraine frequency and risk of cardiovascular disease in women. Neurology 2009; 73:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/57\">",
"      Bigal ME, Kurth T, Hu H, et al. Migraine and cardiovascular disease: possible mechanisms of interaction. Neurology 2009; 72:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/58\">",
"      Kurth T, Gaziano JM, Cook NR, et al. Migraine and risk of cardiovascular disease in women. JAMA 2006; 296:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/59\">",
"      Gudmundsson LS, Scher AI, Aspelund T, et al. Migraine with aura and risk of cardiovascular and all cause mortality in men and women: prospective cohort study. BMJ 2010; 341:c3966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/60\">",
"      Rose KM, Carson AP, Sanford CP, et al. Migraine and other headaches: associations with Rose angina and coronary heart disease. Neurology 2004; 63:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/61\">",
"      Loder E. Migraine with aura and increased risk of ischaemic stroke. BMJ 2009; 339:b4380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/62\">",
"      Thomas DJ. Migraine and ischaemic stroke. BMJ 2005; 330:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/63\">",
"      Wolf ME, Szabo K, Griebe M, et al. Clinical and MRI characteristics of acute migrainous infarction. Neurology 2011; 76:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/64\">",
"      Kruit MC, van Buchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA 2004; 291:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/65\">",
"      Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain 2005; 128:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/66\">",
"      Scher AI, Gudmundsson LS, Sigurdsson S, et al. Migraine headache in middle age and late-life brain infarcts. JAMA 2009; 301:2563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/67\">",
"      Kurth T, Tzourio C. Migraine and cerebral infarct-like lesions on MRI: an observation, not a disease. JAMA 2009; 301:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/68\">",
"      Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Brain stem and cerebellar hyperintense lesions in migraine. Stroke 2006; 37:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/69\">",
"      Swartz RH, Kern RZ. Migraine is associated with magnetic resonance imaging white matter abnormalities: a meta-analysis. Arch Neurol 2004; 61:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/70\">",
"      Henrich JB. The association between migraine and cerebral vascular events: an analytical review. J Chronic Dis 1987; 40:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/71\">",
"      Woods RP, Iacoboni M, Mazziotta JC. Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994; 331:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/72\">",
"      Olesen J, Friberg L, Olsen TS, et al. Ischaemia-induced (symptomatic) migraine attacks may be more frequent than migraine-induced ischaemic insults. Brain 1993; 116 ( Pt 1):187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/73\">",
"      Rothrock JF, Walicke P, Swenson MR, et al. Migrainous stroke. Arch Neurol 1988; 45:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/74\">",
"      Kurth T, Chabriat H, Bousser MG. Migraine and stroke: a complex association with clinical implications. Lancet Neurol 2012; 11:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/75\">",
"      Eikermann-Haerter K, Lee JH, Yuzawa I, et al. Migraine mutations increase stroke vulnerability by facilitating ischemic depolarizations. Circulation 2012; 125:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/76\">",
"      D'Andrea G, Hasselmark L, Alecci M, et al. Platelet secretion from dense and alpha-granules in vitro in migraine with or without aura. J Neurol Neurosurg Psychiatry 1994; 57:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/77\">",
"      Kalendovsky Z, Austin JH. \"Complicated migraine\" its association with increased platelet aggregability and abnormal plasma coagulation factors. Headache 1975; 15:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/78\">",
"      Zeller JA, Frahm K, Baron R, et al. Platelet-leukocyte interaction and platelet activation in migraine: a link to ischemic stroke? J Neurol Neurosurg Psychiatry 2004; 75:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/79\">",
"      Ferrari MD, Odink J, Tapparelli C, et al. Serotonin metabolism in migraine. Neurology 1989; 39:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/80\">",
"      Gallai V, Sarchielli P, Firenze C, et al. Endothelin 1 in migraine and tension-type headache. Acta Neurol Scand 1994; 89:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/81\">",
"      Soriani S, Borgna-Pignatti C, Trabetti E, et al. Frequency of factor V Leiden in juvenile migraine with aura. Headache 1998; 38:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/82\">",
"      Hering-Hanit R, Friedman Z, Schlesinger I, Ellis M. Evidence for activation of the coagulation system in migraine with aura. Cephalalgia 2001; 21:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/83\">",
"      Tietjen GE, Al-Qasmi MM, Athanas K, et al. Increased von Willebrand factor in migraine. Neurology 2001; 57:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/84\">",
"      Waeber C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology 2005; 64:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/85\">",
"      Tietjen GE, Herial NA, White L, et al. Migraine and biomarkers of endothelial activation in young women. Stroke 2009; 40:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/86\">",
"      Lee ST, Chu K, Jung KH, et al. Decreased number and function of endothelial progenitor cells in patients with migraine. Neurology 2008; 70:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/87\">",
"      Silva FA, Rueda-Clausen CF, Silva SY, et al. Endothelial function in patients with migraine during the interictal period. Headache 2007; 47:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/88\">",
"      Crassard I, Conard J, Bousser MG. Migraine and haemostasis. Cephalalgia 2001; 21:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/89\">",
"      Eggers AE. New neural theory of migraine. Med Hypotheses 2001; 56:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/90\">",
"      Scher AI, Terwindt GM, Verschuren WM, et al. Migraine and MTHFR C677T genotype in a population-based sample. Ann Neurol 2006; 59:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/91\">",
"      Shechter A, Stewart WF, Silberstein SD, Lipton RB. Migraine and autonomic nervous system function: a population-based, case-control study. Neurology 2002; 58:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/92\">",
"      Aygun D, Altintop L, Doganay Z, et al. Electrocardiographic changes during migraine attacks. Headache 2003; 43:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/93\">",
"      Caplan LR, Hennerici M. Impaired clearance of emboli (washout) is an important link between hypoperfusion, embolism, and ischemic stroke. Arch Neurol 1998; 55:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/94\">",
"      Rist PM, Diener HC, Kurth T, Sch&uuml;rks M. Migraine, migraine aura, and cervical artery dissection: a systematic review and meta-analysis. Cephalalgia 2011; 31:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/95\">",
"      Silvestrini M, Matteis M, Troisi E, et al. Migrainous stroke and the antiphospholipid antibodies. Eur Neurol 1994; 34:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/96\">",
"      Levine SR, Joseph R, D'Andrea G, Welch KM. Migraine and the lupus anticoagulant. Case reports and review of the literature. Cephalalgia 1987; 7:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/97\">",
"      Cuadrado MJ, Sanna G. Headache and systemic lupus erythematosus. Lupus 2003; 12:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/98\">",
"      Straube A, Padovan CS, F&ouml;rderreuther S, Wick M. [Antinuclear and anticardiolipin antibodies in primary headache syndromes]. Schmerz 1998; 12:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/99\">",
"      Tietjen GE, Gottwald L, Al-Qasmi MM, et al. Migraine is associated with livedo reticularis: a prospective study. Headache 2002; 42:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/100\">",
"      Tietjen GE, Al-Qasmi MM, Shukairy MS. Livedo reticularis and migraine: a marker for stroke risk? Headache 2002; 42:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/101\">",
"      Rebollo M, Val JF, Garijo F, et al. Livedo reticularis and cerebrovascular lesions (Sneddon's syndrome). Clinical, radiological and pathological features in eight cases. Brain 1983; 106 ( Pt 4):965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/102\">",
"      Martinelli A, Martinelli P, Ippoliti M, et al. Sneddon syndrome presenting with hemicranic attacks: a case report. Acta Neurol Scand 1991; 83:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/103\">",
"      Buring JE, Hebert P, Romero J, et al. Migraine and subsequent risk of stroke in the Physicians' Health Study. Arch Neurol 1995; 52:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/104\">",
"      Jousilahti P, Tuomilehto J, Rastenyte D, Vartiainen E. Headache and the risk of stroke: a prospective observational cohort study among 35,056 Finnish men and women. Arch Intern Med 2003; 163:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/105\">",
"      Merikangas KR, Fenton BT, Cheng SH, et al. Association between migraine and stroke in a large-scale epidemiological study of the United States. Arch Neurol 1997; 54:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/106\">",
"      Weir B, Grace M, Hansen J, Rothberg C. Time course of vasospasm in man. J Neurosurg 1978; 48:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/107\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.",
"     </a>",
"    </li>",
"    <li>",
"     Medical eligibility criteria for contraceptive use, 4th ed, World Health Organization, Geneva 2009. file://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf (Accessed on January 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32953/abstract/109\">",
"      Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349:1443.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3344 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-113.53.254.124-C33D2BEBF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32953=[""].join("\n");
var outline_f32_11_32953=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      POSSIBLE RELATIONSHIPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Headache coincidental with stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Coexisting stroke and migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Headache due to stroke or vascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hemorrhagic stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Sentinel headache",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Reversible cerebral vasoconstriction syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Symptomatic migraine and migraine mimics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prolonged aura (complicated migraine)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Migrainous stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Migrainous infarction definition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Migraine-related stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Migraine with clinical features of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Migrainous stroke prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Migrainous stroke incidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MIGRAINE AND ISCHEMIC STROKE RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77337178\">",
"      Acute migrainous infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Subclinical brain lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Interaction of migraine with other stroke risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      NONSPECIFIC HEADACHE AND STROKE RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Drugs to avoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_11_32954="The metabolic syndrome (insulin resistance syndrome or syndrome X)";
var content_f32_11_32954=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32954/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32954/contributors\">",
"     James B Meigs, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32954/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32954/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32954/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/11/32954/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/11/32954/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/11/32954/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity, particularly abdominal obesity, is associated with resistance to the effects of insulin on peripheral glucose and fatty acid utilization, often leading to type 2 diabetes mellitus. Insulin resistance, the associated hyperinsulinemia and hyperglycemia, and adipocyte cytokines (adipokines) may also lead to vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease (CVD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. A similar profile can be seen in individuals with abdominal obesity who do not have an excess of total body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The co-occurrence of metabolic risk factors for both type 2 diabetes and CVD (abdominal obesity, hyperglycemia, dyslipidemia, and hypertension) suggested the existence of a \"metabolic syndrome\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/1,9-11\">",
"     1,9-11",
"    </a>",
"    ]. Other names applied to this constellation of findings have included syndrome X, the insulin resistance syndrome, the deadly quartet, or the obesity dyslipidemia syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/12\">",
"     12",
"    </a>",
"    ]. Genetic predisposition, lack of exercise, and body fat distribution all affect the likelihood that a given obese subject will become overtly diabetic or develop CVD.",
"   </p>",
"   <p>",
"    It should be noted that questions have been raised as to whether the metabolic syndrome, as currently defined, captures any unique pathophysiology implied by calling it a \"syndrome,\" and whether metabolic syndrome confers risk beyond its individual components. These questions raise uncertainty about the value of diagnosing metabolic syndrome in individual patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. These arguments will be reviewed at the end of this discussion (see",
"    <a class=\"local\" href=\"#H29\">",
"     'A critical look at the metabolic syndrome'",
"    </a>",
"    below). Regardless of whether the metabolic syndrome is considered a unique entity, the need is unquestioned to identify and manage its individual components to decrease morbidity and mortality associated with diabetes and cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The definition, prevalence, clinical implications, and therapy of the metabolic syndrome will be reviewed here, including the limited data in children and adolescents. The pathogenesis of the relationship between obesity and type 2 diabetes and other causes of insulin resistance are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis of type 2 diabetes mellitus\", section on 'Role of diet, obesity, and inflammation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28567?source=see_link\">",
"     \"Insulin resistance: Definition and clinical spectrum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The metabolic syndrome should not be confused with another disorder called syndrome X in which angina pectoris occurs in patients with normal coronary arteries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5802?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because metabolic syndrome traits co-occur, patients identified with one or just a few traits are likely to have other traits, as well as insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/17\">",
"     17",
"    </a>",
"    ]. Whether it is valuable to assess insulin resistance in addition to more readily measured traits of the syndrome is uncertain.",
"   </p>",
"   <p>",
"    There are several definitions for the metabolic syndrome, leading to some difficulty in comparing data from studies using different criteria (",
"    <a class=\"graphic graphic_table graphicRef53446 \" href=\"mobipreview.htm?30/44/31437\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/18-24\">",
"     18-24",
"    </a>",
"    ]. The National Cholesterol Education Program",
"    <span class=\"nowrap\">",
"     (NCEP/ATP",
"    </span>",
"    III) is the most widely used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     2001 National Cholesterol Education Program/ATP III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines developed by the 2001 National Cholesterol Education Program (Adult Treatment Panel [ATP] III) focused explicitly on the risk of cardiovascular disease and did not require evidence of insulin or glucose abnormalities, although abnormal glycemia is one of the criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/21\">",
"     21",
"    </a>",
"    ]. ATP III metabolic syndrome criteria were updated in 2005 in a statement from the American Heart Association",
"    <span class=\"nowrap\">",
"     (AHA)/National",
"    </span>",
"    Heart, Lung, and Blood Institute (NHLBI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Updates include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lowering the threshold for abnormal fasting glucose to 100",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      corresponding to the ADA criteria for impaired fasting glucose (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=see_link\">",
"       \"Diagnosis of diabetes mellitus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Explicitly including diabetes in the hyperglycemia trait definition",
"     </li>",
"     <li>",
"      Explicitly including use of drugs for lipid control or blood pressure control in the dyslipidemia and hypertension trait definitions, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current ATP III criteria define the metabolic syndrome as the presence of any",
"    <strong>",
"     three",
"    </strong>",
"    of the following five traits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal obesity, defined as a waist circumference in men &ge;102 cm (40 in) and in women &ge;88 cm (35 in)",
"     </li>",
"     <li>",
"      Serum triglycerides &ge;150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or drug treatment for elevated triglycerides",
"     </li>",
"     <li>",
"      Serum HDL cholesterol &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in men and &lt;50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in women or drug treatment for low HDL-C",
"     </li>",
"     <li>",
"      Blood pressure",
"      <span class=\"nowrap\">",
"       &ge;130/85",
"      </span>",
"      mmHg or drug treatment for elevated blood pressure",
"     </li>",
"     <li>",
"      Fasting plasma glucose (FPG) &ge;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or drug treatment for elevated blood glucose",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     International Diabetes Federation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Diabetes Federation (IDF) updated their metabolic syndrome criteria in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/26\">",
"     26",
"    </a>",
"    ]. Central obesity is an essential element in this definition, with different waist circumference thresholds set for different",
"    <span class=\"nowrap\">",
"     race/ethnicity",
"    </span>",
"    groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased waist circumference, with ethnic-specific waist circumference cut-points (",
"      <a class=\"graphic graphic_table graphicRef76837 \" href=\"mobipreview.htm?29/23/30076\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PLUS any",
"    <strong>",
"     two",
"    </strong>",
"    of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Triglycerides &gt;150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or treatment for elevated triglycerides",
"     </li>",
"     <li>",
"      HDL cholesterol &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.03",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in men or &lt;50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.29",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in women, or treatment for low HDL",
"     </li>",
"     <li>",
"      Systolic blood pressure &gt;130, diastolic blood pressure &gt;85, or treatment for hypertension",
"     </li>",
"     <li>",
"      Fasting plasma glucose &gt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or previously diagnosed type 2 diabetes; an oral glucose tolerance test is recommended for patients with an elevated fasting plasma glucose, but not required",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Comparing criteria in defining populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using data from the National Health and Nutrition Examination Survey 1999 to 2002 database, 39 percent of US adult participants met IDF criteria for the metabolic syndrome, compared to 34.5 percent using the ATP III criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/27\">",
"     27",
"    </a>",
"    ]. The two definitions overlapped for 93 percent of subjects in determining presence or absence of the metabolic syndrome. When applied to an urban population in the US, the IDF criteria categorized 15 to 20 percent more adults with the metabolic syndrome than the ATP III criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative value of different metabolic syndrome definitions in terms of prognosis and management appears to be similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort study of a random sample of British women (n = 3589) aged 60 to 79 years, who were free of coronary heart disease (CHD) at baseline, all three definitions of the metabolic syndrome were modestly and similarly associated with CHD risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/29\">",
"       29",
"      </a>",
"      ]. The age-adjusted hazard ratios for IDF, WHO, and NCEP syndromes were 1.32 (95% CI 1.03-1.70), 1.45 (1.00-2.10), and 1.38 (1.00-1.93), respectively.",
"     </li>",
"     <li>",
"      Similarly, when data from the Framingham population are examined using ATPIII, IDF, and EGIR definitions of the metabolic syndrome, roughly equivalent associations for incident type 2 diabetes (HR 3.5, 95% CI 2.2 to 5.6; 4.6, 2.7 to 7.7; 3.3, 2.1 to 5.1, respectively) and for CVD (1.8, 1.4 to 2.3; 1.7, 1.3 to 2.3; 2.1, 1.6 to 2.7, respectively) are observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/30\">",
"       30",
"      </a>",
"      ]. Thus, risk factor clustering defines increased risk for type 2 diabetes and CVD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The WHO, ATP III, and IDF definitions include type 2 diabetes as syndrome traits. Experts do not all agree that type 2 diabetes should be part of the definition, as the importance of the syndrome is that it identifies patients at increased risk for the development of diabetes. Most patients with type 2 diabetes have features of the metabolic syndrome, in which it identifies those at greater risk of macrovascular but not microvascular complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/32\">",
"     32",
"    </a>",
"    ]. Management of patients with type 2 diabetes should follow clinical guidelines, whether or not they also meet criteria for metabolic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Potential other markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic syndrome has been recognized as a proinflammatory, prothrombotic state, associated with elevated levels of C-reactive protein, interleukin (IL)-6, and plasminogen activator inhibitor (PAI)-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/4,26,33-39\">",
"     4,26,33-39",
"    </a>",
"    ]. Inflammatory and prothrombotic markers are associated with an increased risk for subsequent CVD and type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/35-38\">",
"     35-38",
"    </a>",
"    ], although adipokines and inflammatory markers explained only a small part of the association between the metabolic syndrome and CHD mortality in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/40\">",
"     40",
"    </a>",
"    ]. Additionally, a causal association between elevated CRP and the metabolic syndrome was not demonstrated in a study of phenotype patterns associated with the metabolic syndrome and CRP levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of measurement or treatment of inflammatory or vascular function markers in the setting of metabolic syndrome is unknown. Use of these markers should be considered for clinical purposes only in the setting of CVD risk assessment and reduction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34665?source=see_link\">",
"     \"Screening for cardiovascular risk with C-reactive protein\"",
"    </a>",
"    .)",
"    <span class=\"nowrap\">",
"     AHA/CDC",
"    </span>",
"    guidelines emphasize that CRP testing still belongs in the category of optional, based on clinical judgment rather than recommended routinely because the magnitude of its independent predictive power remains uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVALENCE AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of the metabolic syndrome, as defined by the 2001 ATP III criteria, was evaluated in 8814 adults in the United States participating in the third National Health and Nutrition Examination Survey (NHANES III, 1988 to 1994) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/43\">",
"     43",
"    </a>",
"    ]. The overall prevalence was 22 percent, with an age-dependent increase (6.7, 43.5, and 42.0 percent for ages 20 to 29, 60 to 69, and &gt;70 years, respectively) (",
"    <a class=\"graphic graphic_figure graphicRef63251 \" href=\"mobipreview.htm?40/35/41533\">",
"     figure 1",
"    </a>",
"    ). Mexican-Americans had the highest age-adjusted prevalence (31.9 percent). Among African-Americans and Mexican-Americans, the prevalence was higher in women than in men (57 and 26 percent higher, respectively) (",
"    <a class=\"graphic graphic_figure graphicRef78091 \" href=\"mobipreview.htm?39/9/40093\">",
"     figure 2",
"    </a>",
"    ). Data from NHANES 1999 to 2000 demonstrate that the prevalence has continued to increase, particularly in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The metabolic syndrome is becoming increasingly common. Using data from the National Health and Nutrition Examination Survey 1999 to 2002 database, 34.5 percent of participants met ATP III criteria for the metabolic syndrome compared with 22 percent in NHANES III (1988 to 1994) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/27,43\">",
"     27,43",
"    </a>",
"    ]. In addition, metabolic syndrome, defined by the 2005 revised ATP III criteria, was assessed in 3323 Framingham Heart Study participants, ages 22 to 81, who did not have diabetes or cardiovascular disease at a baseline examination in the early 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/45\">",
"     45",
"    </a>",
"    ]. At baseline, the prevalence of the metabolic syndrome was 26.8 percent in men and 16.6 percent in women. After eight years of follow-up, there was an age-adjusted 56 percent increase in prevalence among men and a 47 percent increase among women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Increased weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased body weight is a major risk factor for the metabolic syndrome. In NHANES III, the metabolic syndrome was present in 5 percent of those at normal weight, 22 percent of those who were overweight, and 60 percent of those who were obese [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=see_link\">",
"     \"Screening for and clinical evaluation of obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the Framingham Heart Study cohort, an increase in weight of 2.25 kg or more over 16 years was associated with a 21 to 45 percent increase in the risk for developing the syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/47\">",
"     47",
"    </a>",
"    ]. A large waist circumference alone identifies up to 46 percent of individuals who will develop the metabolic syndrome within five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rapidly increasing prevalence of obesity among adults in the United States is likely to lead to even higher rates of the metabolic syndrome in the near future [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/49\">",
"     49",
"    </a>",
"    ], highlighting the importance of obesity prevention and improving physical activity levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3418?source=see_link\">",
"     \"Etiology and natural history of obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to age, race, and weight, other factors associated with an increased risk of metabolic syndrome in NHANES III included postmenopausal status, smoking, low household income, high carbohydrate diet, no alcohol consumption, and physical inactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/46\">",
"     46",
"    </a>",
"    ]. In the Framingham Heart Study, soft drink consumption was also associated with an increased risk of developing adverse metabolic traits and the metabolic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/52\">",
"     52",
"    </a>",
"    ]. Use of atypical antipsychotic medications, especially",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , significantly increases risk for the metabolic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, poor cardiorespiratory fitness is an independent and strong predictor of metabolic syndrome in both men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A parental history of metabolic syndrome increases risk, and genetic factors may account for as much as 50 percent of the variation in levels of metabolic syndrome traits in the offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/55-58\">",
"     55-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL IMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic syndrome is an important risk factor for subsequent development of type 2 diabetes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CVD. Thus, the key clinical implication of a diagnosis of metabolic syndrome is identification of a patient who needs aggressive lifestyle modification focused on weight reduction and increased physical activity (",
"    <a class=\"graphic graphic_table graphicRef80387 \" href=\"mobipreview.htm?34/61/35804\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/11,50,59\">",
"     11,50,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Identification of patients at high metabolic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health care providers should assess individuals for metabolic risk at routine clinic visits. The Endocrine Society clinical guidelines suggest evaluation at three-year intervals in individuals with one or more risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/60\">",
"     60",
"    </a>",
"    ]. The assessment should include measurement of blood pressure, waist circumference, fasting lipid profile, and fasting glucose.",
"   </p>",
"   <p>",
"    In patients identified as having the metabolic syndrome (",
"    <a class=\"graphic graphic_table graphicRef53446 \" href=\"mobipreview.htm?30/44/31437\">",
"     table 1",
"    </a>",
"    ), aggressive lifestyle intervention (weight reduction, physical activity) is warranted to reduce the risks of type 2 diabetes and cardiovascular disease. Assessment of 10-year risk for cardiovascular disease, using a risk assessment algorithm, such as the Framingham Risk Score or SCORE, is useful in targeting individuals for medical intervention to lower blood pressure and cholesterol. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link&amp;anchor=H8#H8\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\", section on 'Multivariate risk models'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link&amp;anchor=H18#H18\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\", section on 'Clinical use of risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Risk of type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective observational studies demonstrate a strong association between the metabolic syndrome and the risk for subsequent development of type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/61-65\">",
"     61-65",
"    </a>",
"    ]. In a meta-analysis of 16 multi-ethnic cohort studies, the relative risk of developing diabetes ranged from 3.53 to 5.17, depending upon the definition of metabolic syndrome and the population studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/66\">",
"     66",
"    </a>",
"    ]. As an example, in an analysis of 890 nondiabetic Pima Indians, 144 developed diabetes over four years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/61\">",
"     61",
"    </a>",
"    ]. The metabolic syndrome increased the relative risk (RR) for incident diabetes by 2.1-fold with the ATP III definition and 3.6-fold using the WHO definition. This difference highlights the importance of insulin resistance (a required characteristic of the WHO definition) in the pathogenesis of type 2 diabetes.",
"   </p>",
"   <p>",
"    In several cohorts, the risk of diabetes increased with increasing number of components of the metabolic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/45,59,63\">",
"     45,59,63",
"    </a>",
"    ]. While the metabolic syndrome predicts increased risk for diabetes, it is not clear whether this adds additional important information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In a prospective cohort study of 5842 Australian adults, metabolic syndrome (defined by WHO, ATP III, EGIR, or IDF) was not superior to fasting plasma glucose or a published diabetes prediction model (including age, gender, ethnicity, fasting plasma glucose, systolic blood pressure, HDL cholesterol, BMI, and family history) in identifying individuals who developed diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'A critical look at the metabolic syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Risk of CVD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three meta-analyses, which included many of the same studies, found that the metabolic syndrome increases the risk for incident cardiovascular disease (CVD) (RRs ranging from 1.53 to 2.18) and all cause mortality (RRs 1.27 to 1.60) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased risk appears to be related to the risk factor clustering or insulin resistance associated with the metabolic syndrome rather than simply to obesity. This was illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of the Framingham population, obese people without metabolic syndrome did not have a significantly increased risk of diabetes or CVD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/72\">",
"       72",
"      </a>",
"      ]. Obese people with the metabolic syndrome had a 10-fold increased risk for diabetes and a twofold increased risk for CVD relative to normal weight people without the metabolic syndrome. Normal weight people meeting revised 2005 ATP III criteria for the metabolic syndrome had a fourfold increased risk for diabetes and a threefold increased risk for CVD.",
"     </li>",
"     <li>",
"      In a study of 211 moderately obese (BMI 30 to 35) men and women, insulin sensitivity varied sixfold, and those with the greatest degree of insulin resistance had the highest blood pressure, triglyceride concentrations, fasting and two-hour post oral glucose blood sugar levels, and the lowest HDL concentrations, despite equal levels of obesity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, not all moderately obese individuals have the same risk for developing cardiovascular disease or diabetes; risks differ as a function of insulin sensitivity, with insulin-resistant, obese individuals at highest risk.",
"   </p>",
"   <p>",
"    The risk also may be related to underlying subclinical CVD (as measured by ECG, echocardiography, carotid ultrasound, and ankle-brachial blood pressure) in individuals with metabolic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/74\">",
"     74",
"    </a>",
"    ]. In the Framingham Offspring study, 51 percent of 581 participants with metabolic syndrome had subclinical CVD, and the risk of overt CVD in these individuals was greater than in individuals with metabolic syndrome without subclinical CVD (HR 2.67 versus 1.59). Subclinical CVD was also predictive of overt CVD in subjects without metabolic syndrome (HR 1.93, 95% CI 1.15-3.24).",
"   </p>",
"   <p>",
"    While the metabolic syndrome predicts increased risk for CVD, it is not clear whether this adds additional important information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/67,69,75\">",
"     67,69,75",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated triglyceride and low HDL cholesterol levels were as strong of a predictor of vascular events as the presence of metabolic syndrome (by ATP III criteria) in a prospective study of a population of patients with angiographically-determined coronary artery disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Framingham Risk Score was a better predictor of CHD and stroke than metabolic syndrome (ATP III criteria with obesity defined by an elevated BMI rather than waist circumference) in a prospective study of 5128 British men aged 40 to 59 years followed for 20 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low HDL cholesterol and high blood pressure were better predictors of CHD than the metabolic syndrome in a prospective study of 2737 men from the same cohort [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic syndrome has also been associated with several obesity-related disorders including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fatty liver disease with steatosis, fibrosis, and cirrhosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/78-80\">",
"       78-80",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38105?source=see_link&amp;anchor=H147569346#H147569346\">",
"       \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\", section on 'Associated disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatocellular and intrahepatic cholangiocarcinoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link&amp;anchor=H14#H14\">",
"       \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Diabetes mellitus'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43881?source=see_link&amp;anchor=H60103124#H60103124\">",
"       \"Epidemiology, pathogenesis, and classification of cholangiocarcinoma\", section on 'Metabolic syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic kidney disease (CKD; defined as a glomerular filtration rate less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2) and microalbuminuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]. In a report from NHANES III, the metabolic syndrome in multivariate analysis significantly increased the risk of both chronic kidney disease and microalbuminuria (adjusted odds ratio 2.6 and 1.9, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/81\">",
"       81",
"      </a>",
"      ]. The risk of both complications increased with the number of components of the metabolic syndrome. In a prospective cohort study, 10 percent of individuals with the metabolic syndrome at baseline subsequently developed CKD compared with 6 percent among those without the metabolic syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polycystic ovary syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/84\">",
"       84",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link\">",
"       \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sleep-disordered breathing, including obstructive sleep apnea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/85,86\">",
"       85,86",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link\">",
"       \"Overview of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperuricemia and gout [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1416?source=see_link&amp;anchor=H5#H5\">",
"       \"Asymptomatic hyperuricemia\", section on 'Potential consequences of hyperuricemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several components of the metabolic syndrome, including hyperlipidemia, hypertension, and diabetes have been associated with an increased risk of cognitive decline and dementia. The metabolic syndrome (when associated with a high level of inflammation) may also be associated with cognitive decline in the elderly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36202?source=see_link\">",
"     \"Risk factors for dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2001, ATP III recommended two major therapeutic goals in patients with the metabolic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/21\">",
"     21",
"    </a>",
"    ]. These goals were reinforced by a report from the American Heart Association and the National Institutes of Health (",
"    <a class=\"graphic graphic_table graphicRef80387 \" href=\"mobipreview.htm?34/61/35804\">",
"     table 3",
"    </a>",
"    ) and by clinical guidelines from The Endocrine Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/23,59,60\">",
"     23,59,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treat underlying causes",
"      <span class=\"nowrap\">",
"       (overweight/obesity",
"      </span>",
"      and physical inactivity) by intensifying weight management and increasing physical activity.",
"     </li>",
"     <li>",
"      Treat cardiovascular risk factors if they persist despite lifestyle modification.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no direct evidence that attempting to prevent type 2 diabetes and CVD by treating the metabolic syndrome is as effective as attaining the above goals. It is possible to treat insulin resistance with drugs that enhance insulin action (eg, thiazolidinediones and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    ). However, the ability of such an approach to improve outcomes compared to weight reduction and exercise alone is not yet well supported by clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=see_link\">",
"     \"Metformin in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Prevention of type 2 diabetes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Lifestyle modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention or reduction of obesity, particularly abdominal obesity, is the main therapeutic goal in patients with the metabolic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/50,91\">",
"     50,91",
"    </a>",
"    ]. The importance of weight management in preventing progression of metabolic syndrome components is illustrated by The Coronary Artery Risk Development in Young Adults (CARDIA) study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/92\">",
"     92",
"    </a>",
"    ]. In this observational study of 5115 young adults (ages 18 to 30 years), increasing BMI over 15 years was associated with adverse progression of metabolic syndrome components compared with young adults who maintained stable BMI over the study period, regardless of baseline BMI.",
"   </p>",
"   <p>",
"    Weight reduction is optimally achieved with a multimodality approach including diet, exercise, and possible pharmacologic therapy, as with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/93,94\">",
"     93,94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several dietary approaches have been advocated for treatment of the metabolic syndrome. Most patients with the metabolic syndrome are overweight, and weight reduction, which improves insulin sensitivity, is an important outcome goal of any diet. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3078?source=see_link\">",
"     \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\"",
"    </a>",
"    .) The following specific diet approaches have been recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Mediterranean diet may be beneficial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/95-98\">",
"       95-98",
"      </a>",
"      ]. In a study comparing the Mediterranean diet (high in fruits, vegetables, nuts, whole grains, and olive oil) with a low-fat prudent diet, subjects in the Mediterranean diet group had greater weight loss, lower blood pressure, improved lipid profiles, improved insulin resistance, and lower levels of markers of inflammation and endothelial function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/95\">",
"       95",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2601?source=see_link\">",
"       \"Dietary fat\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=see_link\">",
"       \"Endothelial dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The DASH diet (daily sodium intake limited to 2400 mg, and higher in dairy intake than the Mediterranean diet), compared to a weight reducing diet emphasizing healthy food choices, resulted in greater improvements in triglycerides, diastolic blood pressure, and fasting glucose, even after controlling for weight loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Foods with low glycemic index may improve glycemia and dyslipidemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/100\">",
"       100",
"      </a>",
"      ]. A diet that is low in glycemic",
"      <span class=\"nowrap\">",
"       index/glycemic",
"      </span>",
"      load, replacing refined grains with whole grains, fruits and vegetables, and eliminating high-glycemic beverages, may be particularly beneficial for patients with the metabolic syndrome. The impact of the glycemic index itself versus the increase in high fiber foods that accompanies a lower glycemic index diet is uncertain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/101\">",
"       101",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38649?source=see_link\">",
"       \"Dietary carbohydrates\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise may be beneficial beyond its effect on weight loss by more selectively removing abdominal fat, at least in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/102\">",
"     102",
"    </a>",
"    ]. Current physical activity guidelines recommend practical, regular, and moderate regimens for exercise. The standard exercise recommendation is a daily minimum of 30 minutes of moderate-intensity (such as brisk walking) physical activity. Increasing the level of physical activity appears to further enhance the beneficial effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21144?source=see_link\">",
"     \"Role of physical activity and exercise in obese adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Removal of abdominal adipose tissue with liposuction does not improve insulin sensitivity or risk factors for coronary heart disease, suggesting that the negative energy balance induced by diet and exercise are necessary for achieving the metabolic benefits of weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/104\">",
"     104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of therapy for obesity in adults\", section on 'Liposuction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prevention of type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not strictly addressing the metabolic syndrome, clinical trials have shown that lifestyle modifications can substantially reduce the risk of development of type 2 diabetes and the levels of risk factors for CVD in patients at increased risk. Prevention of type 2 diabetes is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link&amp;anchor=H8#H8\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the Diabetes Prevention Program (DPP), 3234 obese subjects with impaired fasting glucose or impaired glucose tolerance were randomly assigned to one of the following groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/90\">",
"     90",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intensive lifestyle changes with the aim of reducing weight by 7 percent through a low-fat diet and exercise for 150 minutes per week",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      (850 mg twice daily) plus information on diet and exercise",
"     </li>",
"     <li>",
"      Placebo plus information on diet and exercise",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At an average follow-up of three years, fewer patients in the intensive lifestyle group developed diabetes (14 versus 22 and 29 percent in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and placebo groups, respectively). The metabolic syndrome (using ATP III criteria) was present in 53 percent of DPP participants at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/105\">",
"     105",
"    </a>",
"    ]. In the remaining subjects (n = 1523), both intensive lifestyle intervention and metformin therapy reduced the risk of developing the metabolic syndrome (three-year cumulative incidences of 51, 45, and 34 percent in the placebo, metformin, and lifestyle groups, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Oral hypoglycemic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the oral hypoglycemic agents used to treat type 2 diabetes,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and the thiazolidinediones (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    ) improve glucose tolerance in part by enhancing insulin sensitivity. The role of these agents in patients with metabolic syndrome, to prevent diabetes, has not been definitively established and, furthermore, rosiglitazone has been removed from the market. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link&amp;anchor=H19#H19\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Pharmacologic therapy'",
"    </a>",
"    .) As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       Metformin",
"      </a>",
"      may prevent or delay the development of diabetes in subjects with impaired glucose tolerance. In the Diabetes Prevention Program (DPP) trial described above, metformin therapy plus instructions on diet and exercise was associated with a 31 percent reduction in the risk of developing diabetes compared to placebo (at three years, diabetes developed in 22 versus 29 percent); however, metformin was less effective than intensive lifestyle modification (diabetes developed in 22 versus 14 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/90\">",
"       90",
"      </a>",
"      ]. Both intensive lifestyle intervention and metformin therapy were effective for prevention of the metabolic syndrome in patients who did not have the syndrome at baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       Metformin",
"      </a>",
"      may reduce the incidence of diabetes-related end points. In a subgroup analysis from the United Kingdom Prospective Diabetes Study (UKPDS), metformin was associated with significant reductions in any diabetes-related end point (sudden death, hypo- or hyperglycemia causing death, MI, angina, heart failure, stroke, renal failure, amputation, retinopathy, monocular blindness or cataract extraction) and all cause mortality compared to conventional therapy with diet [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no data on glycemic control goals in patients with the metabolic syndrome who are not diabetic. Current recommendations are to treat impaired fasting glucose and impaired glucose tolerance with weight loss of about 5 to 10 percent of the baseline weight; at least 30 minutes per day of moderately intense physical activity; and dietary therapy with a low intake of saturated fats, trans fats, cholesterol, and simple sugars, and increased intake of fruits, vegetables, and whole grains.",
"   </p>",
"   <p>",
"    Routine pharmacoprevention for diabetes with any agent is not recommended. However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    could be considered in certain individuals with both IFG and IGT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link&amp;anchor=H20#H20\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Metformin'",
"    </a>",
"    .) In addition, when patients cross the diabetic diagnostic threshold, immediate therapy with metformin is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/107\">",
"     107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cardiovascular risk reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduction of risk factors for cardiovascular disease includes treatment of hypertension, cessation of smoking, glycemic control in patients with diabetes, and lowering of serum cholesterol according to recommended guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/108,109\">",
"     108,109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Lipid-lowering",
"    </span>",
"    &nbsp;&mdash;&nbsp;ATP III recommended a goal serum LDL cholesterol of less than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for secondary prevention in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/21\">",
"     21",
"    </a>",
"    ], and subsequent studies have suggested a more aggressive goal of less than 80",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    with a regimen that includes administration of a statin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link&amp;anchor=H13#H13\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current evidence does not support the metabolic syndrome as a coronary risk equivalent in terms of goals for lipid management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/110\">",
"     110",
"    </a>",
"    ]. However, among patients with elevated serum LDL-cholesterol and established coronary disease in the 4S trial of lipid lowering with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , those with characteristics of the metabolic syndrome (lowest quartile for HDL cholesterol and highest quartile for triglycerides) had both the highest risk of major coronary events and the greatest benefit (48 percent risk reduction) from statin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. Treatment of patients with known coronary disease and the metabolic syndrome with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80 mg, compared to atorvastatin 10 mg, decreased the rate of major cardiovascular events at five years (9.5 versus 13 percent, HR 0.71, 95% CI 0.61-0.84) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Antihypertensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on whether angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) used to treat hypertension in type 2 diabetes may also help to reduce insulin resistance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertension control is important in patients with diabetes mellitus. The goal blood pressure may be somewhat lower than that in the general population and varies with the presence or absence of diabetic nephropathy with proteinuria. It is not clear if the lower goal applies to patients with metabolic syndrome, but it may be reasonable to aim for such a goal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The value of ACE inhibitors and ARBs in hypertensive patients with the metabolic syndrome who do not have CVD or diabetes is not known. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CHILDREN AND ADOLESCENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic syndrome also occurs in children and adolescents but there is no consensus on the definition (",
"    <a class=\"graphic graphic_table graphicRef66120 \" href=\"mobipreview.htm?19/20/19788\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/114-118\">",
"     114-118",
"    </a>",
"    ]. As in adults, this lack of consensus makes it difficult to compare studies that use different diagnostic criteria and leaves the clinician without any clear parameters for assessing the long-term clinical implications of the metabolic syndrome in children or for tracking the effectiveness of lifestyle interventions. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Clinical implications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The International Diabetes Federation (IDF) definition of metabolic syndrome in children 10 to 16 years old is similar to that used by the IDF for adults, except that the definition for adolescents uses ethnic-specific waist circumference percentiles and one cutoff level for HDL rather than a sex-specific cutoff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. For children 16 years and older, the adult criteria can be used. For children younger than 10 years of age, metabolic syndrome cannot be diagnosed, but vigilance is recommended if the waist circumference is &ge;90 percentile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Prevalence and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;When clinically applied, these pediatric definitions result in varying prevalence rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/120-123\">",
"     120-123",
"    </a>",
"    ]. The US prevalence of metabolic syndrome (defined by the modified ATP III criteria) is estimated to be about 9 percent based upon a NHANES III survey of 1960 children &gt;12 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/124\">",
"     124",
"    </a>",
"    ]. However, pubertal growth and development is characterized by changes in metabolic traits that characterize the syndrome, resulting in significant individual variability in the categorical diagnosis. In one study of 1098 adolescents, as many as half of the adolescents initially classified as having metabolic syndrome lost the diagnosis during the three-year observation period, while others acquired the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The racial and ethnic distribution of metabolic syndrome is similar to that seen in adults, with the highest prevalence in Mexican-Americans, followed by non-Hispanic whites, and non-Hispanic blacks (12.9, 10.9, and 2.9 percent, respectively). Native Americans may be the ethnic group at greatest risk for metabolic syndrome as illustrated by a population-based study of Canadian Native (Oji-Cree) children and adolescents (10 to 19 years) that reported a 19 percent prevalence rate (defined by ATP III criteria) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among obese children, the prevalence of the metabolic syndrome is high and increases with worsening obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. This was illustrated in a study of 439 obese, 31 overweight, and 20 normal-weight children and adolescents who underwent a comprehensive metabolic assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/115\">",
"     115",
"    </a>",
"    ]. The metabolic syndrome was present in 39 and 50 percent of the moderately and severely obese subjects, respectively. In contrast, no overweight or normal-weight children met the criteria for the metabolic syndrome.",
"   </p>",
"   <p>",
"    Risk factors in childhood that could predict emergence of metabolic syndrome were identified in a longitudinal study of a cohort from the National Heart, Lung, and Blood Institute Growth and Health Study (NGHS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/126\">",
"     126",
"    </a>",
"    ]. Girls aged 9 and 10 years (n = 1192) were followed for 10 years. Metabolic syndrome (defined by ATP III criteria) was present in 0.2 percent at baseline and in 3.5 percent of black and 2.4 percent of white girls at ages 18 and 19. Waist circumference and serum triglycerides at baseline were predictive of subsequent metabolic syndrome. For every increase of 1 cm in waist circumference at year two, the risk of developing metabolic syndrome increased by 7.4 percent; for every increase of 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in triglyceride level at baseline, the risk of metabolic syndrome increased 1.3 percent. Race was not a significant independent factor in this study.",
"   </p>",
"   <p>",
"    In summary, the prevalence of the metabolic syndrome is high among obese children and adolescents and increases with the severity of the obesity, and with central adiposity in particular. However, there is instability in the diagnosis of metabolic syndrome during pubertal development, making prevalence estimates less reliable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/121,127\">",
"     121,127",
"    </a>",
"    ]. Consistency in the clinical diagnosis is required to better define the natural history of the syndrome in children and adolescents and to assess the long-term clinical implications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Clinical implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few longitudinal studies in children and adolescents with metabolic syndrome. In contrast to the data from adults, therefore, long-term cardiovascular and diabetes risks are not well defined. In one cohort study of 771 adults (mean age 38) who had participated in the Lipid Research Clinics study as children and adolescents 22 to 31 years previously, the incidence of self-reported CVD was more common in adults who exhibited metabolic syndrome traits as children than in those who did not (19.4 versus 1.5 percent, odds ratio 14.6, 95% CI 4.8-45.3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/128\">",
"     128",
"    </a>",
"    ]. Of 31 children who had metabolic syndrome traits in the initial study, 21 (68 percent) had adult metabolic syndrome. Increasing BMI was strongly associated with risk of adult metabolic syndrome.",
"   </p>",
"   <p>",
"    Thus, the definition of metabolic syndrome may be clinically useful for risk stratification and therapeutic intervention in pediatrics. However, lifestyle modification that emphasizes reduction of established risk factors, such as promotion of exercise, weight loss, and smoking cessation, is the main therapeutic goal in obese children and adolescents, regardless of a metabolic syndrome diagnosis. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Lifestyle modification'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     A CRITICAL LOOK AT THE METABOLIC SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Diabetes Association and the European Association for the Study of Diabetes published a joint statement raising questions about whether the components of the metabolic syndrome, as defined above, warrant classification as a true \"syndrome\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/13\">",
"     13",
"    </a>",
"    ]. The arguments raised include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of clarity of definition, with criteria differing between the ATP, WHO, and other definitions; many published studies use further modifications to classify subjects with the metabolic syndrome.",
"     </li>",
"     <li>",
"      Multiple different phenotypes included within the metabolic syndrome, with indications for differing treatment strategies. As an example, a patient with a large waist circumference, high triglycerides, and high fasting glucose would need to be managed differently than a patient with high blood pressure, low HDL, and high triglycerides.",
"     </li>",
"     <li>",
"      Lack of a consistent evidence-base for setting the thresholds for the various components in the definitions.",
"     </li>",
"     <li>",
"      Inclusion of patients with clinical CVD or diabetes as part of the syndrome which is intended to define risk for these diseases.",
"     </li>",
"     <li>",
"      Unclear pathogenesis uniting the components of the syndrome; insulin resistance may not underlie all factors, and is not a consistent finding in some definitions.",
"     </li>",
"     <li>",
"      Other risk factors for CVD that are not components of the metabolic syndrome, such as inflammatory markers, may have equal or greater bearing on risk.",
"     </li>",
"     <li>",
"      The CVD risk associated with the metabolic syndrome has not been shown to be greater than the sum of its individual components [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/11/32954/abstract/23,129,130\">",
"       23,129,130",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The critical weakness of the current metabolic syndrome construct is that treatment of the syndrome is no different than treatment for each of its components. Virtually all agree clustering of risk factors for diabetes and cardiovascular disease is a real phenomenon. All agree that the presence of one component of the metabolic syndrome should lead to evaluation for other risk factors. Whether patient benefit is gained from diagnosing patients with a syndrome of such uncertain characteristics or predictive value remains an open question. The advice remains to treat individual risk factors when present and to prescribe therapeutic lifestyle changes and weight management for obese patients with multiple risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/24/5507?source=see_link\">",
"       \"Patient information: Metabolic syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/56/42881?source=see_link\">",
"       \"Patient information: The metabolic syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2435699\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The metabolic syndrome is defined as the co-occurrence of metabolic risk factors for both type 2 diabetes and cardiovascular disease (abdominal obesity, hyperglycemia, dyslipidemia, and hypertension). There are several definitions for the metabolic syndrome (",
"      <a class=\"graphic graphic_table graphicRef53446 \" href=\"mobipreview.htm?30/44/31437\">",
"       table 1",
"      </a>",
"      ). The National Cholesterol Education Program",
"      <span class=\"nowrap\">",
"       (NCEP/ATP",
"      </span>",
"      III) is the most widely used. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The metabolic syndrome is an important risk factor for subsequent development of type 2 diabetes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CVD. Thus, the key clinical implication of a diagnosis of metabolic syndrome is identification of a patient who needs aggressive lifestyle modification focused on weight reduction and increased physical activity (",
"      <a class=\"graphic graphic_table graphicRef80387 \" href=\"mobipreview.htm?34/61/35804\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical implications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Lifestyle modification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention of type 2 diabetes is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link&amp;anchor=H8#H8\">",
"       \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reduction of risk factors for cardiovascular disease includes treatment of hypertension, cessation of smoking, glycemic control in patients with diabetes, and lowering of serum cholesterol according to recommended guidelines. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link\">",
"       \"Hypertension: Who should be treated?\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link&amp;anchor=H13#H13\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Questions have been raised as to whether the metabolic syndrome, as currently defined, captures any unique pathophysiology implied by calling it a \"syndrome,\" and whether metabolic syndrome confers risk beyond its individual components. The critical weakness of the current metabolic syndrome construct is that treatment of the syndrome is no different than treatment for each of its components. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'A critical look at the metabolic syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/1\">",
"      Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/2\">",
"      DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/3\">",
"      Lindsay RS, Howard BV. Cardiovascular risk associated with the metabolic syndrome. Curr Diab Rep 2004; 4:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/4\">",
"      Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005; 46:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/5\">",
"      Richelsen B, Pedersen SB. Associations between different anthropometric measurements of fatness and metabolic risk parameters in non-obese, healthy, middle-aged men. Int J Obes Relat Metab Disord 1995; 19:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/6\">",
"      Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 1998; 47:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/7\">",
"      Conus F, Allison DB, Rabasa-Lhoret R, et al. Metabolic and behavioral characteristics of metabolically obese but normal-weight women. J Clin Endocrinol Metab 2004; 89:5013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/8\">",
"      St-Onge MP, Janssen I, Heymsfield SB. Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual. Diabetes Care 2004; 27:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/9\">",
"      Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/10\">",
"      Haffner SM, Valdez RA, Hazuda HP, et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992; 41:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/11\">",
"      Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/12\">",
"      Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/13\">",
"      Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/14\">",
"      Ferrannini E. Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 2007; 92:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/15\">",
"      Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 2006; 113:2943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/16\">",
"      Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007; 92:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/17\">",
"      Meigs JB. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000; 152:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/18\">",
"      Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/19\">",
"      Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/20\">",
"      Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/21\">",
"      Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/22\">",
"      Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26:3160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/23\">",
"      Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/24\">",
"      Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet 2005; 366:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/25\">",
"      Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640.",
"     </a>",
"    </li>",
"    <li>",
"     International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome, 2006. file://www.idf.org/webdata/docs/MetS_def_update2006.pdf (Accessed on September 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/27\">",
"      Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28:2745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/28\">",
"      Adams RJ, Appleton S, Wilson DH, et al. Population comparison of two clinical approaches to the metabolic syndrome: implications of the new International Diabetes Federation consensus definition. Diabetes Care 2005; 28:2777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/29\">",
"      Lawlor DA, Smith GD, Ebrahim S. Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women's Heart and Health Study. Diabetologia 2006; 49:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/30\">",
"      Meigs JB, Rutter MK, Sullivan LM, et al. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007; 30:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/31\">",
"      Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/32\">",
"      Cull CA, Jensen CC, Retnakaran R, Holman RR. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation 2007; 116:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/33\">",
"      Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/34\">",
"      Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/35\">",
"      Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/36\">",
"      Festa A, D'Agostino R Jr, Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/37\">",
"      Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/38\">",
"      Hu FB, Meigs JB, Li TY, et al. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/39\">",
"      Rutter MK, Meigs JB, Sullivan LM, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/40\">",
"      Langenberg C, Bergstrom J, Scheidt-Nave C, et al. Cardiovascular death and the metabolic syndrome: role of adiposity-signaling hormones and inflammatory markers. Diabetes Care 2006; 29:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/41\">",
"      Timpson NJ, Lawlor DA, Harbord RM, et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 2005; 366:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/42\">",
"      Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/43\">",
"      Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/44\">",
"      Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care 2004; 27:2444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/45\">",
"      Wilson PW, D'Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112:3066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/46\">",
"      Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/47\">",
"      Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/48\">",
"      Palaniappan L, Carnethon MR, Wang Y, et al. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004; 27:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/49\">",
"      Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999; 282:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/50\">",
"      Manson JE, Skerrett PJ, Greenland P, VanItallie TB. The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians. Arch Intern Med 2004; 164:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/51\">",
"      Ferreira I, Twisk JW, van Mechelen W, et al. Development of fatness, fitness, and lifestyle from adolescence to the age of 36 years: determinants of the metabolic syndrome in young adults: the amsterdam growth and health longitudinal study. Arch Intern Med 2005; 165:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/52\">",
"      Dhingra R, Sullivan L, Jacques PF, et al. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation 2007; 116:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/53\">",
"      Lamberti JS, Olson D, Crilly JF, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006; 163:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/54\">",
"      LaMonte MJ, Barlow CE, Jurca R, et al. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. Circulation 2005; 112:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/55\">",
"      Pankow JS, Jacobs DR Jr, Steinberger J, et al. Insulin resistance and cardiovascular disease risk factors in children of parents with the insulin resistance (metabolic) syndrome. Diabetes Care 2004; 27:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/56\">",
"      Mills GW, Avery PJ, McCarthy MI, et al. Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes. Diabetologia 2004; 47:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/57\">",
"      Meigs JB, Panhuysen CI, Myers RH, et al. A genome-wide scan for loci linked to plasma levels of glucose and HbA(1c) in a community-based sample of Caucasian pedigrees: The Framingham Offspring Study. Diabetes 2002; 51:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/58\">",
"      Panhuysen CI, Cupples LA, Wilson PW, et al. A genome scan for loci linked to quantitative insulin traits in persons without diabetes: the Framingham Offspring Study. Diabetologia 2003; 46:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/59\">",
"      Grundy SM, Hansen B, Smith SC Jr, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/60\">",
"      Rosenzweig JL, Ferrannini E, Grundy SM, et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/61\">",
"      Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the \"metabolic syndrome\" and incidence of type 2 diabetes. Diabetes 2002; 51:3120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/62\">",
"      Resnick HE, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. Diabetes Care 2003; 26:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/63\">",
"      Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 2002; 25:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/64\">",
"      Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/65\">",
"      Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008; 371:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/66\">",
"      Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/67\">",
"      Stern MP, Williams K, Gonz&aacute;lez-Villalpando C, et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27:2676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/68\">",
"      Cameron AJ, Magliano DJ, Zimmet PZ, et al. The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. J Intern Med 2008; 264:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/69\">",
"      Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/70\">",
"      Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/71\">",
"      Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/72\">",
"      Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91:2906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/73\">",
"      McLaughlin T, Abbasi F, Lamendola C, Reaven G. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med 2007; 167:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/74\">",
"      Ingelsson E, Sullivan LM, Murabito JM, et al. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes 2007; 56:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/75\">",
"      Kohli P, Greenland P. Role of the metabolic syndrome in risk assessment for coronary heart disease. JAMA 2006; 295:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/76\">",
"      Saely CH, Koch L, Schmid F, et al. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care 2006; 29:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/77\">",
"      Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005; 165:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/78\">",
"      Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/79\">",
"      Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/80\">",
"      Hanley AJ, Williams K, Festa A, et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005; 54:3140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/81\">",
"      Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/82\">",
"      Zhang L, Zuo L, Wang F, et al. Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older. Mayo Clin Proc 2007; 82:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/83\">",
"      Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/84\">",
"      Pasquali R, Gambineri A, Anconetani B, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 1999; 50:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/85\">",
"      Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000; 85:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/86\">",
"      Ip MS, Lam B, Ng MM, et al. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002; 165:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/87\">",
"      Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/88\">",
"      Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/89\">",
"      Meigs JB. The metabolic syndrome. BMJ 2003; 327:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/90\">",
"      Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/91\">",
"      Magkos F, Yannakoulia M, Chan JL, Mantzoros CS. Management of the metabolic syndrome and type 2 diabetes through lifestyle modification. Annu Rev Nutr 2009; 29:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/92\">",
"      Lloyd-Jones DM, Liu K, Colangelo LA, et al. Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. Circulation 2007; 115:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/93\">",
"      Reaven G, Segal K, Hauptman J, et al. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001; 87:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/94\">",
"      Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/95\">",
"      Esposito K, Marfella R, Ciotola M, et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 292:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/96\">",
"      Tortosa A, Bes-Rastrollo M, Sanchez-Villegas A, et al. Mediterranean diet inversely associated with the incidence of metabolic syndrome: the SUN prospective cohort. Diabetes Care 2007; 30:2957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/97\">",
"      Salas-Salvad&oacute; J, Fern&aacute;ndez-Ballart J, Ros E, et al. Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: one-year results of the PREDIMED randomized trial. Arch Intern Med 2008; 168:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/98\">",
"      Kastorini CM, Milionis HJ, Esposito K, et al. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol 2011; 57:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/99\">",
"      Azadbakht L, Mirmiran P, Esmaillzadeh A, et al. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care 2005; 28:2823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/100\">",
"      Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2003; 26:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/101\">",
"      McKeown NM, Meigs JB, Liu S, et al. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 2004; 27:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/102\">",
"      Despr&eacute;s JP, Pouliot MC, Moorjani S, et al. Loss of abdominal fat and metabolic response to exercise training in obese women. Am J Physiol 1991; 261:E159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/103\">",
"      Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107:3109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/104\">",
"      Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/105\">",
"      Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/106\">",
"      Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/107\">",
"      Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/108\">",
"      Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/109\">",
"      Eberly LE, Prineas R, Cohen JD, et al. Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care 2006; 29:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/110\">",
"      Marroquin OC, Kip KE, Kelley DE, et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation 2004; 109:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/111\">",
"      Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104:3046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/112\">",
"      Py&ouml;r&auml;l&auml; K, Ballantyne CM, Gumbiner B, et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004; 27:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/113\">",
"      Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006; 368:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/114\">",
"      Goodman E. Pediatric metabolic syndrome: smoke and mirrors or true magic? J Pediatr 2006; 148:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/115\">",
"      Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350:2362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/116\">",
"      Cook S, Weitzman M, Auinger P, et al. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003; 157:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/117\">",
"      Jolliffe CJ, Janssen I. Development of age-specific adolescent metabolic syndrome criteria that are linked to the Adult Treatment Panel III and International Diabetes Federation criteria. J Am Coll Cardiol 2007; 49:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/118\">",
"      Zimmet P, Alberti G, Kaufman F, et al. The metabolic syndrome in children and adolescents. Lancet 2007; 369:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/119\">",
"      Fern&aacute;ndez JR, Redden DT, Pietrobelli A, Allison DB. Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. J Pediatr 2004; 145:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/120\">",
"      Chi CH, Wang Y, Wilson DM, Robinson TN. Definition of metabolic syndrome in preadolescent girls. J Pediatr 2006; 148:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/121\">",
"      Goodman E, Daniels SR, Meigs JB, Dolan LM. Instability in the diagnosis of metabolic syndrome in adolescents. Circulation 2007; 115:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/122\">",
"      DuBose KD, Stewart EE, Charbonneau SR, et al. Prevalence of the metabolic syndrome in elementary school children. Acta Paediatr 2006; 95:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/123\">",
"      Reinehr T, de Sousa G, Toschke AM, Andler W. Comparison of metabolic syndrome prevalence using eight different definitions: a critical approach. Arch Dis Child 2007; 92:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/124\">",
"      de Ferranti SD, Gauvreau K, Ludwig DS, et al. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 2004; 110:2494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/125\">",
"      Retnakaran R, Zinman B, Connelly PW, et al. Nontraditional cardiovascular risk factors in pediatric metabolic syndrome. J Pediatr 2006; 148:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/126\">",
"      Morrison JA, Friedman LA, Harlan WR, et al. Development of the metabolic syndrome in black and white adolescent girls: a longitudinal assessment. Pediatrics 2005; 116:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/127\">",
"      Gustafson JK, Yanoff LB, Easter BD, et al. The stability of metabolic syndrome in children and adolescents. J Clin Endocrinol Metab 2009; 94:4828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/128\">",
"      Morrison JA, Friedman LA, Gray-McGuire C. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics 2007; 120:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/129\">",
"      Sundstr&ouml;m J, Vallhagen E, Ris&eacute;rus U, et al. Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care 2006; 29:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/11/32954/abstract/130\">",
"      Bayturan O, Tuzcu EM, Lavoie A, et al. The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med 2010; 170:478.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1784 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32954=[""].join("\n");
var outline_f32_11_32954=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2435699\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      2001 National Cholesterol Education Program/ATP III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      International Diabetes Federation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Comparing criteria in defining populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Potential other markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVALENCE AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Increased weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Identification of patients at high metabolic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Risk of type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Risk of CVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other associations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lifestyle modification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prevention of type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Oral hypoglycemic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cardiovascular risk reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Lipid-lowering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CHILDREN AND ADOLESCENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Prevalence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Clinical implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      A CRITICAL LOOK AT THE METABOLIC SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2435699\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1784\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1784|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/35/41533\" title=\"figure 1\">",
"      Metabolic syndrome age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/9/40093\" title=\"figure 2\">",
"      Metabolic syndrome race",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1784|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/44/31437\" title=\"table 1\">",
"      Definition metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/23/30076\" title=\"table 2\">",
"      Ethnic values waist circ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/61/35804\" title=\"table 3\">",
"      Therapeutic goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/20/19788\" title=\"table 4\">",
"      Metabolic syndrome definitions in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1416?source=related_link\">",
"      Asymptomatic hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5802?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38649?source=related_link\">",
"      Dietary carbohydrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2601?source=related_link\">",
"      Dietary fat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43881?source=related_link\">",
"      Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3418?source=related_link\">",
"      Etiology and natural history of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28567?source=related_link\">",
"      Insulin resistance: Definition and clinical spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/24/5507?source=related_link\">",
"      Patient information: Metabolic syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/56/42881?source=related_link\">",
"      Patient information: The metabolic syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36202?source=related_link\">",
"      Risk factors for dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21144?source=related_link\">",
"      Role of physical activity and exercise in obese adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34665?source=related_link\">",
"      Screening for cardiovascular risk with C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_11_32955="Osteoporosis prevention in COPD";
var content_f32_11_32955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations to decrease osteoporosis risk in COPD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Measure BMD in the following high-risk patients at baseline:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Those on chronic oral glucocorticoids or high-dose inhaled glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Postmenopausal women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Premenopausal women with amenorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypogonadal men",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        History of fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        BMI &lt;22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follow BMD every 6 to 12 mo in those receiving oral glucocorticoids or every 12 to 24 mo in those not taking oral glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Give supplements to ensure daily intake of 1000 to 1500 mg calcium and 400 to 800 IU vitamin D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encourage an exercise program to improve strength and balance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Offer gonadal hormone replacement to all postmenopausal women, premenopausal women with amenorrhea, and hypogonadal men (unless contraindicated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider bisphosphonates or calcitonin in patients with osteoporosis or in high-risk patients in whom HRT is not effective or indicated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Biskobing DM. COPD and osteoporosis. Chest 2002; 121:609. Copyright &copy; 2002 American College of Chest Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32955=[""].join("\n");
var outline_f32_11_32955=null;
var title_f32_11_32956="Risk of significant CHD in UA";
var content_f32_11_32956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guidelines: likelihood that signs and symptoms represent an acute coronary syndrome secondary to coronary artery disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        High likelihood",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intermediate likelihood",
"       </td>",
"       <td class=\"subtitle1\">",
"        Low likelihood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any of the following features",
"       </td>",
"       <td>",
"        Absence of high likelihood",
"features and any of the following",
"       </td>",
"       <td>",
"        Absence of high or",
"intermediate likelihood features but may have",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chest or left arm pain or discomfort as chief symptom",
"reproducing prior documented angina",
"       </td>",
"       <td>",
"        Chest or left arm pain or discomfort as chief symptom",
"       </td>",
"       <td>",
"        Probable ischemic symptoms in absence of any of the",
"intermediate likelihood features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"        Known history of CAD including MI",
"       </td>",
"       <td>",
"        Age &gt;70 years&nbsp;&nbsp;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male sex&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transient mitral regurgitation, hypotension,",
"diaphoresis, pulmonary edema, or rales",
"       </td>",
"       <td>",
"        Extracardiac vascular disease",
"       </td>",
"       <td>",
"        Chest discomfort reproduced by palplation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        ECG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        New or presumably new transient ST segment deviation (&ge;0.05 mV) or T wave",
"inversion (&ge;0.2 mV)",
"with symptoms",
"       </td>",
"       <td>",
"        Fixed Q waves",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        T-wave flattening or inversion in leads with dominant R",
"waves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal ST segments or T waves no documented to be new",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Cardiac",
"markers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Elevated cardiac cTnI, cTnT, or CK-MB",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Braunwald E, Antman E, Beasley J, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction- summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 40:1366; and from Braunwald, E, Antman, EM, Beasley, JW, et al. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000; 36:970.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32956=[""].join("\n");
var outline_f32_11_32956=null;
var title_f32_11_32957="Effect of weight loss in OHS";
var content_f32_11_32957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Weight loss lowers arterial carbon dioxide (PaCO2) in OHS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 280px; background-image: url(data:image/gif;base64,R0lGODlh7AEYAdUAAP///wAAAGYzZm8/b/Xy9ezl7IiIiHlMeeLZ4u7u7oJZgp9/n5Vylc+/zzMzM6mMqREREaqqqrKZssWyxbylvLu7u4xljNnM2Xd3d8zMzERERFVVVSIiIt3d3WZmZpmZmZh1mOPa43tPe209bWs5a5RwlIliiaGCoWw7bGg2aNrO2n1RfZx7nJRxlIVchbWctW4+bmc1Z2o4aoBWgMi2yI1njY9qj5ZzlsKtwq2SrXJDcnFBcQAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADsARgBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIhw4GQwYBAQ4JABUQARwZydnafBXPzAAZAdgOGAAQzBgO2+vsdRrfBuoABhrh0t1Ez/r67f3+YO+E0BPIAd+0AB2UBPjHsOGVgPPk0bN3cMlChxgzNoEYbly5cwDSWdRIsuSQbs84CHwWbVq1ayNNypxp5SLNmziZ2MzJs6eQ/50+g9IEKrQoSaK7CjAoYLRpzWAWBDBwSlUK0lwUBAxgWrVrk6u3CgwQQMGr2Zi9olo4yxYJ2FpZBXBtS/dnL7ECJNTdC+DtLAYCFPDd6zdWAwECEAyuW/gVgbF6F9Nt7AqwYMmTdR1OjDkzrsd5O3u+ZVn06FqbFZtmSzkV6Aer27ZGtUDAAQKxWdu6gPhCbt20CBwQAPv32dmlHtjGrUfpXOOvkI/iLcD3nqhTocOSHko4cT5Zt2rfPkv57T14y46PLou6dT1q15OH5X0BeK3P5a/i7kn5AOZ5pKcfe68ggFgDfMQ3oCv8caKAVPeJt2ArDWoigVYA4oHAWOpNyP9KhZgYKACCezy4locUuvJgdnpcKCGK+7XiYoZ3iNghjKqAWImIJOphIo4prrIiHy7mB+QpOk5S5B42HvmhKgUgdiMePzoZYyoKtoihlZVswBI21FiDjUKphGdkHTxySUkEECTkgAfmoCNPEkk+ImCJEKo5SQcBMPMORQbRiUqWecyoJyUbbOCAAx0Y1E1CP+3DjylmMnngoZPEI5ADgPpVJyN3+pgnppEY0CYAHqgDkkhklkIoHoaSKokGX7okJlqixHUmHWnKisqnieAVmags+moKsIiUtkesxtoRAQYYGFDBGsgakpqlIzZrxwccSKrBtGhUSwhow+YxpLZ0OKP/wQcdJNCBAd2Ca4a4gyir5X/o0hHtER5EEG4o1+rR6xIFLLBrvlxIg4TC84JCLh/nMlGbfQiTkUAEGGM85r+f2FvolkyIeHDFW0QgaQBwctxJwHlQ1+MSUVFMshgRcADtBhDQunEZ9Prx2h7eFasEdSPPnIWmACQQwAcB+HtGz33Udp4e/tGYRMxGj+GMAc8u3bTKmri3h8tOEJ21GAlUw1I3O5MBtR7eFZdH0E9gfTbaBkQrDcMNb2Ke1XVUXTZiRd99yNt4iK0H2U5EVa7hXEArObSQgm1J3EAPJzMTvOELeRdKn+y05ZX8vYfpTjz4+Oda3BzABpSrgXgdirfc/9sTE4DMuhcmjy47JvVl/t0Tw62+OxYJXNx08tRiIjjVy+Gu+/FZhC6p733veOnitxMfGvVbWL8P9jxfEjEemEvvOfhaJO8+879XwiweqDtRPPugp7OoA/I+rX223KsOFHJ3APx1wRnji98kztcG5xwhfd6bgAG54Ix2wS8Ns3vD/NjQgLEITQj1a8KFCjjB8C0jY3zLHiQG1oYLBcZItWsCaCRYQi1kQG3PIJ/bFjgqNhAgKgLY3BAg6IQR1nALGECZ5Crnv0gsqQ0IGM4AaGiEEDJhhkfUgsmYqEBHRIksbsidbVRjhBiK0DZZ1AI19se/LjbiVWggQG2kAjgAEP9RhmOhYhqtYLIEYhASlVpDAR70PSRIrY5JuNBl9oi89zXPixzi4FgG8J4jbKaSeBQgMRrwAEwOJoNpgKMZXKiAkf0sChc6ETAKQAHAIEZuyEiA/hbVPxUqIpBxBKIQjwCYqT3hi57MBSeHgxjbdBIVnAzm0a7nRkSE6gwb0ooekXBJKdRGlblgpSuLyQAKFG4TBZgAA8YyPC9U0H2PXIQoxxAXBZAxCaeEAjCF+QBiIuYAD3gZKRAgAULe85hfSMAJMZbC8i1CV3GcIwMQSYReMtSQAsCmLLRZTMR085uaIEADFkBOxFiAAu/8wg39SLpCCAsNCCDklJJQzSjMUxb/w6woPvU5CooWcwALmMBDkajE2P1RER4jQwe1okwjPMyaEYVFOMdZ0Yui4gL1rKgCAIqGLboBlGNgGRmUE5idDiGoTvhiSJ/6AH8ak6aiIMAEONpUb7ZhjfurpUEPcVQy/PCVUNDqEyYGJXF2NKJuPQUCKGDWAywArWrooz50OAashgGsYIjmFKFQVyiI7BRQLexhvbqJjdozMBIY6xveV9C5FkKvYGinaJUA2SbYTRRL/etHVwuKpVZ0AAzQaR0+UNoMyFUMjvVCZcFAAFcuNAqobYLZQJFZmW4WFQgoq0zzmYd0YM9UjFVCB2gVgGmFCSatKkRruZBSKUlhuHUL/6InYlvR2aJCo2wt5kcx6oYMOAAaHsCAB7q1gdIugQMtEcKq5uQWayGGtlqYwCQRnITxLmG5mWhuMQ3bAM4KbAEMlgIrgYgYnFY4EPF4Rs6yqwQ2MaxTuApEPMHAVQtYmAjJda16L8Fe+YI0EQSgADF3SYWYFnOqGd7DBadgKhFXwFEIGcLJnlGIQ4aBAISEJWUhQwUIS0LC93xuIi4wR61g2ApqZSo3J0DfTGlACBi4RgDu4SlCmJELF5gkYpvgYJgV0k5+be+NFcFKeypAt1Tgp2bn3IkbYkMkA06xz4YjZS6otgox5tz0FoFl22hZEQ3Y5gAeEGRqLuCzCtgzKv8QyClbgVdQgrCiFoqLmAW8uAjofYLqQJVnG3f6DwWQgD0tMM1ftvK2OX11Iirg3y8EFwtvzkJ5wWiFOishd+szhKCd++FGTIDDmy7zECqNz6JC4oYQKIcDSNyFY4OZ0V9QsFZuTc0DV+F+hVBrfD0qalA9oKMMIDQS5P1Xp25CA2+CQKrIzQVzV0HVWJiji68QaydAW9hxmPZNL80ItXL4ABLQ9mA57OVqd2Lc4IAABAi+BYNPIdlWGCRijCeFqCxyCvD22Vr/qoDQRgIB8z4scqP6Y5uLwgMbEEI3SK4Fk0cheHCWcxbiwu4iPLwPEu9wsCOhVn8egAIWrrFWcqv/bUswjNhN7MPztEDKrh/hpO++sx34LVWfR4LLFV2At4sQ9bOmotimFdj2ssDqIEL8CC63AgE11E9gA5rqOv7x4ZUAX9nW2xQYqEa42WB0WffwClFETK+rwHQrDGfzbWB7z5tOiI1OPMg2lfriUeEBSaXsp8uadBXUfQDSJwHtVDBixAs/8dVDIte79n0ZeY6Yqc6dFOHwQAYSkIHWty3vNdr7FRT+dyQEvgpYDP3M22770mv6AUUTvUUDCwuTMUxpRC84xC5PBZWrHQvh6b4QdK+GuuNU+L+/t3xBP4TBDtoWJiMvQ9dMdbBBUzBUA6BvGhZJ2JdHcbR9o5cJ1zZh/xmnBJ7FfbrAARAAOzijEgQ4ByyUe8VndnYmUVJAf2Ngf1MXIvpnUXNmWzeVW9WHCiMlYs8HfXTAQOelS1+AS1OQfcS1UTTndpdQdRNGfnQnXRNGXcGQAHljAHgHXB/zIlOQeZPlBc80BYoUWRTAcfc3g4WAcx0ldw8khHpGgrCwAWcmBBoQdB8IB1+0UgN0T/JXggw3FsdHWRcYgZuQY/Z0dVazYcDmccMQDt8wD+Lwhm+wTjKkUGCYBD6ohUmlbF14W1zXCXAndWPlY8XHadnQO0MAirBHB5H4S4TEclmQhRrWPVQAX6BGVeCUeMW3eGHWb2S2DiZTDmj2NaMoB/+q6AQImIdVABgmiFTF2AQbZ4m36AmZdlOe2H+8l2UKaAz8hQFeAgHpNAfEKIIvNAYOlHKsKEN72InCKAnAt38w9mlS9Xj9UIMBAAEfkI2+uBQ72Gp/cE1OkIwxuIyfMIEdBn5CkHpehn/+4ITRwkVhdwiSxX928FL7No6BAYvr1YJSQSLcJpEl4UiK+AePdo+TaAT62GGX2B3+aBsZJ35SgYQykQDclUMbyQdyZFGPiAZiRQSuKFUY6QliWEyHFZIdN5PZ4AwcAGAQ8FuNJW0qJQh8BQA+iVv8SJJWRwE0QHygVYf+kA6Uk4i9CAjBKAgiggPq+GM5+QmZiBggkAP/YrZ1TykU6cAtTJN+JUcIXKUAQEmTIlBRaomGiGdPK8AAMzBd05gTTBMmp7KVMAlEjbYHnBiR5ZgJpocYKCACI6BnVmkS0pABGHCDOwQIC+kHApkCAmACemmOulZMOmB4dakRCaAoGBCFUsiRxVeZQkWV+PQChHMKzYgYMYCTjVkULemG8jg3xpWaXSCQKckVrwVbDwADeDl+o8kTStMvreeaYFB5yJiUd7CYM1UEVtaPLtCcFGYa6Kc8Q5aQeKBuAyCbXGCc/mYEjhMKCFACMoCXNaeeQiE+i/WSb9BixGkFUPVZ2zk0socJIXACf0UCNkCQmIGfLmmYcgBleEUH/1x1nKnzfpaAACywAxU1AiAQmAtKWtTpBdZ5BHGmFR56BlB1ogDwdEVohsVEAjcQAoxkF3bQkYkQc5MgiDfVAjWgAjOaD3XQd662CCwaCYsJZD96BCMqBMsmh4aAoxVXaxa1lkkKpHKAnvZ5pQMqbdFoaSq6RyNKfY4ApdYSlsXHjlWKam7gfqhoCIN3CAL5hWkaBUZXogkICZ9XCBfZm3OqZG5QdpCAgjI3bxTapwBAK0L3Eprpp2sgpP35oA7oB01JcX3aeheRaOGFUsTEkIggqIlDlfVpqEaQDs4ADmtWEUq2ZGpAe1m6dpF6OiJJpaI6DxzQAUyDqo+SqWUgpv+S4Kmf+qU/2i37gGK6KgZsSglAOKuLcKtxEhIEpqRnABh3SglbqKyNwKzftag0WgbfOAmgwafW+ghLygipFK6hMK58Fo7mygnomgj4uK6f0K5wqq7wqgnyagjvWq+dcK+E4JD6ugn8Ogj5+q8AmxTuRrDsugtLibAFqwsF85wMSwgBG7E3MbEUOxMWe7EmkbEaexQdqyYc+7EYEbIi2xAkW7L/cLIo2w8qu7Ls0LIuuw0wG7PZMLM0iww2e7PGkLM6Sww827PC8LNACwxCO7S+ULRGywtIm7S6sLRMiwtO+7S2ELVSSwtUW7WycLVYOx9buxpa27VBArai8bViOwn/LMkS96Coila2N7FdycMBzICpasq2QbEMxDq3dMsTmoJklbNkfvu3gBu4gju4hFu4hnu4iJu4iru4jNu4jvu4kBu5kiu5gZAql3mqgVJgeHCvE9u5m/u5dhCyHfAmRCC3mnsHnLsHnou6oFsHIcs0+qAS2bq2cpC6erC6odu6dEC225q7rHu7qqu7u/u7eVu8xnu8yJu8SYpA8MiGz/B6aWAyJ6G2h/q8bCC9u3gr1YsybIABa9gM3QUAo/sM8YgG3jsE2/UM0zK+S6MGyzAEXgINYEK9ZPABalO+3JUyswsM6BcSKgEv7jJyasBdQ5BoANwBApwGBCwEG4ANiUKr/wEMl0UXAN8LALA7LQ9sfk9DwUMAYAyTwadqBijxDWziJnBiumKAAfFoKhCMwP6Cwr3AAf1lAEEHO2x4iGhgEChmw4eKw2eQuWhWw7oIEWkwEELAJgFoDk4TvmdgxCZWuktslGEAEXziJwZwt2bAJgDAw3+CubzbBvGgAQXRw2wIvT98EXwLERpgxiIMFNSQEGrMxmVgxN1QAXwyLUzcvk28hkX2jngMLnp8BkScKIvSKGicZGbQARzgL3HMt8DQKas5xD7cxkKww5K8BpnLLWPCxZM8x2toqfpADVGMBkZsxGmmxD8hxQABDxLBKV58BjdUvpyMxb0QDv7CNE7IAf8RjMk2YcC67MK8PAQAxzAHnMBFXMHiG74gHKJaYMSG5qxbHHQajAYQYSoJkSrNyipkAC8bU8wvLCfCwLz4a70DrA/xuL/5uwYtyS6SAsfkjEH6UDl3LL73Fcg8E8+IKL/0TL45HLvOq8/7SwbCys/pbGraqrwIndAKvdAM3dAO/dAQHdESPdEUXdEWfdEYndEavdEc3dEe/dEgHdIiPdIkjdAmA5xL0Hr+cl8H7SXlW9KSEC/VywxMI8csfQQnTQTh8KwAkItCcNP/5YEwHQmtF7cc3Hov7QQ5PQQ7bQQaAAEKA9RK4AxJPdSN0A0e0A0ilwDdkhAI1CdbnIjxWw37GAMN9xUNOOQ7OTMELJ1EQce8AaCLfILSVt0IEAC3fZLXZ+YM5dDVXpIBzlDDTWMyZ0YrVwwNRcAnr3dfbm2q/xvXBczTda0ItHLXfFINzBC/i/XXXpLZg/06IdEnTU0Eis3W5oyIbw3ZAibZk40ICAQnwjotzgC9f83X1VvWQZdEhy3UBfy998UmbdIN6mDbyUzXrZ0IfBK+zoCNK6EPGfDXZwsBv53Tuh3WvMiGUP3T4sA06pBE0KDaVH3cpMDViKzUqq0EtFK+QyneoWA9zRsFKo0E9azaLs3e9n3f+J3f+r3f/N3f/v3fAB7gAj7gBF7gBn7gCL7fQQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Weight loss in patients with the obesity hypoventilation syndrome (OHS) lowers the arterial PaCO",
"    <sub>",
"     2",
"    </sub>",
"    . Each line represents a different patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Rochester DF, Enson Y. Current concepts in the pathogenesis of the obesity-hypoventilation syndrome. Am J Med 1974; 57:402. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32957=[""].join("\n");
var outline_f32_11_32957=null;
var title_f32_11_32958="IgE levels with age";
var content_f32_11_32958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F83424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F83424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Normal total IgE levels with age (in the US population)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 529px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Based on 2005-6 data from the National Health and Nutrition Examination Survey (NHANES).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Gergen PT, Arbes SJ Jr, Calatroni A, et al. Total IgE levels and asthma prevalence in the US population: Results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2009; 124:447.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32958=[""].join("\n");
var outline_f32_11_32958=null;
var title_f32_11_32959="Otitis media bacterial isolates";
var content_f32_11_32959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Bacteria recovered in acute otitis media versus otitis media with effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 706px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of distribution of isolates in 2807 effusions from patients with acute otitis media (AOM) and 4589 effusions from patients with otitis media with effusion (OME) at the Pittsburgh Otitis Media Research Center, 1980 to 1989. The total percentages add up to more than 100 percent because multiple organisms were frequently recovered.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Bluestone CD, Klein JO. Otitis Media in Infants and Children. WB Saunders, Philadelphia, 2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_11_32959=[""].join("\n");
var outline_f32_11_32959=null;
